Abbreviations {#no8790}
=============

Aci

:   acinetaminic acid (for abbreviations of Aci variants, see [Table 4](#t0025){ref-type="table"})

ALL

:   acute lymphoblastic leukemia

Asn

:   asparagine

ATP

:   adenosine triphosphate

BHK

:   baby hamster kidney

CDP

:   cytidine diphosphate

CE

:   capillary electrophoresis

CIMS

:   chemical-ionization mass spectrometry

CMAH

:   CMP-Neu5Ac hydroxylase

CMP

:   cytidine monophosphate

CTP

:   cytidine triphosphate

DIFO

:   difluorinated cyclooctyne

DMB

:   1,2-diamino-4,5-methylenedioxybenzene

DTH

:   delayed-type hypersensitivity

EIMS

:   electron-impact mass spectrometry

EPR

:   electron paramagnetic resonance

ESIMS

:   electrospray ionization mass spectrometry

Fab

:   fragment antigen-binding (region on antibody)

FABMS

:   fast-atom bombardment mass spectrometry

Fc

:   fragment crystallizable (region on antibody)

FLAG

:   Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys octapeptide

Fuc

:   fucose

Gal

:   galactose

GalNAc

:   *N*-acetylgalactosamine

Glc

:   glucose

GLC

:   gas--liquid chromatography

GlcNAc

:   *N*-acetylglucosamine

GlcNGc

:   *N*-glycolylglucosamine

GNE

:   UDP-GlcNAc 2-epimerase

HD

:   Hanganutziu--Deicher

HE

:   hemagglutinin-esterase

HEF

:   hemagglutinin-esterase-fusion

HEV

:   high endothelial venules

HFB

:   heptafluorobutyryl

HIBM

:   hereditary inclusion body myopathy

HPAEC--PAD

:   high-performance anion-exchange chromatography with pulsed amperometric detection

HPLC

:   high-performance liquid chromatography

HSEA

:   hard-sphere exo-anomeric

IR

:   infrared

ISAV

:   Infectious Salmon Anemia Virus

ISSD

:   Infantile Sialic Acid Storage Disease

Kdn

:   ketodeoxynononic acid

LAD II

:   leukocyte adhesion deficiency type II syndrome

Leg

:   legionaminic acid (for abbreviations of derivatives and variants of Leg, see [Table 4](#t0025){ref-type="table"})

LFA

:   *Limax flavus* agglutinin

MAA

:   *Maackia amurensis* agglutinin

MAG

:   myelin-associated glycoprotein

MALDI-TOFMS

:   matrix-assisted laser-desorption ionization time-of-flight mass spectrometry

Man

:   mannose

ManNAc

:   *N*-acetylmannosamine

ManNAz

:   *N*-azidoacetylmannosamine

ManNGc

:   *N*-glycolylmannosamine

MD

:   molecular dynamics

MERS-CoV

:   Middle East Respiratory Syndrome Coronavirus

MM

:   molecular mechanics

MNK

:   ManNAc kinase

MS

:   mass spectrometry

NADH/NAD^+^

:   nicotinamide adenine dinucleotide (reduced and oxidized form)

NADPH

:   nicotinamide adenine dinucleotide phosphate

Neu

:   neuraminic acid \[for abbreviations of derivatives (sialic acids), see [Table 1](#t0010){ref-type="table"}\]

NMR

:   nuclear magnetic resonance

NOE

:   nuclear Overhauser effect

NulO

:   non-2-ulosonic acid

OPD

:   *o*-phenylenediamine

PAPS

:   peroxidase--antibody--peroxidase smear

PAS

:   periodic acid--Schiff

PPCA

:   protective protein cathepsin A

Pse

:   pseudaminic acid (for abbreviations of derivatives of Pse, see [Table 4](#t0025){ref-type="table"})

QM

:   quantum mechanical

RDE

:   receptor-destroying enzyme (sialidase)

ROS

:   reactive oxygen species

SDS-PAGE

:   sodium dodecyl sulfate--polyacrylamide gel electrophoresis

Ser

:   serine

Sia

:   sialic acid

SNA

:   *Sambucus nigra* agglutinin

SOAT

:   sialate *O*-acetyltransferase

Thr

:   threonine

TLC

:   thin-layer chromatography

TS

:   *trans*-sialidase

UDP

:   uridine diphosphate

UTP

:   uridine triphosphate

UV

:   ultraviolet

WGA

:   wheat germ agglutinin

X-ray

:   Röntgen radiation

1. Introduction {#s0010}
===============

Alfred Gottschalk, discussing the state of the glycoprotein research at the "C.N.R.S. Colloque Internationale sur les Glycoconjugués" (later named the 2nd International Symposium on Glycoconjugates), organized by Jean Montreuil in 1973 at the Université des Sciences et Technologies de Lille (Villeneuve d'Ascq, France), stated: "We are not at the end of all progress, but at the beginning; we have but reached the shores of a great unexplored continent."[@bb0010] And this certainly held for his favorite topic: sialic acid research. Gottschalk encouraged students interested in research to work in the field of carbohydrate (bio)chemistry/glycobiology, which rapidly expanded in the 1970s. Since then, as this review will show, many questions regarding the chemistry, analysis, biochemistry, and biology of sialic acids could be answered, and the important influences of this family of sugar molecules on and in our lives have been documented in a myriad of publications.

Sialic acids are frequently found in Nature in many molecular forms, and detailed reviews have been available since the 1960s.[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040] These compounds are regularly present in higher animals like *Echinoderma*, *Hemichorda*, *Cephalocorda*, and *Vertebrata* and could also sporadically be identified in some members of other groups of animals, such as the Platyhelminthes (*Polychoerus carmelensis*), *Cephalopoda*, and *Crustaceae* (*Homarus americanus*). It is, however, not clear whether the sialic acids are produced by the animals themselves or originate from nutrition or microorganisms. Sialic acid concentrations have been measured in subcellular membrane fractions of various cell types, showing highest values in the plasma membrane (65%--70% of the total sialic acid quantity of the cell) and in much lower amounts in the smooth endoplasmic reticulum.[@bb0020] Generally, most of these sugars are bound to glycoproteins with the exception of nerve and brain cells, where they prevail on glycolipids. The overall sialic acid level in the various organelles was assumed to be influenced by endogenous sialidase, but no experimental evidence existed. Interestingly, also insects were shown to contain sialic acids and to express corresponding enzymes.[@bb0045], [@bb0050], [@bb0055], [@bb0060] Sialic acids were found in some viruses, various bacteria, protozoa, and pathogenic fungi. They are absent in plants and in most animals in the evolutionary tree lower than the echinoderms. The various studies show that sialic acids appeared relatively late in evolution, which led to the assumption that acquisition of these monosaccharides accelerated differentiation of the higher animals.[@bb0015], [@bb0025] Deaminated neuraminic acid is often seen in vertebrates and bacteria, but its abundant occurrence in animals is limited to the lower vertebrates.[@bb0065] Further details are included in the various sections in this chapter, when applicable.

In naturally occurring sialic acid-containing structures, the sialic acid units play important roles in many physiological and pathological processes via carbohydrate--protein interactions, including cellular recognition and communication, cellular aggregation and development, controlling the lifetimes of glycoconjugates in organisms, mediating bacterial and viral infections, being involved in tumor growth and metastasis, playing a great role in immunology, in the biology of the microbiome, in cell signaling, in reproduction biology, and in neurobiology. Sialic acids, which occur mostly as the terminal part of many glycoconjugates (glycoproteins; glycolipids) and carbohydrate chains (oligosaccharides, capsular and tissue polysialic acids, bacterial lipooligo/polysaccharides) occur in various chemical forms, which can dramatically influence their biology. *O*-Acetyl and *N*-glycolyl groups, in particular, are most effective in determining sialic acid function. Many genes and enzymes control the anabolism and catabolism of sialic acids, which are of importance not only in health but also in disease situations. Increasing information about the regulation of sialic acid expression on the genetic level of various hereditary diseases can be gathered. Sialopharmacy is still in its infancy, but recently more publications show progress in this field. But it was not too long ago that groups of scientists worldwide were trying to elucidate the primary structures and the basic biochemical reactions of these unusual monosaccharides.

Nowadays, the basic structural features of the sialic acid (Sia) family, a subclass of the superfamily of naturally occurring non-2-ulosonic acids (NulOs), are well known ([Fig. 1](#f0010){ref-type="fig"} ). The mother molecule of the family, neuraminic acid (Neu), which does not occur in free form in nature due to its immediate cyclization to form an internal Schiff base, is a nine-carbon-containing monosaccharide, chemically defined as a combination of a 2-keto-carboxylic acid, a deoxysugar, and an aminosugar. It is systematically named 5-amino-3,5-dideoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid (Neu; C~9~H~17~NO~8~) (C7 is the anomeric reference atom). The intramolecular (cyclic) hemiketal form of Neu (C2--O--C6) comprises a pyranose ring in a ^2^ *C* ~5~ chair conformation with an equatorially oriented glycerol side chain at C6. The amino group at C5 is generally N-acetylated \[5-acetamido-3,5-dideoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulopyranosonic acid (IUPAC/IUBMB Recommendations 1996/1997[@bb0070]); *N*-acetylneuraminic acid, Neu5Ac; C~11~H~19~NO~9~\] (for different views, see [Fig. 2](#f0015){ref-type="fig"} ) or N-glycolylated \[5-hydroxyacetamido-3,5-dideoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulopyranosonic acid (IUPAC/IUBMB Recommendations 1996/1997[@bb0070]); *N*-glycolylneuraminic acid, Neu5Gc; C~11~H~19~NO~10~\]. Note that the full name for Neu5Ac, as presented in the IUPAC/IUB document 1969/1971,[@bb0075] namely, 5-acetamido-3,5-dideoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-2-nonulopyranosonic acid, is no longer used. The amino group at C5 can also be replaced by a hydroxyl function, yielding 3-deoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulopyranosonic acid (ketodeoxynononic acid, Kdn; C~9~H~16~O~9~) (IUPAC/IUBMB Recommendations 1996/1997[@bb0070]), usually called deaminated neuraminic acid (other names used: 2-keto-3-deoxy-nononic acid, 3-deoxynon-2-ulosonic acid, 2-keto-3-deoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-nononic acid). To indicate the absolute configuration, up to the 1980s the trivial names of the mother molecule and the derived members were presented with the configurational prefix [d]{.smallcaps}, e.g., [d]{.smallcaps}-neuraminic acid, *N*-acetyl-[d]{.smallcaps}-neuraminic acid, *N*-glycolyl-[d]{.smallcaps}-neuraminic acid. According to the IUPAC/IUBMB Recommendations 1996/1997,[@bb0070] this prefix should not be used, as the [d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto* configuration is implied in the trivial names.Fig. 1The "mother" molecule of the family Sialic Acids (Neu), together with the three major "children" (Neu5Ac, Neu5Gc, Kdn), presented in the α-configuration, as occurring in sialic acid-containing carbohydrate chains.Fig. 1Fig. 2Chemical structures of *N*-acetylneuraminic acid (5-acetamido-3,5-dideoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid, Neu5Ac) in different views according to IUPAC/IUBMB recommendations. (A) Neu5Ac in Fischer projection formula, open chain; (B) β-Neu5Ac/*N*-acetyl-β-neuraminic acid/5-acetamido-3,5-dideoxy-[d]{.smallcaps}-*glycero*-β-[d]{.smallcaps}-*galacto*-non-2-ulopyranosonic acid in Fischer projection formula, cyclic chain, pyranose ring; (C) β-Neu5Ac in Haworth representation, pyranose ring; and (D) β-Neu5Ac in ^2^*C*~5~ chair conformation.Fig. 2

The abbreviations used for sialic acids have a long and controversial history, i.e., for *N*-acetylneuraminic acid: NANA, *N*-AN, NAN, NANS, NeuNAc, AcNeu, and Ac-Neu; for *N*-glycolylneuraminic acid: NGNA, *N*-GN, NGN, NGNS, NeuNGl, NeuNGc, GlNeu, and Gc-Neu; for ketodeoxynononic acid: KDN. At present, the IUPAC/IUBMB recommendations are Neu5Ac (or NeuAc), Neu5Gc (or NeuGc), and Kdn. For neuraminic acid, the abbreviation is Neu, whereas the recommended abbreviation for sialic acid is Sia. A still frequently used old abbreviation for 2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid (Neu2en5Ac) is DANA.

Sialic acids are relatively strong acids, e.g., Neu5Ac has a p*K* ~a~ value found in the range of 2.0--3.0 in various studies with an average of 2.6. This strong acidity is responsible for processes such as autohydrolysis of sialic acid-containing glycan chains, and for repulsive effects, leading, for example, to the high viscosity of mucins, and for the binding and transport of cationic substances.

In [Table 1](#t0010){ref-type="table"} a survey of the over 80 known naturally occurring members of the sialic acid family, together with their abbreviations and relevant references,[@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205], [@bb0210], [@bb0215], [@bb0220], [@bb0225], [@bb0230], [@bb0235], [@bb0240], [@bb0245], [@bb0250], [@bb0255], [@bb0260], [@bb0265], [@bb0270], [@bb0275], [@bb0280], [@bb0285], [@bb0290], [@bb0295], [@bb0300], [@bb0305], [@bb0310], [@bb0315], [@bb0320], [@bb0325], [@bb0330], [@bb0335], [@bb0340], [@bb0345], [@bb0350], [@bb0355], [@bb0360], [@bb0365], [@bb0370], [@bb0375], [@bb0380], [@bb0385], [@bb0390], [@bb0395], [@bb0400], [@bb0405], [@bb0410], [@bb0415], [@bb0420], [@bb0425], [@bb0430], [@bb0435], [@bb0440] is presented. In the case of Neu, besides *N*-acetyl or *N*-glycolyl groups at C5, the hydroxy groups at C4, C7, C8, and C9 may be free, esterified (acetylated, glycolylated, lactylated, sulfated, phosphorylated) or etherified (methylated). Most free sialic acids occur predominantly in the more thermodynamically stable β-anomeric form (\>93%), whereas in nature bound sialic acids, with one exception, possess the α-anomeric configuration. The exception is the nucleotide-bound sialic acid, the activated CMP-donor, e.g., CMP-β-Neu5Ac ([Fig. 3](#f0020){ref-type="fig"}C). Crystalline Neu5Ac occurs specifically in the β-anomeric form. The mother molecule Neu and Neu1,5lactam (neuraminic acid 1,5-lactam) ([Fig. 3](#f0020){ref-type="fig"}A) only exist in bound form. A number of other members (can) only occur as free form, i.e., Neu5Ac9P (9-*O*-phospho-*N*-acetylneuraminic acid), (O-substituted) Neu2en5Ac ([Fig. 3](#f0020){ref-type="fig"}B), or Neu2en5Gc (2-deoxy-2,3-didehydro-*N*-glycolylneuraminic acid), (O-substituted) Neu2,7an5Ac (2,7-anhydro-*N*-acetylneuraminic acid) ([Fig. 3](#f0020){ref-type="fig"}D) or Neu2,7an5Gc (2,7-anhydro-*N*-glycolylneuraminic acid), and Neu4,8an5Ac (4,8-anhydro-*N*-acetylneuramic acid) ([Fig. 3](#f0020){ref-type="fig"}F) or Neu4,8an5Gc (4,8-anhydro-*N*-glycolylneuraminic acid). In the case of Kdn, the hydroxy groups at C4, C5, C7, C8, and C9 may be free, esterified (acetylated, phosphorylated) or etherified (methylated). In Neu5Gc, the hydroxy group at C7 can be replaced by an acetamido group, yielding in fact another variant of Neu, with the full name of 7-acetamido-5-hydroxyacetamido-3,5,7-trideoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid, so far only found with one or two *O*-acetyl groups.Table 1Survey of Reported Structures of Naturally Occurring Members of the Sialic Acid Family[a](#tf0010){ref-type="table-fn"}Table 1NameAbbreviationReferencesNeuraminic acid[b](#tf0015){ref-type="table-fn"}Neu[@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105]Neuraminic acid 1,5-lactam[c](#tf0020){ref-type="table-fn"}Neu1,5lactam[@bb0105], [@bb0110]5-*N*-Acetyl-neuraminic acidNeu5Ac[@bb0035], [@bb0100], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170]5-*N*-Acetyl-4-*O*-acetyl-neuraminic acidNeu4,5Ac~2~[@bb0035], [@bb0100], [@bb0120], [@bb0125], [@bb0140], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175]5-*N*-Acetyl-7-*O*-acetyl-neuraminic acidNeu5,7Ac~2~[@bb0035], [@bb0100], [@bb0120], [@bb0125], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0180], [@bb0185], [@bb0190], [@bb9015], [@bb0195]5-*N*-Acetyl-8-*O*-acetyl-neuraminic acidNeu5,8Ac~2~[@bb0035], [@bb0100], [@bb0155], [@bb0165], [@bb0170], [@bb0190]5-*N*-Acetyl-9-*O*-acetyl-neuraminic acidNeu5,9Ac~2~[@bb0035], [@bb0100], [@bb0140], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0185], [@bb0190], [@bb0195], [@bb0200]5-*N*-Acetyl-4,9-di-*O*-acetyl-neuraminic acidNeu4,5,9Ac~3~[@bb0035], [@bb0100], [@bb0140], [@bb0155], [@bb0170]5-*N*-Acetyl-7,8-di-*O*-acetyl-neuraminic acid[d](#tf0025){ref-type="table-fn"}Neu5,7,8Ac~3~[@bb0180]5-*N*-Acetyl-7,9-di-*O*-acetyl-neuraminic acidNeu5,7,9Ac~3~[@bb0035], [@bb0100], [@bb0140], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0190], [@bb0195], [@bb9015], [@bb0205]5-*N*-Acetyl-8,9-di-*O*-acetyl-neuraminic acidNeu5,8,9Ac~3~[@bb0035], [@bb0100], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0190], [@bb0195], [@bb9015], [@bb0205]5-*N*-Acetyl-4,7,9-tri-*O*-acetyl-neuraminic acidNeu4,5,7,9Ac~4~[@bb0100]5-*N*-Acetyl-7,8,9-tri-*O*-acetyl-neuraminic acidNeu5,7,8,9Ac~4~[@bb0035], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0190]5-*N*-Acetyl-4,7,8,9-tetra-*O*-acetyl-neuraminic acidNeu4,5,7,8,9Ac~5~[@bb0100]5-*N*-Acetyl-4-*O*-glycolyl-neuraminic acidNeu5Ac4Gc[@bb0210]5-*N*-Acetyl-7-*O*-glycolyl-neuraminic acidNeu5Ac7Gc[@bb0210]5-*N*-Acetyl-9-*O*-lactyl-neuraminic acid[e](#tf0030){ref-type="table-fn"}Neu5Ac9Lt[@bb0035], [@bb0100], [@bb0155], [@bb0165], [@bb0170], [@bb0215], [@bb0220]5-*N*-Acetyl-4-*O*-acetyl-9-*O*-lactyl-neuraminic acidNeu4,5Ac~2~9Lt[@bb0035], [@bb0100], [@bb0155], [@bb0170], [@bb0225]5-*N*-Acetyl-7-*O*-acetyl-9-*O*-lactyl-neuraminic acidNeu5,7Ac~2~9Lt[@bb0100]5-*N*-Acetyl-8-*O*-acetyl-9-*O*-lactyl-neuraminic acidNeu5,8Ac~2~9Lt[@bb0230]5-*N*-Acetyl-8-*O*-methyl-neuraminic acidNeu5Ac8Me[@bb0035], [@bb0100], [@bb0130], [@bb0170], [@bb0235]5-*N*-Acetyl-4-*O*-acetyl-8-*O*-methyl-neuraminic acidNeu4,5Ac~2~8Me[@bb0100]5-*N*-Acetyl-9-*O*-acetyl-8-*O*-methyl-neuraminic acidNeu5,9Ac~2~8Me[@bb0035], [@bb0100], [@bb0170], [@bb0235]5-*N*-Acetyl-9-*O*-methyl-neuraminic acidNeu5Ac9Me[@bb0240]5-*N*-Acetyl-4-*O*-sulfo-neuraminic acidNeu5Ac4S[@bb0245]5-*N*-Acetyl-8-*O*-sulfo-neuraminic acidNeu5Ac8S[@bb0100], [@bb0165], [@bb0250], [@bb0255]5-*N*-Acetyl-4-*O*-acetyl-8-*O*-sulfo-neuraminic acidNeu4,5Ac~2~8S[@bb0100]5-*N*-Acetyl-9-*O*-phospho-neuraminic acid[f](#tf0035){ref-type="table-fn"}, [g](#tf0040){ref-type="table-fn"}Neu5Ac9P[@bb0260]5-*N*-Acetyl-2-deoxy-2,3-didehydro-neuraminic acid[g](#tf0040){ref-type="table-fn"}, [h](#tf0045){ref-type="table-fn"}Neu2en5Ac[@bb0035], [@bb0155], [@bb0170], [@bb0220], [@bb0265], [@bb0270], [@bb0275]5-*N*-Acetyl-9-*O*-acetyl-2-deoxy-2,3-didehydro-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2en5,9Ac~2~[@bb0280], [@bb0285]5-*N*-Acetyl-2-deoxy-2,3-didehydro-9-*O*-lactyl-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2en5Ac9Lt[@bb0280], [@bb0285]5-*N*-Acetyl-2,7-anhydro-neuraminic acid[g](#tf0040){ref-type="table-fn"}, [i](#tf0050){ref-type="table-fn"}Neu2,7an5Ac[@bb0035], [@bb0170], [@bb0280], [@bb0290], [@bb0295]5-*N*-Acetyl-4,8-anhydro-neuraminic acid[j](#tf0055){ref-type="table-fn"}Neu4,8an5Ac[@bb0160], [@bb0165], [@bb0300], [@bb0305]5-*N*-Acetyl-neuraminic acid 1,7-lactoneNeu5Ac1,7lactone[@bb0100], [@bb0310], [@bb0315]5-*N*-Acetyl-9-*O*-acetyl-neuraminic acid 1,7-lactoneNeu5,9Ac~2~1,7lactone[@bb0100]5-*N*-Acetyl-4,9-di-*O*-acetyl-neuraminic acid 1,7-lactoneNeu4,5,9Ac~3~1,7lactone[@bb0100]1-Tauryl 5-*N*-acetyl-neuraminic amideNeu5Ac1Tau[@bb0320]5-*N*-Glycolyl-neuraminic acidNeu5Gc[@bb0035], [@bb0100], [@bb0120], [@bb0135], [@bb0140], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0325], [@bb0330], [@bb0335]4-*O*-Acetyl-5-*N*-glycolyl-neuraminic acidNeu4Ac5Gc[@bb0035], [@bb0140], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0210]7-*O*-Acetyl-5-*N*-glycolyl-neuraminic acidNeu7Ac5Gc[@bb0035], [@bb0155], [@bb0165], [@bb0170], [@bb0190]8-*O*-Acetyl-5-*N*-glycolyl-neuraminic acidNeu8Ac5Gc[@bb0165], [@bb0280]9-*O*-Acetyl-5-*N*-glycolyl-neuraminic acidNeu9Ac5Gc[@bb0035], [@bb0100], [@bb0140], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0190]4,7-Di-*O*-acetyl-5-*N*-glycolyl-neuraminic acidNeu4,7Ac~2~5Gc[@bb0100]4,9-Di-*O*-acetyl-5-*N*-glycolyl-neuraminic acidNeu4,9Ac~2~5Gc[@bb0100]7,9-Di-*O*-acetyl-5-*N*-glycolyl-neuraminic acid[k](#tf0060){ref-type="table-fn"}Neu7,9Ac~2~5Gc[@bb0035], [@bb0100], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0190]8,9-Di-*O*-acetyl-5-*N*-glycolyl-neuraminic acidNeu8,9Ac~2~5Gc[@bb0035], [@bb0100], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0190]4,7,9-Tri-*O*-acetyl-5-*N*-glycolyl-neuraminic acidNeu4,7,9Ac~3~5Gc[@bb0100]7,8,9-Tri-*O*-acetyl-5-*N*-glycolyl-neuraminic acidNeu7,8,9Ac~3~5Gc[@bb0035], [@bb0155], [@bb0160], [@bb0170], [@bb0190]4,7,8,9-Tetra-*O*-acetyl-5-*N*-glycolyl-neuraminic acidNeu4,7,8,9Ac~4~5Gc[@bb0100]5-*N*-Glycolyl-9-*O*-lactyl-neuraminic acidNeu5Gc9Lt[@bb0100], [@bb0165], [@bb0280]4-*O*-Acetyl-5-*N*-glycolyl-9-*O*-lactyl-neuraminic acidNeu4Ac5Gc9Lt[@bb0100]7-*O*-Acetyl-5-*N*-glycolyl-9-*O*-lactyl-neuraminic acidNeu7Ac5Gc9Lt[@bb0100]8-*O*-Acetyl-5-*N*-glycolyl-9-*O*-lactyl-neuraminic acidNeu8Ac5Gc9Lt[@bb0100]4,7-Di-*O*-acetyl-5-*N*-glycolyl-9-*O*-lactyl-neuraminic acidNeu4,7Ac~2~5Gc9Lt[@bb0100]7,8-Di-*O*-acetyl-5-*N*-glycolyl-9-*O*-lactyl-neuraminic acidNeu7,8Ac~2~5Gc9Lt[@bb0100]5-*N*-Glycolyl-8-*O*-methyl-neuraminic acid[l](#tf0065){ref-type="table-fn"}Neu5Gc8Me[@bb0035], [@bb0160], [@bb0165], [@bb0170], [@bb0235], [@bb0340], [@bb0345]4-*O*-Acetyl-5-*N*-glycolyl-8-*O*-methyl-neuraminic acidNeu4Ac5Gc8Me[@bb0350]7-*O*-Acetyl-5-*N*-glycolyl-8-*O*-methyl-neuraminic acidNeu7Ac5Gc8Me[@bb0165], [@bb0350]9-*O*-Acetyl-5-*N*-glycolyl-8-*O*-methyl-neuraminic acidNeu9Ac5Gc8Me[@bb0035], [@bb0160], [@bb0165], [@bb0170], [@bb0235], [@bb0280]4,7-Di-*O*-acetyl-5-*N*-glycolyl-8-*O*-methyl-neuraminic acidNeu4,7Ac~2~5Gc8Me[@bb0350]7,9-Di-*O*-acetyl-5-*N*-glycolyl-8-*O*-methyl-neuraminic acidNeu7,9Ac~2~5Gc8Me[@bb0160]5-*N*-Glycolyl-9-*O*-methyl-neuraminic acidNeu5Gc9Me[@bb0240], [@bb0355]5-*N*-Glycolyl-8-*O*-sulfo-neuraminic acidNeu5Gc8S[@bb0100], [@bb0165], [@bb0250], [@bb0360]5-*N*-Glycolyl-9-*O*-sulfo-neuraminic acidNeu5Gc9S[@bb0365]5-*N*-(*O*-Acetyl)glycolyl-neuraminic acidNeu5GcAc[@bb0035], [@bb0170], [@bb0370]5-*N*-(*O*-Methyl)glycolyl-neuraminic acidNeu5GcMe[@bb0375]2-Deoxy-2,3-didehydro-5-*N*-glycolyl-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2en5Gc[@bb0035], [@bb0170], [@bb0285], [@bb0380]9-*O*-Acetyl-2-deoxy-2,3-didehydro-5-*N*-glycolyl-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2en9Ac5Gc[@bb0285]2-Deoxy-2,3-didehydro-5-*N*-glycolyl-9-*O*-lactyl-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2en5Gc9Lt[@bb0280], [@bb0285]2-Deoxy-2,3-didehydro-5-*N*-glycolyl-8-*O*-methyl-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2en5Gc8Me[@bb0280]2,7-Anhydro-5-*N*-glycolyl-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2,7an5Gc[@bb0170], [@bb0280], [@bb0295]2,7-Anhydro-5-*N*-glycolyl-8-*O*-methyl-neuraminic acid[g](#tf0040){ref-type="table-fn"}Neu2,7an5Gc8Me[@bb0280]4,8-Anhydro-5-*N*-glycolyl-neuraminic acid[j](#tf0055){ref-type="table-fn"}Neu4,8an5Gc[@bb0165]5-*N*-Glycolyl-neuraminic acid 1,7-lactoneNeu5Gc1,7lactone[@bb0100]9-*O*-Acetyl-5-*N*-glycolyl-neuraminic acid 1,7-lactoneNeu9Ac5Gc1,7lactone[@bb0100]7-Acetamido-9-*O*-acetyl-7-deoxy-5-*N*-glycolyl-neuraminic acidNeu9Ac5Gc7NAc[@bb0100]7-Acetamido-8,9-di-*O*-acetyl-7-deoxy-5-*N*-glycolyl-neuraminic acid[m](#tf0070){ref-type="table-fn"}Neu8,9Ac~2~5Gc7NAc[@bb0100]2-Keto-3-deoxy-nononic acidKdn[@bb0100], [@bb0165], [@bb0385], [@bb0390], [@bb0395]5-*O*-Acetyl-2-keto-3-deoxy-nononic acidKdn5Ac[@bb0100], [@bb0165]7-*O*-Acetyl-2-keto-3-deoxy-nononic acidKdn7Ac[@bb0100], [@bb0165]8-*O*-Acetyl-2-keto-3-deoxy-nononic acidKdn8Ac[@bb0400]9-*O*-Acetyl-2-keto-3-deoxy-nononic acidKdn9Ac[@bb0100], [@bb0165], [@bb0405], [@bb0410]4,5-Di-*O*-acetyl-2-keto-3-deoxy-nononic acidKdn4,5Ac~2~[@bb0100]4,7-Di-*O*-acetyl-2-keto-3-deoxy-nononic acidKdn4,7Ac~2~[@bb0100]5,9-Di-*O*-acetyl-2-keto-3-deoxy-nononic acidKdn5,9Ac~2~[@bb0165]7,9-Di-*O*-acetyl-2-keto-3-deoxy-nononic acidKdn7,9Ac~2~[@bb0100], [@bb0165]8,9-Di-*O*-acetyl-2-keto-3-deoxy-nononic acidKdn8,9Ac~2~[@bb0100]2-Keto-3-deoxy-5-*O*-methyl-nononic acidKdn5Me[@bb0415]2-Keto-3-deoxy-9-*O*-phospho-nononic acid[g](#tf0040){ref-type="table-fn"}, [n](#tf0075){ref-type="table-fn"}Kdn9P[@bb0420][^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15]Fig. 3Chemical structures of (A) Neu1,5lactam (^5,2^*B* conformation), (B) Neu2en5Ac (^4^*H*~5~ conformation), (C) CMP-β-Neu5Ac, (D) Neu2,7an5Ac (^5^*C*~2~ conformation), (E) Neu5Ac1,7lactone (^5^*C*~2~ conformation), and (F) Neu4,8an5Ac (^7^*C*~4~ conformation; two tautomers).Fig. 3

This chapter will review the fascinating story of the isolation and structural elucidation of the sialic acids and their importance as biological molecules in a historical perspective. It will describe how the founders of the sialic acid field since the mid-1930s, over a period of more than 20 years, were struggling with the chemical structure of these molecules in a period in which mass spectrometry and NMR spectroscopy did not exist. And it will show how sialic acid constituents of glycoproteins, glycolipids, oligosaccharides, and polysaccharides have grown to be considered biologically and medically highly essential factors of the daily life on earth.

Although not discussed in biological and medical detail in this chapter, also the expansion of the more recently well-established "sialic acid-like" subclasses of the superfamily of NulOs, namely, the 5,7-diamino-3,5,7,9-tetradeoxynon-2-ulosonic acids, with the mother molecules pseudaminic acid (Pse), legionaminic acid (Leg), 4-*epi*-legionaminic acid (4eLeg), 8-*epi*-legionaminic acid (8eLeg), acinetaminic acid (Aci), and 8-*epi*-acinetaminic acid (8eAci), so far exclusively found in bacterial polysaccharides and glycoproteins, will be subjects of a limited review.

Over the years several books[@bb0445], [@bb0450], [@bb0455], [@bb0460], [@bb0465], [@bb0470], [@bb0475], [@bb0480] and book chapters (e.g., refs. [@bb0035] and [@bb0485], [@bb0490], [@bb0495], [@bb0500], [@bb0505], [@bb0510], [@bb0515], [@bb0520], [@bb0525], [@bb0530], [@bb0535], [@bb0540], [@bb0545], [@bb0550], [@bb0555], [@bb0560], [@bb0565], [@bb0570], [@bb0575]) dealing with the progress in the fields of sialic acid chemistry, biology, medicine, and food science have been published, as well as a number of reviews in scientific journals (e.g., refs. [@bb0040], [@bb0120], and [@bb0040], [@bb0120], [@bb0580], [@bb0585], [@bb0590], [@bb0595], [@bb0600], [@bb0605], [@bb0610], [@bb0615], [@bb0620], [@bb0625], [@bb0630], [@bb0635], [@bb0640], [@bb0645], [@bb0650], [@bb0655], [@bb0660], [@bb0665], [@bb0670], [@bb0675], [@bb0680], [@bb0685], [@bb0690], [@bb0695], [@bb0700], [@bb0705], [@bb0710], [@bb0715], [@bb0720], [@bb0725], [@bb0730], [@bb0735], [@bb0740]) (additional review references are included in the specific sections), but no updated review in a historic perspective about this strongly growing field is available. It is therefore our intention to describe the historical development of the multifaceted sialochemistry/biology field and throw some light also on its present state and future.

2. Paving the Way With Ehrlich\'s Aldehyde and Bial\'s Orcinol Reagents {#s0015}
=======================================================================

It was in 1877, more than 140 years ago, that the German scientist Hoppe-Seyler (1825--1895) described a substance released from epithelial mucins by mild acid treatment at elevated temperature as an acidic compound, being stronger than carbonic acid. When heated under alkaline conditions, the solution turned brown. The compound reduced cupric oxide or bismuth oxide or indigosulfuric acid, contained nitrogen, and was unfermentable by brewer\'s yeast. Its purification was a continual problem.[@bb0745] Similar observations were made by Hoppe-Seyler,[@bb0750] Green,[@bb0755] Krukenberg,[@bb0760] and Zeller,[@bb0765] when investigating the mild acid-released material from nests of Asian swiftlets (genus *Collocalia*). For the construction of their nests, these birds use mucin secreted by their salivary glands. The bird\'s nests are edible and are used in several nutritional and medicinal applications."Interestingly, Green claimed the formation of crystals of sugar from the released material, a claim that could not be confirmed by Zeller. Citation of Zeller: "Apparently, Green has inorganic material considered as sugar" (translated from the German)."

Many years later, collocalia mucin would form an excellent source for the isolation of gram quantities of *N*-acetylneuraminic acid, simply by boiling pulverized edible bird\'s nest under reflux for 5 h.[@bb0770], [@bb0775]

In 1898, Ehrlich in Germany observed the formation of a purple color after heating mucins with *p*-dimethylaminobenzaldehyde in acid solution.[@bb0780], [@bb0785] In the same year, Müller in Germany also described the formation of a splendid red color when mucus substances, made alkaline and heated slightly, were incubated with acidic *p*-dimethylaminobenzaldehyde at higher temperature.[@bb0790] Although initially the mixture of *p*-dimethylaminobenzaldehyde in 50% (v/v) HCl, called Ehrlich\'s reagent, was frequently applied for the detection of indoles, pyrroles, and related nitrogen-containing compounds, this reaction was going to play an important role in the unraveling of the structure of sialic acids. It turned out that incubation of the newly discovered components, in bound and free form, with Ehrlich\'s reagent before ("direct" Ehrlich) and after ("indirect" Ehrlich) treatment with alkali yielded a red--violet color (see [Section 7.1](#s0100){ref-type="sec"}).

Later, in 1927, Walz in Germany and Levine and Landsteiner in the United States reported that on heating isolated lipid material of bovine spleen,[@bb0795] or equine kidney/bovine kidney/bovine brain,[@bb0800] respectively, with orcinol in hydrochloric acid containing ferric chloride[@bb0795] or copper acetate,[@bb0800] a red--violet color was formed. In fact, the orcinol/concd. HCl/FeCl~3~ mixture, introduced in 1902 by Bial[@bb0805] and later called Bial\'s reagent, was used as a general test for the presence of carbohydrates. A pentose is dehydrated with concd. acid to form furfural, which condenses with orcinol to a product that gives in the presence of ferric ions a bluish-green color. With hexoses, whereby 5-hydroxymethylfurfural is formed, a yellow--brown color is seen. So, the observed red--violet/purple color was quite unusual (see [Section 7.1](#s0100){ref-type="sec"}).

2.1. The First Scoutings {#s0020}
------------------------

The research groups who made the first steps in the discovery and isolation of sialic acids were located in different countries around the world: Gunnar Blix[@bb0810] ([Fig. 4](#f0025){ref-type="fig"}A) and coworkers at the University of Uppsala (Sweden); Ernst Klenk[@bb0815] ([Fig. 4](#f0025){ref-type="fig"}B) and coworkers at the University of Tübingen and the University of Cologne (Germany); and Alfred Gottschalk[@bb0820], [@bb0825] ([Fig. 4](#f0025){ref-type="fig"}C) and coworkers at the Walter and Eliza Hall Institute in Melbourne (Australia) and the Max-Planck-Institute for Virology in Tübingen (Germany). Interestingly, materials from completely different biological sources played an important role in their journeys of exploration.Fig. 4(A) Gunnar Blix (1894--1981), (B) Ernst Klenk (1896--1971), (C) Alfred Gottschalk (1894--1973)*.*Fig. 4Panel (A): Reprinted from Lundblad, A. Gunnar Blix and His Discovery of Sialic Acids---Fascinating Molecules in Glycobiology. *Upsala J. Med. Sci.***2015**, *120*, 104--112. With permission of the Board. Panel (B): Photo courtesy of Prof. Dr. Hans-Dieter Klenk. Panel (C): Photo courtesy of one of the authors (R.S.).

In 1936 Blix reported the isolation of a strongly acidic compound from a boiling water solution of bovine submaxillary gland mucin, that he called "**Kohlenhydrat I**."[@bb0830] The compound, generated via autohydrolysis and obtained in crystalline form, had reducing power. Elemental analyses yielded C~14~H~24~NO~11~ as the preferred chemical formula. Microacetyl determinations suggested the presence of two acetyl groups in one molecule, whereas a negative ninhydrin reaction supposed the presence of one *N*-acetyl group. The product had an mp of 140--150°C (dec.). UV spectroscopy showed the absence of ethylene bonds. The compound turned out to be very sensitive to heating with dilute mineral acid, giving rise to dark humin formation. When heated with Ehrlich\'s reagent, both with and without alkali pretreatment, an intense red--violet color was formed. Taking into account these and later observations, **a disaccharide structure composed of an N-acetylated hexosamine part and a polyhydroxy acid part with six carbon atoms, being not a hexuronic acid**, was suggested (note that hexosamine was not isolated from the substance).[@bb0830], [@bb0835], [@bb0840] An initial suggestion that the hexosamine part should be chondrosamine (galactosamine)[@bb0835] was withdrawn when chondrosamine was isolated, separated from "Kohlenhydrat I," and it was stated that both compounds were "probably bound with an easily split linkage."[@bb0840] An additional earlier suggestion was that the polyhydroxy acid could be a deoxy-hexuronic acid.[@bb0845] Because of the salivary origin of "Kohlenhydrat I" (the Greek name for saliva is "sialon"), Blix called the compound "**sialic acid**."[@bb0840]

In further studies, Blix found that the so-called \"protagon" lipid fraction of bovine brain tissue gave similar Ehrlich\'s and Bial\'s color reactions as found for the mucin-derived compound.[@bb0845] A few years earlier, a red color with Bial\'s reagent had already been mentioned by Klenk for lipid material of the human brain,[@bb0850] and the isolation of a nitrogen-containing organic acid in crystalline form, called "**neuraminic acid**" (related to the source: neurons), followed in 1941.[@bb0855] Because of the observed lability in acidic medium, leading to dark humin formation, a methanolic-HCl release protocol was chosen. So, the lipid material was treated with 5% methanolic HCl (3 h, 105°C), and the released substance was converted, via its barium salt, into the free acid {elemental analysis: preferred chemical formula C~11~H~21~NO~9~; \[α\]^20^ ~D~ −54.9° (*c* 3.2, H~2~O)}. A positive ninhydrin reaction indicated a free amino group, whereas reducing power was not detected. The Bial and Ehrlich colorimetric assays were both strongly positive. Protocols directed to the detection of a hexosamine part in "neuraminic acid" were negative, and a suggestion for **an aliphatic polyoxy-aminodicarboxylic acid** structure was made. When Klenk realized that the isolated substance contained a methoxy group, introduced during the methanolic-HCl treatment (in the 1950s proved with ^14^C-labeled CH~3~OH[@bb0860]), he renamed "neuraminic acid" as "**methoxyneuraminic acid**" and kept the name "**neuraminic acid**" for the compound with chemical formula C~10~H~19~NO~9~ (  000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000  C~11~H~21~NO~9~ − CH~2~).[@bb0865] Then, "neuraminic acid" might contain a reactive carbonyl function, which enabled the formation of a glycosidic linkage with other monosaccharides. In the latter study, the term "ganglioside" was introduced for brain glycolipids containing "neuraminic acid."

Besides scientific interest from the mucin and brain glycolipid research areas for these new, but still unknown compounds, an interesting new angle of incidence came from the virology field. At the end of the 1940s, Burnet reported that the ability of various mucoproteins (i.e., serum mucoprotein, ovarian cyst mucoid, chorionic gonadotropin) to act as competitive inhibitors for hemagglutination by heated influenza B virus was lost after pretreatment of the mucoproteins with active virus.[@bb0870] Then, Gottschalk and Lind found that incubation of the Melbourne strain of influenza A virus with ovomucin, a protein fraction containing a strong virus hemagglutinin inhibitor, yielded a water-soluble, nitrogen-containing compound with reducing power, that gave, after alkaline treatment, with Ehrlich\'s reagent, a purple color; furthermore, the Molisch carbohydrate test (concd. H~2~SO~4~, α-naphthol) was strongly positive.[@bb0875] Acid treatment resulted in black insoluble humin formation. Incubation of ovomucin with a *Vibrio cholerae* filtrate yielded a substance with similar properties.[@bb0880] In these years, the enzyme-like agent in the filtrates was called "receptor-destroying enzyme" (RDE) (see [Section 11.7](#s0220){ref-type="sec"}). Based on the results so far, the enzymatic liberation of a "**carbohydrate--peptide complex**" was suggested, and it was stated that the carbohydrate moiety should be "**an oligosaccharide containing one or more** ***N*** **-acyl (acetyl) hexosamine residues linked by an alkali-labile glycosidic linkage to a non-amino-sugar**." Two years later, Gottschalk repeated the incubation experiments with human urinary mucoprotein[@bb0885] and influenza B virus and suggested now that the released compound should be an "**N-substituted** ***iso*** **glucosamine**" (a fructosamine; an *N*-1-deoxy-1-ketose amino acid or peptide).[@bb0890] Interestingly, the presence of a keto function was indicated by a positive Seliwanoff resorcinol/concd. HCl test, an assay whereby ketoses, in contrast to aldoses, rapidly give a red color (ketoses are more rapidly dehydrated than aldoses with concd. acid)."In 1975, Blix described in a letter to Klaus Störiko (Behringwerke AG, Marburg, Germany) about his first contact with Gottschalk: "... I recall how I at the first international biochemist congress in Cambridge 1949 talked with Stacey and Gottschalk, when the latter described the general properties of the carbohydrate component in mucins that inhibited virus haemagglutination and asked for advice from Stacey. It struck me immediately that some of the properties Gottschalk mentioned strongly reminded me about those of sialic acid. When I got home I mailed Gottschalk what we had written about sialic acid and told him that we intended to test the matter closer. Gottschalk obviously did not, at this time, know about sialic acid, which outside Cologne and Uppsala still was of low interest. I had on my part limited knowledge about Burnet\'s investigations. We agreed later on to study in each of our laboratories the carbohydrate component in the well defined Tamm--Horsfall urinary protein and to publish our results in 1952 simultaneously in *Nature* ..." (from the archive of Blix\'s scientific correspondence, available at Uppsala University Library).[@bb0810]"

2.2. The Growing Knowledge About the Substance {#s0025}
----------------------------------------------

At the beginning of the 1950s, in their search for more structural details and to elucidate contrasting results, several overlapping studies were published by the Uppsala, Cologne, and Melbourne groups. Step by step the structural relationship among Blix\'s "sialic acid," Klenk\'s "neuraminic acid"/"methoxyneuraminic acid," and Gottschalk\'s "N-substituted *iso*glucosamine" was growing. Of course, it was also a period of close competition, reflected by several relatively short communications. But, although critical comments on each other\'s work can be picked up from the literature reports, the groups were also in good contact with each other, exchanging information when necessary.

To start with, Odin (Uppsala group)[@bb0895] suggested in a paper published in parallel with Gottschalk\'s paper about the monosaccharide constituents of human urinary mucoprotein[@bb0900] the close chemical relationship between Gottschalk\'s "N-substituted *iso*glucosamine" and Blix\'s "sialic acid.""Earlier, the Uppsala group had stated that Klenk\'s "neuraminic acid" "is probably to be regarded as a degradation product of the native disaccharide compound" (the suggested structure by Blix, composed of an N-acetylated hexosamine part and a polyhydroxy acid part with six carbon atoms).[@bb0835] However, this conclusion was contradicted by Klenk, saying that, based on further research, "there is no reason to doubt that "neuraminic acid" is a native residue of gangliosides" (translated from the German).[@bb0905] So, it was not a hexosamine-containing cleavage product."

In further work, the Uppsala group reported the occurrence of "sialic acid" in many biological sources, i.e., egg white, ovomucin, allantoic fluid, ovarian cysts, bovine follicular fluid, cancer fluid, blood serum, plasma glycoproteins, human tears, bovine milk, epithelial mucins, human saliva, meconium, and gangliosides.[@bb0895], [@bb0910], [@bb0915], [@bb0920], [@bb0925], [@bb0930], [@bb0935]

In the same period, the Cologne group prepared "methoxyneuraminic acid" from bovine submaxillary gland mucin and human urinary mucoprotein,[@bb0940] following their earlier applied protocol[@bb0855] for gangliosides. In subsequent investigations, heating of an aqueous bovine submaxillary gland mucin preparation (2 h, 110°C) yielded, after isolation, a crystalline material with a chemical formula of C~12~H~21~NO~10~ and \[α\]^20^ ~D~ −31.7° (*c* 2.6, H~2~O) that they called "***N*** **-acetylneuraminic acid**."[@bb0115] The various chemical reactions, carried out earlier on "sialic acid," gave similar results for "*N*-acetylneuraminic acid" (Ehrlich and Bial reaction: red color; reducing power: positive; ninhydrin reaction: negative), except that "*N*-acetylneuraminic acid" contained only one acetyl group. Treatment of "*N*-acetylneuraminic acid" with 40% NaOH (2 h, 100°C) yielded pyrrole-2-carboxylic acid, a product identified 1 year earlier by Gottschalk[@bb0945] in an alkaline hydrolysate of bovine submaxillary gland mucin (see [Section 3](#s0035){ref-type="sec"}). In additional studies, crystalline "*N*-acetylneuraminic acid" (C~12~H~21~NO~10~) could be obtained from enzymatic incubations of human urinary mucoprotein with influenza virus B-Lee,[@bb0950] and of human urinary mucoprotein and bovine submandibular gland mucin with the RDE from *V. cholerae*.[@bb0955] It was concluded that both the influenza virus and the RDE are acting as O-glycosidases. Following the methanolyis protocol,[@bb0855] crystalline "methoxyneuraminic acid" (neuraminic acid methyl glycoside: C~11~H~21~NO~9~) could be isolated from porcine and equine submaxillary gland mucin and bovine colostrum mucin,[@bb0960] from amyloidose liver,[@bb0965] from fetuin,[@bb0970] and from bovine stroma protein.[@bb0975] "The paper of Klenk and Uhlenbruck[@bb0960] gives a clear insight into the competition between Klenk ("neuraminic acid") and Blix ("sialic acid") in the slowly developing field. At the end of a long criticism in a footnote (we write 1956), Klenk ends with "As long as the information provided by Blix can not be confirmed by other sources, it must be doubted that a chemically well-defined, uniform compound has been presented here" (translated from the German)."

In these years, besides color reactions, elemental analyses, and optical rotations, IR spectroscopy and X-ray analysis were introduced as helpful techniques in comparing different isolates. As an illustration of the application of IR spectroscopy, in [Fig. 5](#f0030){ref-type="fig"} the IR spectra of enzymatically and chemically released "*N*-acetylneuraminic acid" are depicted (indications for carboxyl and amide groups).[@bb0955] Fig. 5IR spectra of "*N*-acetylneuraminic acid," enzymatically released (*V. cholerae*) from (1) human urinary mucoprotein, (2) bovine submaxillary gland mucin (crystallization fraction I), and (3) bovine submaxillary gland mucin (crystallization fraction II), and chemically released from (4) bovine submaxillary gland mucin.Fig. 5Reproduced from Faillard, H. Über die Abspaltung von *N*-Acetyl-neuraminsäure aus Mucinen durch das "Receptor-Destroying-Enzyme" aus *Vibrio cholerae. Hoppe-Seyler's Z. Physiol. Chem.***1957**, *307*, 62--86/*308*, 187. Copyright De Gruyter Publishers.

Further studies of the Uppsala group focused on bovine, porcine, ovine, and equine submaxillary gland mucins.[@bb0120], [@bb0980] Crystalline "sialic acids" were generated via hydrolytic protocols (1 h, 100°C; pH 3.5--4.0). An overview of some physical parameters (elemental analysis, optical rotation, decomposition range, type of N- and O-substituents, the number of hydroxyl functions) is presented in [Table 2](#t0015){ref-type="table"} . The chemical formulas for "methoxyneuraminic acid," isolated from the mucins and purified "sialic acids" following the methanolic HCl protocol of Klenk, were found to be C~10~H~19~NO~8~ (preferred) or C~11~H~21~NO~9~, being the composition earlier reported by Klenk.[@bb0855] Both the Blix and Klenk "methoxyneuraminic acid" samples showed the same X-ray powder patterns. Bial\'s and Ehrlich\'s reactions gave red--violet and red--purple colors for all four "sialic acids," respectively. As the "sialic acids" can be reduced with sodium borohydride and subsequent hydrolysis did not produce a reducing substance, whereas the Bial and Ehrlich tests on the reduced compounds were negative, it was stated that, in contrast to earlier conclusions of the Uppsala group,[@bb0830] this almost excludes the presence of a glycosidic linkage in "sialic acid." Quantitative determination of hydroxy groups (via an O-acetylation/NaOH titration protocol) showed the presence of five hydroxy groups for the ovine preparation and six hydroxy groups for the porcine preparation. Amino-group determinations revealed the absence of significant amounts of amino nitrogen, so amino groups are substituted. Periodate studies on bovine "sialic acid" showed the consumption of 1 mol of periodate and no formic acid production (CH~2~OH--CHOH--CHOAc-- element), whereas the periodate consumptions for the porcine and ovine "sialic acids" were 2 mol of periodate (CH~2~OH--CHOH--CHOH-- element) and 1 mol of formic acid formation; in all cases 1 mol of formaldehyde was found. As shown in [Table 2](#t0015){ref-type="table"}, the isolated porcine "sialic acid" contained an *N*-glycolyl group, a result confirmed one year later by the Cologne group. Here, "***N*** **-glycolylneuraminic acid**" was chemically and enzymatically released from porcine submaxillary gland mucin, and a colorimetric method for the quantitative determination of glycolic acid was developed.[@bb0325] See also ref. [@bb0985]. For further discussions on the structure of the presented "sialic acids," see [Section 3](#s0035){ref-type="sec"}. To give an impression of the use of X-ray powder diffraction analysis for comparison purposes, [Fig. 6](#f0035){ref-type="fig"} illustrates the diagrams of various "sialic acids."Table 2Some Physical Parameters of Crystalline "Sialic Acids" Isolated From Bovine, Porcine, Ovine, and Equine Submaxillary Gland Mucins[@bb0120]Table 2Mucin SourceElemental Analysis[a](#tf0080){ref-type="table-fn"}\[α\]^20^~D~ (5%, H~2~O)Decomposition Range (°C)*N*,*O*-Acyl Groups[b](#tf0085){ref-type="table-fn"}Hydroxy GroupsBovine[c](#tf0090){ref-type="table-fn"}C~13~H~21~NO~10~+ 8° ± 2°134--137NAc, OAcn.a.OvineC~11~H~19~NO~9~− 31° ± 2°185--187NAc5PorcineC~11~H~19~NO~10~− 32° ± 2°185--187NGc6Equine[c](#tf0090){ref-type="table-fn"}C~13~H~21~NO~10~− 59° ± 2°183--187NAc, OAcn.a.[^16][^17][^18][^19]Fig. 6X-ray powder diagrams of "sialic acid" isolated from submaxillary gland mucins \[(A) bovine, (B) ovine, (C) porcine, (D) equine\] and "methoxyneuraminic acid" (E). Guinier camera. Nickel-filtered copper K-radiation.Fig. 6Reproduced from Blix, G.; Lindberg, E.; Odin, L.; Werner, I. Studies on Sialic Acids. *Acta Soc. Med. Upsalien*. **1956**, *61*, 1--25. With permission of the Board.

2.3. The Expanding Network of Researchers {#s0030}
-----------------------------------------

Parallel to the research activities of the Uppsala, Cologne, and Melbourne groups, in the 1950s other reports with information about the existence of such Bial\'s and Ehrlich\'s reagent-positive products also appeared. In this context, among others, the groups of Tamio Yamakawa[@bb0990] and coworkers at the University of Tokyo (Japan), Richard Kuhn[@bb0995] and coworkers at the Max-Planck-Institute in Heidelberg (Germany), and Paul György[@bb1000] and coworkers at the University of Pennsylvania in Philadelphia (USA) should be mentioned.

In 1951, Yamakawa and Suzuki reported the isolation of an unknown crystalline nitrogen-containing polyhydroxy-carboxylic acid (elemental analysis: C~10~H~19~NO~8~) from a methanolysate (8% methanolic HCl, 3 h, 100°C; work-up via a barium salt and treatment with diluted H~2~SO~4~) of an equine blood stroma glycolipid. The glycolipid was called "hematoside" and the released compound "**hemataminic acid**."[@bb1005] Both substances gave a red color with Bial\'s and Ehrlich\'s reagents. The ninhydrin test for "hemataminic acid" was positive only in the presence of a trace of alkali. After acid hydrolysis the reducing power changed from negative to positive. As "hemataminic acid" (\[α\]^20^ ~D~ −54.2°) was suspected to be a methyl glycoside (and suggested to correspond with Klenk\'s "methoxyneuraminic acid," \[α\]^20^ ~D~ −54.9°,[@bb0855] the hypothetical free compound should have the chemical formula C~9~H~17~NO~8~; it was called "**prehemataminic acid**," described as **a 2-amino-2-deoxy-nonuronic acid** (corresponding with Klenk\'s "neuraminic acid") (for a proposal of the structure, see [Section 3](#s0035){ref-type="sec"}).[@bb1010] "Here, a citation of Yamakawa and Suzuki[@bb1010] illustrates the initial controversy with respect to "neuraminic acid" vs "hemataminic acid": "According to a private communication from Dr. Klenk, which we received some days ago, he found chondrosamine in his preparation of ganglioside, and maintained that his 'neuraminic acid' gave, contrary to our '**hemataminic acid**', no reducing hydrolysate after cleavage with hydrochloric acid. For this reason, he was doubtful of the identity of these two substances." However, in the same year, after having analyzed the same material, Klenk withdrew his doubts by saying: "The "prehemataminic acid" occurring therein as a characteristic building block is identical with "neuraminic acid"" (translated from the German).[@bb1015]"

From a hydrolysate of equine serum mucoprotein (pH 1--2, 1 h, 80°C), a similar crystalline compound could be isolated that was called "**sero-lactaminic acid**."[@bb1020]

In another investigation by Kuhn et al., acid hydrolysis (pH 1, 40 min, 70--80°C) of a mucoprotein fraction of bovine colostrum afforded, after work-up (use of methanol), a low-molecular-mass ninhydrin-negative product, that they called the **methoxy derivative of** "**lactaminic acid**."[@bb1025] The crystalline material had similar Ehrlich and Bial colorimetric properties as reported for "sialic acid" and "methoxyneuraminic acid." However, the paper chromatographic *R* ~f~ values of the methoxy derivative of "lactaminic acid" in two solvent systems were different from that of "methoxyneuraminic acid." In a subsequent paper, the notation methoxy derivative of "lactaminic acid" was reformulated as "**lactaminic acid methyl ester**" (de-esterification with alkali).[@bb1030] Furthermore, "**lactaminic acid**" (C~11~H~19~NO~9~; mp 183--185°C with decomposition; \[α\]^21^ ~D~ −31.0°, *c* 1, H~2~O)[@bb1035] was established to be identical with Blix\'s ovine "sialic acid."[@bb0120] The same conclusion was drawn by Faillard for "lactaminic acid" in relation to *N*-acetylneuraminic acid.[@bb0955] In further screening studies for low-molecular-mass compounds in bovine milk, human milk, and bovine, human, ovine, caprine, and porcine colostrum, thereby demonstrating the presence of Ehrlich- and Bial-positive materials, the Heidelberg group isolated an oligosaccharide from bovine colostrum, which turned out to be *O*-acetyl-lactaminic acid-lactose.[@bb1030], [@bb1040]

György and coworkers reported that nondialyzable preparations of human milk afforded red colors with Bial\'s and Ehrlich\'s reagents,[@bb1045] and similarities with "sialic acid" and "neuraminic acid" were suggested. The methanolic-HCl protocol was followed to prepare crystalline "methoxyneuraminic acid" {\[α\]^20^ ~D~ −49.5° (*c* 3.3, H~2~O); elemental analysis: C~11~H~21~NO~9~}. In additional reports, a milk oligosaccharide fraction was hydrolyzed under mild conditions (pH 1, 2 h, 80°C), and subsequent work-up, including ion-exchange chromatography, yielded an anhydrous product in crystalline form (no use of methanol), that was called "**gynaminic acid**," a name that referred to human milk.[@bb1050], [@bb1055] The final substance[@bb1055] was published with the following analytical parameters: elemental analysis, C~11~H~19~NO~9~; \[α\]^25^ ~D~ −32.1° (*c* 2, H~2~O); mp 176--177°C (dec.); positive with Bial\'s and Ehrlich\'s reagents; negative with ninhydrin reagent; presence of acetyl group; absence of methoxy group; consumption of 2 mol of periodate; four acetylizable hydroxy groups. In a similar way, "gynaminic acid" was isolated from human meconium. The X-ray powder diagrams of "gynaminic acid" were identical with that of "sialic acid," isolated by the Uppsala group from ovine submaxillary gland mucin.

Other interesting studies from the 1950s by other authors focused on the detection of sialic acids in different biological materials. Those that should be mentioned are those on pooled and fractionated human serum proteins, transudates, urine, cerebrospinal fluid, milk, saliva, and a large variety of animal serum proteins,[@bb1060], [@bb1065] and those on the isolation of neuramin-lactose from rat mammary glands.[@bb1070], [@bb1075]

3. The First Creation of Chemical Structures {#s0035}
============================================

The first creations of a chemical structure were directly influenced by the finding that the Ehrlich reaction should be based on the formation of pyrrole-2-carboxylic acid as reactant for *p*-dimethylaminobenzaldehyde to give the specific red--violet color.

Already in 1949, Hiyama published a first proposal.[@bb1080] Bovine sublingual gland mucin was treated with 10% KOH for 10 h at 100°C. After neutralization and work-up, a product was obtained that gave a red color with *p*-dimethylaminobenzaldehyde (absorption max. near 550 nm), and was identified as pyrrole-2-carboxylic acid by comparison with its synthetic analogue. Subjecting Blix\'s "Kohlenhydrat I"[@bb0830] (see [Section 2.1](#s0020){ref-type="sec"}), isolated from bovine submaxillary gland mucin, to the same alkaline treatment, also afforded pyrrole-2-carboxylic acid. Based on these results, and taking into account Blix\'s suggestion that "Kohlenhydrat I" should contain an acetylated hexosamine part (one *N*- and one *O*-acetyl group), a completely substituted pyrrolidine ring with a [d]{.smallcaps}-glucosamine part incorporated in its structure (C~13~H~21~NO~10~) was tentatively proposed ([Scheme 1](#sch0010){ref-type="fig"} ). The reduction of hot alkaline copper solution by "Kohlenhydrat I" was ascribed to the presence of [d]{.smallcaps}-erythrose.Scheme 1Proposed structure of "Kohlenhydrat I" with the formation of pyrrole-2-carboxylic acid (and [d]{.smallcaps}-erythrose), according to Hiyama, taking into account Blix\'s findings.[@bb0830], [@bb1080]Scheme 1

A drawing of a probable structure for the reagent-positive "hemataminic acid" of Ehrlich and Bial was reported in 1952 by Yamakawa and Suzuki ([Fig. 7](#f0040){ref-type="fig"} ).[@bb1010] As mentioned in [Section 2.3](#s0030){ref-type="sec"}, "hemataminic acid" was isolated from hematoside via the methanolysis protocol and suggested to be identical to Klenk\'s "methoxyneuraminic acid." The assumed structure was based on a series of observations, e.g.: (i) the gasometric α-amino-carboxyl determination with ninhydrin, used to detect α-amino acids,[@bb1085] did not liberate CO~2~; (ii) reduction of alkaline ferricyanide or Fehling\'s reagent after heating with HCl: presence of an aldehyde group; (iii) presence of one methoxy group and a free amino group adjacent to a hydroxy group; (iv) absence of an acetyl group; and (v) consumption of 3 mol of periodate with concomitant formation of 1 mol each of formic acid and glyoxylic acid (CHO--COOH) which was an indication for an α,β-dihydroxy-carboxylic acid.Fig. 7Structure proposal of Yamakawa and Suzuki for "hemataminic acid" (C~10~H~19~NO~8~), a methoxy derivative of a 2-amino-2-deoxy-nonuronic acid.[@bb1010]Fig. 7

In 1953, just like Hiyama, Gottschalk also reported that the alkaline hydrolysate of bovine submaxillary gland mucin was shown to contain pyrrole-2-carboxylic acid \[comparison with synthetic pyrrole-2-carboxylic acid; formation of [dl]{.smallcaps}-proline (pyrrolidine-2-carboxylic acid) on reduction with PtO~2~/H~2~\].[@bb0945] Based on the different findings,[@bb0875], [@bb0890], [@bb0945] it was hypothesized that the substance released with the influenza viral enzyme ([Section 2.1](#s0020){ref-type="sec"}) is built up from a pyrrole-2-carboxylic acid, whereby the pyrrole nitrogen is glycosidically linked to an undefined sugar residue (structure **A**) ([Fig. 8](#f0045){ref-type="fig"} ).[@bb0945], [@bb1090] In bound form, the *N*-glycosyl-pyrrole-2-carboxylic acid **A** was assumed to be connected via an amide linkage with the nitrogen of an adjacent hexosamine (structure **B**), probably [d]{.smallcaps}-chondrosamine ([d]{.smallcaps}-galactosamine). When incubated with the influenza viral/*V. cholerae* enzymes, and accepting these are amidases, the amide linkage is cleaved, thereby releasing structure **A**. Both nitrogen linkages of structure **B** were expected to be alkali labile, thereby explaining the formation of pyrrole-2-carboxylic acid from the mucoprotein in the Ehrlich\'s test with *p*-dimethylaminobenzaldehyde.Fig. 8Gottschalk\'s *N*-glycosyl-pyrrole-2-carboxylic acid proposal (A, free form; B, bound form) for the structure of the enzymatically released substance from mucoprotein.[@bb0945], [@bb1090]Fig. 8

However, the latter hypothesis was withdrawn in a publication that followed.[@bb1095] As UV absorption spectra of the untreated mucoprotein did not give indications for the presence of a pyrrole derivative (absence of a peak at 256 nm), it was suggested that pyrrole-2-carboxylic acid was formed by alkaline degradation (0.05 M Na~2~CO~3~, 20 min, 100°C) of the enzymatically or chemically released substance from the mucoprotein, in a way as visualized in [Scheme 2](#sch0015){ref-type="fig"}A. The precursor of pyrrole-2-carboxylic acid was supposed to be pyrroline-4-hydroxy-2-carboxylic acid, stabilized by the engagement of its enolic hydroxy group in an O-glycosidic linkage apparently with a pentose, being the released substance. The latter compound is very sensitive to alkaline hydrolysis. The choice of position 4 for the hydroxy group was based on the biogenetic relationship to hydroxyproline. In a subsequent paper from 1955, however, an isomeric structure for the *O*-glycosyl-pyrrole-2-carboxylic was assumed ([Scheme 2](#sch0015){ref-type="fig"}B).[@bb1100] In aqueous solution, such a structure will undergo a reversible ring opening, yielding a product that would be unstable to alkali (or acid), and gives, under the expulsion of the sugar, pyrrole-2-carboxylic acid."From a citation of Gottschalk[@bb1095] discussing the earlier report of Hiyama[@bb1080] about the formation of pyrrole-2-carboxylic acid (see [Scheme 1](#sch0010){ref-type="fig"}): "It is not known whether pyrrolidines are transformed into pyrroles under the conditions applied, and Hiyama\'s results cannot therefore be interpreted."" Scheme 2Gottschalk\'s *O*-glycosyl-pyrrole-2-carboxylic acid proposals for the structure of the (bio)chemically released substance from mucoprotein with the formation of pyrrole-2-carboxylic acid.[@bb1095], [@bb1100]Scheme 2

Then, inspired by the data of the Uppsala and Cologne groups, Gottschalk reinterpreted his earlier structural data[@bb1095], [@bb1100] and formulated a new correlation among his finding of pyrrole-2-carboxylic acid, the bovine "sialic acid" data ([Section 2](#s0015){ref-type="sec"}), and the "methoxyneuraminic acid"/"neuraminic acid" data ([Section 2](#s0015){ref-type="sec"}). Taking into account the revised chemical formula C~13~H~21~NO~10~·H~2~O for bovine "sialic acid,"[@bb0980] with one *N*- and one *O*-acetyl group, C~9~-sugar structures were constructed as depicted in [Scheme 3](#sch0020){ref-type="fig"} .[@bb1105] In this proposal, "neuraminic acid" **c** is presented as an aldol type of condensation product of a 2-amino-2-deoxy-hexose with pyruvic acid. For the cyclization to pyrrole-2-carboxylic acid **d**, the α-keto function, the δ-amino function, and the γ-hydroxyl function of the open deacetylated chain (**a**  →  **c**) are in the right positions relative to the carboxyl group. Blix and coworkers stated that the supposed pyranose ring form is in accordance with their periodate experiments, carried out on bovine, porcine, ovine, and equine "sialic acids."[@bb0120] Gottschalk\'s proposal also included for terminal "*N*-acetylneuraminic acid" an enzymatic release from mucoproteins via a glycosidase instead of an amidase.[@bb0490], [@bb1110] See also ref. [@bb0955]. A first unraveling of the mechanism behind the enzymatic release had to wait until the 1980s."The citation of Blix and coworkers (1956) in view of their finding that the *O*-acetyl group should be on C7 instead of C4 ([Scheme 3](#sch0020){ref-type="fig"}): "The bovine 'sialic acid' consumes only 1 mole of oxidant per mole, and produces no formic acid. This indicates that the C7 group is acetylated in this substance. The position of the *O*-acetyl group in Gottschalk\'s formula is therefore probably wrong."[@bb0120] The structure was corrected in 1957.[@bb1115]" Scheme 3Reaction scheme to explain Gottschalk\'s proposal for the structures of "sialic acid" (**a** and **b**) (C~13~H~21~NO~10~), "neuraminic acid" (**c**), and "methoxyneuraminic acid" (**f**, C~10~H~19~NO~8~), including the formation of pyrrole-2-carboxylic acid (**d**) and the tetrose (**e**), and a possible intermediate **g**.[@bb1105], [@bb1115]Scheme 3

Experiments, whereby [d]{.smallcaps}-glucosamine and pyruvic acid were coupled in alkaline medium (pH 11) for 20 min at 100°C via an aldol condensation, and pyrrole-2-carboxylic acid was formed in trace amounts, formed a further support for this correlation.[@bb1105], [@bb1115] Also a possible other degradation route **a**  →  **g**  →  **d** (**g** is an unstable 4-hydroxypyrroline derivative) has been included in [Scheme 3](#sch0020){ref-type="fig"}.[@bb1115] Although the positive aldol condensation with [d]{.smallcaps}-glucosamine also fixed in fact the stereochemistry around C5, C6, C7, and C8, these have been left open in [Scheme 3](#sch0020){ref-type="fig"} and will be further discussed in [Section 4.1](#s0045){ref-type="sec"}. Note that "sialic acid" (**a**), but not "methoxyneuraminic acid" (**f**), can be converted into pyrrole-2-carboxylic acid.

A different proposal for the structure of "methoxyneuraminic acid" appeared in 1956 by Klenk and coworkers.[@bb0860] Based on the earlier investigations on "methoxyneuraminic acid," now called "neuraminic acid methyl glycoside," the following observations were taken together[@bb0115], [@bb0855], [@bb0865], [@bb1010], [@bb1045] (see also [Section 2](#s0015){ref-type="sec"}): (i) presence of a carboxyl group; (ii) presence of a primary amino group, but not in an α-position to the carboxyl group; (iii) presence of a methoxyl group; (iv) absence of an acetyl group, an acetamido group, or a reducing group; (v) consumption of 3 mol of periodate, and formation of 1 mol of formic acid and 1 mol of formaldehyde in mild periodate oxidation experiments; (vi) IR support for a carboxyl group; (vii) for "*N*-acetylneuraminic acid" it holds that the acetamido group should be situated next to the glycosidic C-atom. Further, using a plethora of chemical reactions, the authors arrived finally at a structure for "methoxyneuraminic acid" (C~11~H~21~NO~9~), as formulated in [Fig. 9](#f0050){ref-type="fig"} .Fig. 9Structure of "methoxyneuraminic acid" according to Klenk and coworkers; C~11~H~21~NO~9~ (mw 311) was the best fit with the elemental analysis.[@bb0860] Note that the ultimately correct chemical formula, C~10~H~19~NO~8~ (mw 281), was pushed aside. Interestingly, molecular weight determination, via cryoscopy in water, yielded 273 and 276 Da.Fig. 9

Taking together all structural data so far available, Gottschalk\'s proposal of a C~9~-sugar[@bb1105], [@bb1115] ([Fig. 10](#f0055){ref-type="fig"} , Starting Structure) turned out to be the right direction to continue the battle for the chiralities of the carbon atoms in the final structure. The problems with the great variations in elemental analyses (including separate nitrogen determinations) on different preparations of the isolated substances, published over a long period of time, certainly delayed the progress in the field. One of the causes for these variations was due to the frequent use of methanol in work-up procedures, leading to contaminating methyl-esterification of the relatively strong acids. Another complication was mentioned to be the hygroscopicity of the substances. But also the possible presence of closely related family members in specific preparations should not be excluded.Fig. 10Survey of the search for the stereochemistry around C4, C5, C6, C7, and C8 of *N*-acetylneuraminic acid in a historical perspective: a path of trial and error (see [Section 4](#s0040){ref-type="sec"}).Fig. 10

In view of all the foregoing, after more than 20 years of activity in many laboratories, Blix, Gottschalk, and Klenk finally arrived, in 1957, at a joint statement on the chemical relationship of the substances designated over the years by various names, such as "sialic acid," "neuraminic acid," "methoxyneuraminic acid," "lactaminic acid," "sero-lactaminic acid," "gynaminic acid," "hemataminic acid," and "prehemataminic acid." It was formulated as follows: "In order to avoid further confusion, we propose to call the basic, unsubstituted compound **neuraminic acid**. Sialic acid is suggested as group name for the acylated neuraminic acids (for example, *N*-acetylneuraminic acid, *N*-glycolylneuraminic acid, and diacetylneuraminic acids). For the enzyme, which splits the glycosidic linkage joining the terminal sialic acid to the residual oligo- or polysaccharide, the names **neuraminidase** and **sialidase** may be used synonymously. We have agreed to use this nomenclature in future."[@bb1120] Looking back, one can say that this joint statement was really a breakthrough after many years of experiments and competition."Gottschalk wrote in a letter to Klenk (in 1957) about the final phase of the *Nature* publication: "... I have just returned the corrected proofs of our joint note to *Nature*, ordered and paid 250 reprints in all and asked the printers to send all reprints to you. I am sorry that I could not consult you with regard to the reprints; however, I had to deal with the proof by return mail and the reprints have to be ordered when returning the proof. I have informed Blix accordingly and asked him to claim reprints (up to 85) from you. I hope you agree with this arrangement ..." (from the archive of Ernst Klenk, held by his son Hans-Dieter Klenk)."

Fifteen years later, Scott, Yamashina, and Jeanloz proposed to change the terminology by replacing the name neuraminic acid by aminosialosonic acid (the reference sugar should be a hypothetical 3-deoxynonulose, called sialose and abbreviated Sia), which means that *N*-acetylneuraminic acid should be named acetylaminosialosonic acid.[@bb1125] But the proposal was rejected by the IUPAC-IUB Commission on Biochemical Nomenclature.[@bb1130] Only the abbreviation Sia survived, but it is now used as an abbreviation for sialic acids in general.

4. The Battle for the Stereochemistry {#s0040}
=====================================

4.1. The C5, C6, C7, and C8 Chiralities {#s0045}
---------------------------------------

As mentioned in [Section 3](#s0035){ref-type="sec"}, the sialic acid formula (C5--C8 chiralities) of Gottschalk was partly based on an aldol condensation product of [d]{.smallcaps}-glucosamine and pyruvic acid, yielding pyrrole-2-carboxylic acid in alkaline medium ([Fig. 10](#f0055){ref-type="fig"}, Structure I).[@bb1105], [@bb1115] Support for such a structure was supplied by studies of Kuhn and Brossmer.[@bb1035] Heating (90 min, 100°C) of "lactaminic acid" (*N*-acetylneuraminic acid) with Ni(OAc)~2~·4H~2~O in pyridine yielded *N*-acetyl-[d]{.smallcaps}-glucosamine ([d]{.smallcaps}-GlcNAc), which afforded the chiralities for C5, C6, C7, and C8 ([Fig. 10](#f0055){ref-type="fig"}, Structure I), and carbon dioxide \[--CH(OH)--CH~2~--CO--COOH → --CH(OH)--CH~2~--CHO + CO~2~\]. Because of the anomeric C2 atom, "lactaminic acid" should occur in α- and β-forms; therefore, it was surprising that no mutarotation was observed (see [Section 4.3](#s0055){ref-type="sec"}). Also Zilliken and Glick demonstrated that incubation of "gynaminic acid" (*N*-acetylneuraminic acid) with 0.1 M NaOH (5--10 min at 90°C) afforded [d]{.smallcaps}-GlcNAc and pyruvic acid.[@bb1135] In another study, incubation of bovine submaxillary gland mucin with a *V. cholerae* filtrate, containing the RDE, yielded besides sialic acid, also [d]{.smallcaps}-GlcNAc, leading to the suggestion that still another enzyme should be present in the extract.[@bb1140] Additional incubation of sialic acid with the same extract gave equimolar amounts of [d]{.smallcaps}-GlcNAc and pyruvic acid, and an aldolase mechanism for this splitting was suggested (see [Section 12](#s0230){ref-type="sec"}). Finally, *N*-acetylneuraminic acid could be synthesized from [d]{.smallcaps}-GlcNAc and oxaloacetic acid at pH 11 in 1%--2% yield ([Scheme 4](#sch0025){ref-type="fig"} ).[@bb1145] Scheme 4Synthesis of *N*-acetylneuraminic acid (Structure I; [Fig. 10](#f0055){ref-type="fig"}) from *N*-acetyl-[d]{.smallcaps}-glucosamine and oxaloacetic acid.[@bb1145]Scheme 4

In the same period, however, another player in the field, i.e., the group of Saul Roseman[@bb1150], [@bb1155] ([Fig. 11](#f0060){ref-type="fig"} ) and coworkers at the University of Michigan, Ann Arbor (USA) and later at the Johns Hopkins University, Baltimore (USA), reported enzymatic experiments that were not in agreement with the assigned chirality around C5, as discussed earlier.[@bb1160], [@bb1165] Incubation of *N*-acetyl- and *N*-glycolylneuraminic acid with an enzyme purified from *Clostridium perfringens* (pH 7.2, 3 h, 37°C) yielded in an aldol-type cleavage an *N*-acyl-hexosamine and pyruvic acid. In the case of *N*-acetylneuraminic acid, the *N*-acyl-hexosamine was identified as *N*-acetyl-[d]{.smallcaps}-mannosamine ([d]{.smallcaps}-ManNAc), not [d]{.smallcaps}-GlcNAc ([Fig. 10](#f0055){ref-type="fig"}, Structure II). Note that the [d]{.smallcaps}-configuration was established by a chemical degradation reaction of mannosamine, yielding [d]{.smallcaps}-arabinose. Note also that [d]{.smallcaps}-GlcNAc and [d]{.smallcaps}-ManNAc could only be separated by paper chromatography, when using borate-treated paper. The reaction was reversible; thus incubation of [d]{.smallcaps}-ManNAc and pyruvate using this enzyme led to the formation of *N*-acetylneuraminic acid ([Scheme 5](#sch0030){ref-type="fig"} ). The enzyme was inactive with [d]{.smallcaps}-GlcNAc and *N*-acetyl-[d]{.smallcaps}-galactosamine ([d]{.smallcaps}-GalNAc). Phosphoenolpyruvate could not replace pyruvate. In view of its activity, the enzyme was called *N*-acetylneuraminic acid aldolase \[later called sialate (acylneuraminate)-pyruvate lyase; see [Section 12](#s0230){ref-type="sec"}\]. Incubation of the enzyme with *N*-glycolyl-[d]{.smallcaps}-mannosamine and pyruvic acid afforded *N*-glycolylneuraminic acid.Fig. 11Saul Roseman (1921--2011).Fig. 11Photo courtesy of Prof. Dr. Ronald Schnaar.Scheme 5*N*-Acetylneuraminic acid aldolase-catalyzed cleavage and synthesis of *N*-acetylneuraminic acid (Structure II; [Fig. 10](#f0055){ref-type="fig"}) with *N*-acetyl-[d]{.smallcaps}-mannosamine and pyruvic acid as counter compounds.[@bb1160], [@bb1165]Scheme 5

Pushed by the results of Comb and Roseman, Kuhn and Brossmer repeated the degradation of *N*-acetylneuraminic acid by Ni(OAc)~2~·4H~2~O in hot pyridine and concluded that the primary formation of [d]{.smallcaps}-ManNAc was followed by a rapid epimerization to [d]{.smallcaps}-GlcNAc.[@bb1170] Besides the unexpected epimerization in hot pyridine + Ni(OAc)~2~ (an epimerization was hardly seen in hot pyridine alone), of which the balance lies strongly on the side of [d]{.smallcaps}-GlcNAc, a paper chromatography system used earlier by these authors was not able to separate [d]{.smallcaps}-ManNAc and [d]{.smallcaps}-GlcNAc. However, using borate-treated paper in a time-course experiment, the initial formation of [d]{.smallcaps}-ManNAc, next to [d]{.smallcaps}-GlcNAc, was clearly seen. The [d]{.smallcaps}-ManNAc ↔ [d]{.smallcaps}-GlcNAc reversible epimerization (ratio 1:4) was also observed in aqueous alkaline solution (pH 10--11) at room temperature,[@bb1170], [@bb1175], [@bb1180] thereby explaining the earlier results of Zilliken and Glick[@bb1135] and of Cornforth and coworkers.[@bb1145] Repetition of the synthesis of *N*-acetylneuraminic acid from oxaloacetic acid and either [d]{.smallcaps}-GlcNAc or [d]{.smallcaps}-ManNAc confirmed this view. In both cases *N*-acetylneuraminic acid was formed ([Scheme 6](#sch0035){ref-type="fig"} ; [Fig. 10](#f0055){ref-type="fig"}, Structure II).[@bb1180], [@bb1185] Replacing oxaloacetic acid by its di-*tert*-butyl ester gave higher yields.[@bb1190] In a repeated study, incubating *N*-acetylneuraminic acid with a *V. cholerae* filtrate (pH 6.1, 70 h, 37°C), [d]{.smallcaps}-ManNAc, but not [d]{.smallcaps}-GlcNAc, was found.[@bb1195] The earlier observation of splitting into [d]{.smallcaps}-GlcNAc and pyruvate[@bb1140] was also attributable to a paper chromatography protocol that could not separate [d]{.smallcaps}-GlcNAc and [d]{.smallcaps}-ManNAc.[@bb1195] In another report, the system [d]{.smallcaps}-ManNAc/phosphoenolpyruvate/ATP/rat liver extract (not [d]{.smallcaps}-GlcNAc or [d]{.smallcaps}-GalNAc; not pyruvic acid) was described for the synthesis of *N*-acetylneuraminic acid.[@bb1200] Finally, several years later a protocol was described to determine the absolute configuration of *N*-acetylneuraminic acid by converting it into [d]{.smallcaps}-arabinose by chemical degradation.[@bb1205] Scheme 6Synthesis of *N*-acetylneuraminic acid (Structure II; [Fig. 10](#f0055){ref-type="fig"}) from [d]{.smallcaps}-GlcNAc or [d]{.smallcaps}-ManNAc and oxaloacetic acid.[@bb1180], [@bb1185]Scheme 6

4.2. The C4 Chirality {#s0050}
---------------------

Also the estimation of the stereochemistry around C4 required a few years, whereby the Heidelberg group of Kuhn and Brossmer played a major role. Reaction of *N*-acetylneuraminic acid with C~2~H~5~SH/concd. HCl yielded the γ-lactone of *N*-acetylneuraminic acid diethyl dithioacetal. With reference to Hudson\'s lactone rules,[@bb1210] the strong levorotary value of the γ-lactone {\[α\]^23^ ~D~ −83° (*c* 1, CH~3~OH)} was interpreted as belonging to a Fischer projection formula structure with the lactone ring drawn to the left. This meant for *N*-acetylneuraminic acid that the OH group at C4 should project to the left ([Fig. 10](#f0055){ref-type="fig"}, Structure III; [Scheme 7](#sch0040){ref-type="fig"} ).[@bb1215], [@bb1220] Using Raney nickel, the diethyl dithioacetal could easily be converted into the corresponding levorotating desulfurized γ-lactone. Oxidation of the desulfurized γ-lactone with HNO~3~ at 120°C yielded succinic acid.[@bb1220] Scheme 7Chemical reactions to search for the chirality of the C4 atom of *N*-acetylneuraminic acid: The OH group at C4 should project to the *left* in the Fischer projection formula (Structure III; [Fig. 10](#f0055){ref-type="fig"}).[@bb1220]Scheme 7

However, additional experiments along three chemical pathways by Kuhn and Brossmer led to a correction of the stereochemistry around C4 ([Scheme 8](#sch0045){ref-type="fig"} ).[@bb1225] First of all, the desulfurized γ-lactone mentioned earlier could be converted into (−)-(*R*)*-*1,4,5-pentanetriol {\[α\]^20^ ~D~ −18° (pyridine)} (route 1). The same pentanetriol could also be synthesized from (+)-[l]{.smallcaps}-glutamic acid via (−)-[l]{.smallcaps}-α-hydroxyglutaric acid (route 2), and from the Wittig condensation product of (+)-2,3-*O*-isopropylidene-[d]{.smallcaps}-glyceraldehyde and bromoacetic acid ethyl ester (route 3). So, in the Fischer projection formula the OH group at C4 should project to the right instead of to the left ([Fig. 10](#f0055){ref-type="fig"}, Structure IV).Scheme 8Three routes to prove the correct chirality around C4 of *N*-acetylneuraminic acid: The OH group at C4 should project to the *right* in the Fischer projection formula (Structure IV; [Fig. 10](#f0055){ref-type="fig"}).[@bb1225]Scheme 8

A fourth chemical route, described by Kuhn and Baschang[@bb1190] also led to an OH group at C4 projected to the right ([Scheme 9](#sch0050){ref-type="fig"} ). Here, ozonolysis of the generated γ-lactone of *N*-acetylneuraminic acid[@bb1230] and reductive work-up afforded oxalic acid and 3-acetamido-3-deoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-heptose, and not 3-acetamido-3-deoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*talo*-heptose.Scheme 9Synthesis of 3-acetamido-3-deoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-heptose from the γ-lactone of *N*-acetylneuraminic acid (Structure IV; [Fig. 10](#f0055){ref-type="fig"}).[@bb1230]Scheme 9

4.3. The C2 Chirality and the Ring Form/Conformation {#s0055}
----------------------------------------------------

From the time that a C~9~ structure with a keto group on C2 and an acetamido group at C5 was generally accepted for sialic acid, a pyranose ring form between C2 and C6 was drawn, although still in a Fischer projection formula. A furanose ring form was not possible, and a seven-membered ring was not obvious. As mentioned in [Section 3](#s0035){ref-type="sec"}, results from periodate oxidation studies were in agreement with such a pyranose ring form.[@bb0120] Further support for a C2--C6 hemiacetal was supplied by detailed inspection of the IR spectra of Blix\'s bovine, porcine, ovine, and equine sialic acids.[@bb1235]

Studies focused on the α,β-anomericity at C2 of sialic acids started with a more detailed characterization of lactaminic acid-lactose (*N*-acetylneuraminyl-lactose) ([Section 2.3](#s0030){ref-type="sec"}) by the Heidelberg group. Isolated crystalline *N*-acetylneuraminic acid showed an increasing mutarotation in (CH~3~)~2~SO as follows: \[α\]^23^ ~D~ −115° (*t*  = 7 min) → −37° (*t*  = 23 min) → −24° (final value) (*c* 0.2) (extrapolated to *t*  = 0 min, \[α\]^23^ ~D~ should be −150° to −200°). This observation was correlated with the β-form for the crystalline product, which means that the OH group at C2 in the Fischer formula should project to the left.[@bb1215] As in H~2~O no change in mutarotation was observed, it was concluded that in this solvent the mutarotation was too fast (strong acid) to be followed in the polarimeter. Note that in other studies no mutarotation could be observed in (CH~3~)~2~SO,[@bb1240] whereas in H~2~O mutarotation was seen.[@bb1245] Applying Hudson\'s isorotation rules,[@bb1250] comparison of the optical rotations in (CH~3~)~2~SO of (*N*-acetylneuraminic acid)-(α,β-lactose) (\[α\]^23^ ~D~ +6°), α,β-lactose (\[α\]^23^ ~D~ +53°), and assumed β-*N*-acetylneuraminic acid (\[α\]^23^ ~D~ −150° to −200°; see above), it was hypothesized that the bound *N*-acetylneuraminic acid occurred in the α-form. In case of a β-glycosidic linkage, a negative optical rotation was expected for (*N*-acetylneuraminic acid)-(α,β-lactose).[@bb1255], [@bb1260] But it was stated that for further support pairs of epimeric α- and β-ketosides should be synthesized. Note that the Fischer projection formulae used in these reports (chiralities around C4 and C5) were still not the final ones.

Indeed, in the following years large series of glycosides were synthesized to study the α,β-anomericity at C2 (for a review, see ref. [@bb1265]), and two examples will be given. Meindl and Tuppy[@bb1270] prepared a series of alkyl and aryl glycosides of *N*-acetylneuraminic acid, starting from *N*-acetylneuraminic acid via 2,4,7,8,9-penta-*O*-acetyl-*N*-acetylneuraminic acid and 4,7,8,9-tetra-*O*-acetyl-*N*-acetyl-2-chloro-2-deoxy-neuraminic acid as intermediates (Koenigs--Knorr protocol). It turned out that all glycosides could be cleaved with *V. cholerae* and influenza virus sialidases, and based on the earlier studies of Kuhn and Brossmer, the compounds were assigned as α-ketosides.[@bb1270], [@bb1275] Kuhn and coworkers converted *N*-acetylneuraminic acid methyl ester via 2,4,7,8,9-penta-*O*-acetyl-*N*-acetylneuraminic acid methyl ester and 4,7,8,9-tetra-*O*-acetyl-*N*-acetyl-2-chloro-2-deoxy-neuraminic acid methyl ester as intermediates (Koenigs--Knorr protocol) into *N*-acetylneuraminic acid methyl ester methyl glycoside with \[α\]^20^ ~D~ −6° (CH~3~OH), and *N*-acetylneuraminic acid, using a CH~3~OH/Dowex-50 \[H^+^\] (24 h, boiling under reflux) protocol, into *N*-acetylneuraminic acid methyl ester methyl glycoside with \[α\]^20^ ~D~ −46° (CH~3~OH).[@bb1280] As the first preparation was less levorotatory than the second preparation, the first one was hypothesized to be the α-anomer, and the second one the β-anomer (Hudson\'s isorotation rules[@bb1250]). The first preparation and its free acid form were susceptible to *V. cholerae* sialidase, while the second preparation and its free acid form were resistant.

The application of 100-MHz ^1^H NMR (nuclear magnetic resonance) spectroscopy (1968) gave conclusive evidence for the occurrence of pyranose ring forms in ^2^ *C* ~5~ (1*C*) chair conformations.[@bb1285], [@bb1290] Taking the per-O-methylated methyl ester benzyl glycosides α-**3** and β-**3** as examples, ^1^H NMR analysis in CDCl~3~ showed axial positions for H3a, H4, H5, and H6 (*J* ~3a,4~, *J* ~4,5~, *J* ~5,6~ \>10 Hz) and an equatorial position for H3e (*J* ~3e,4~ \~5 Hz), so equatorial positions for OR^2^, NHAc, and the glycerol side chain at C4, C5, and C6, respectively ([Fig. 12](#f0065){ref-type="fig"} ). Although not discussed,[@bb1290] the large *J* coupling constant between H7 and H8 (*J* ~7,8~ \~8 Hz) in the per-O-acetylated methyl ester benzyl glycoside α-**2** is in agreement with a staggered anti orientation of the OR^2^ groups at C7 and C8; the *J*-value for the coupling between H6 and H7 is small (\~2 Hz). Finally, in the ^1^H NMR spectrum of methyl ester **1**, recorded in dimethyl sulfoxide-*d* ~6~:benzene-*d* ~6~  = 8:3, a long-range coupling between H3a and HO2 (*J* 2.1 Hz) indicated that HO2 occurs in the axial orientation, in agreement with a β-configuration (H3a--C--C--HO2 in a W conformation). For a further discussion on the conformation of the glycerol side chain, see [Section 6](#s0070){ref-type="sec"}.Fig. 12Conclusive evidence for the ^2^*C*~5~ chair conformation of the pyranose ring, and the anomeric configuration assignment, of *N*-acetylneuraminic acid methyl ester (derivatives), based on 100-MHz ^1^H NMR analysis.[@bb1290]Fig. 12

With guidance from the observed optical rotation measurements, combined with Hudson\'s isorotation rules, several studies suggested the α-configuration for bound *N*-acetylneuraminic acid. However, there was a general feeling of caution, given the initially wrong configurational assignment of the hydroxy group at C4 using Hudson\'s lactone rule.

Conclusive data about the C2 α,β-anomericity were published in 1969 by Yu and Ledeen.[@bb1295] For this study, use was made of the earlier synthesized[@bb1280] methyl esters of the sialidase-sensitive and sialidase-resistant forms of *N*-acetylneuraminic acid methyl glycoside. Both compounds were subjected to mild periodate oxidation followed by sodium borohydride reduction, and the degradation products that formed were treated with *N*,*N*′-dicyclohexylcarbodiimide in pyridine ([Scheme 10](#sch0055){ref-type="fig"} ). The C~7~ product related to the sialidase-sensitive methyl glycoside did not give rise to lactone formation, whereas the C~7~ product related to the sialidase-resistant methyl glycoside gave rise to lactone formation. IR analysis of the isolated lactone fraction \[preparative thin-layer chromatography (TLC)\] revealed evidence for a δ (major) +  γ (minor) lactone mixture. The trimethylsilyl derivative of the major lactone, isolated via gas--liquid chromatography (GLC), was analyzed by electron-impact mass spectrometry (EIMS), and shown to be a δ-lactone. Boat conformations of the lactones were supported by Dreiding modeling. All these findings were in agreement with an axial orientation of the carboxyl function (α-configuration) in the case of the sialidase-susceptible methyl glycoside and with an equatorial orientation of the carboxyl function (β-configuration) in the case of the sialidase-resistant methyl glycoside. So, sialidases (here *V. cholerae* sialidase) were proven to be α-sialidases (see [Section 11.7](#s0220){ref-type="sec"}). Note that also the glycerol-side-chain-trimmed α-anomer was susceptible to sialidase, but the β-analogue not susceptible. Note also that *N*-acetyl-α-neuraminic acid methyl ester methyl glycoside was totally inactive with sialidase, which is contrary to results published three years earlier.[@bb1280] Scheme 10Elucidation of the stereochemistry around the anomeric carbon atom via a search for lactone formation, by subjecting the two anomeric *N*-acetylneuraminic acid methyl ester methyl glycosides to sequential periodate degradation, borohydride reduction, and treatment with *N*,*N′*-dicyclohexylcarbodiimide (DCC).[@bb1295] The two starting compounds differ, after de-esterification, in their susceptibility to sialidase.Scheme 10

4.4. The Replacement of NH~2~-C5 by HO-C5 {#s0060}
-----------------------------------------

The history with respect to deaminated neuraminic acid (ketodeoxynononic acid, Kdn; [Fig. 1](#f0010){ref-type="fig"}) started in 1986.[@bb0065] In that year, the groups of Sadako and Yasuo Inoue et al. at the Showa University and the University of Tokyo, Tokyo (Japan) reported an unknown sialic acid-like component (SiaX) in the monosaccharide GLC analysis of some glycopeptide fractions prepared from *Salmo gairdneri* (rainbow trout) egg polysialoglycoprotein.[@bb1300] In subsequent studies,[@bb0385] SiaX could be isolated as its methyl ester methyl glycoside. In comparison with permethylated *N*-glycolylneuraminic acid, the EIMS fragmentation pattern of permethylated SiaX supported a structure in which the N(CH~3~)COCH~2~OCH~3~ group at C5 was replaced by an OCH~3~ group (for EIMS data of sialic acids, see [Section 5](#s0065){ref-type="sec"}). Further support for a hydroxy group instead of an *N*-acyl group at C5 was supplied by the ^1^H NMR spectrum of the SiaX methyl ester methyl glycoside (for NMR data of sialic acids, see [Section 5](#s0065){ref-type="sec"}). The spectrum turned out to be identical with deaminated neuraminic acid methyl ester methyl glycoside, synthesized from *N*-glycolylneuraminic acid.[@bb1305] Referring to the earlier work of Roseman et al. ([Section 4.1](#s0045){ref-type="sec"}), incubation of free SiaX with *N*-acetylneuraminic acid aldolase yielded [d]{.smallcaps}-mannose and pyruvate. Finally, SiaX showed the same absorption spectrum as *N*-acetyl- and *N*-glycolylneuraminic acid in the thiobarbituric acid assay. In conclusion, SiaX could be assigned as 3-deoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid. For information with respect to the metabolism of Kdn and the enzymatic release of this sialic acid from glycoconjugates, see [Sections 11.5.3](#s0205){ref-type="sec"} and [11.7](#s0220){ref-type="sec"}, respectively.

5. Elucidating the O-Substitution Patterns {#s0065}
==========================================

From the beginning, there were indications for the presence of *O*-acetyl groups in addition to *N*-acetyl or *N*-glycolyl groups in sialic acids. As mentioned in [Section 2.1](#s0020){ref-type="sec"}, the first studies, reported in 1936, spoke of the presence of an *O*-acetyl group in the unknown substance, isolated from bovine submandibular gland mucin.[@bb0830] It is to be noted that for the release of (O-acylated) sialic acids from sialoglycoconjugates/sialooligosaccharides, the chosen acid hydrolysis conditions must be such that the labile glycosidic linkage between sialic acid and a neighboring monosaccharide is efficiently cleaved, but also that the applied conditions do not cause too much de-esterification. Note that conditions that are too harsh lead to acid- and heat-mediated degradation to chromogens (humin formation). Over the years, the three acid hydrolysis systems most applied are formic acid pH 2.0 (1 h, 70°C) \[in later years followed by HCl pH 1.0 (1 h, 80°C)\],[@bb0125], [@bb0525] 2 M acetic acid (3 h, 80°C),[@bb1310] and 2 M propionic acid (4 h, 80°C)[@bb1315]; however, other systems have been advocated. Although these conditions do not lead to significant N-deacylation, O-deacylation has been shown to occur to an extent of approximately 30%--50%. The use of aqueous H~2~SO~4~ is no longer recommended.[@bb0035], [@bb0170], [@bb0775] Besides mild acid hydrolysis, in later years sialidases made their appearance.[@bb0035], [@bb0775] As mentioned in [Section 2.1](#s0020){ref-type="sec"}, even the acidity of mucin suspensions (pH 3.5--4.0) was low enough to initiate release of sialic acids.[@bb0120]

As reported in [Section 3](#s0035){ref-type="sec"}, analysis of the sialic acids released from bovine submaxillary gland mucin gave Neu5,7Ac~2~, as deduced from periodate oxidation experiments.[@bb0120] In additional investigations based on periodate oxidation, besides Neu5,7Ac~2~ (consumption of 1 mol of periodate), also Neu5Ac/Neu5Gc (consumption of 2 mol of periodate), and Neu5,7,8/9Ac~3~ (no consumption of periodate) were found.[@bb1320] In the same report, equine submaxillary gland mucin was shown to contain Neu4,5Ac~2~ (consumption of 2 mol of periodate). Also the RDE of *V. cholerae* was used to release *N*,*O*-acylneuramic acids from bovine submaxillary gland mucin, yielding Neu5Ac, Neu5Gc, and di- and triacetylated Neu5Ac.[@bb1325]

For the isolation of sialic acid variants, at the end of the 1960s Faillard and Schauer at the Ruhr-Universität Bochum (Germany) introduced a combination of anion-exchange and cellulose column chromatography.[@bb0125], [@bb0600], [@bb0775] Subsequently, the positions of the *O*-acetyl groups in the isolated sialic acids were determined by a combined approach as follows:(i)Polarographic determination of the periodic acid consumption during mild periodate oxidation (pH 3). It was assumed that Neu5Ac, Neu5Gc, and Neu4,5Ac~2~ consumed 2 mol of periodate/mol sialic acid, Neu5,7Ac~2~ and Neu5,9Ac~2~ 1 mol of periodate/mol sialic acid, and Neu5,8Ac~2~, 0 mol of periodate/mol sialic acid.(ii)Colorimetric assay using periodic acid/thiobarbituric acid according to Aminoff.[@bb1330] The periodate oxidation was carried out at pH 1--2 and 37°C, whereby it was assumed that Neu5Ac, Neu5Gc, Neu4,5Ac~2~, and Neu5,9Ac~2~, but not Neu5,7Ac~2~ and Neu5,8Ac~2~, were degraded to β-formylpyruvic acid, the chromogen that forms a red chromophore with thiobarbituric acid (see [Section 7.1](#s0100){ref-type="sec"}).[@bb1330], [@bb1335], [@bb1340], [@bb1345], [@bb1350](iii)TLC on cellulose and silica-gel layers. Neu5Ac and Neu4,5Ac~2~ are discriminated on the basis of different *R* ~f~ values. Also Neu5,7Ac~2~ and Neu5,8Ac~2~ have different *R* ~f~ values (see [Section 7.2](#s0105){ref-type="sec"}).[@bb1350]

Following this combined protocol, a series of *N*,*O*-acylneuraminic acids, released from bovine and equine submaxillary gland mucin via mild formic acid hydrolysis (pH 2--2.5, 1 h, 70°C), were characterized ([Fig. 13](#f0070){ref-type="fig"} ).[@bb0125] In case of the bovine source, Neu5Ac, Neu5Gc, Neu5,7Ac~2~, and Neu5,8Ac~2~ were identified, and in the case of the equine source, Neu5Ac, Neu5Gc, and Neu4,5Ac~2~ were identified. Furthermore, it was suggested that the bovine material also contained Neu5,7,8Ac~3~, and the equine material Neu4,5,?Ac~3~. The consumption lines of Neu5Ac and Neu4,5Ac~2~ showed overconsumption after 40 min, due to opening of the pyranose ring. In theory, Neu5,8Ac~2~ should give no consumption of periodate; the slow consumption of periodate (0.25 mol/mol sialic acid in 40 min) combined with only a partial positive Aminoff test (extinction coefficient 47% of that obtained with free Neu5Ac) was explained as the result of a slow O-deacetylation. In fact, a possible presence of Neu5,9Ac~2~ was excluded, because the combination of "1 mol periodate consumption and a positive Aminoff test" was not found. The number of *N*-glycolyl groups was estimated using a microanalysis protocol for glycolic acid,[@bb1355] and the number of *O*-acetyl groups was determined with the colorimetric Hestrin assay (alkaline hydroxylamine/Fe(ClO~4~)~3~; see [Section 7.1](#s0100){ref-type="sec"}).[@bb1360] Note that all bovine sialic acids could also be released with the sialidases of *V. cholerae* and *C. perfringens*, although at different rates, but equine Neu4,5Ac~2~ and di-O-acetylated Neu5Ac (presumably one of the *O*-acetyl groups attached at C4) were resistant to these enzymes (see [Section 11.5.2](#s0200){ref-type="sec"}). In the same period, Neu5,8Ac~2~, assigned via polarographic periodate oxidation studies, was found to occur in fish brain gangliosides.[@bb1365] Fig. 13(A) Polarographic measurement of the periodic acid consumption at 0°C of isomeric *N*-acetyl-mono-*O*-acetyl-neuraminic acids.[@bb0125] Neu5Ac, *cross*; Neu4,5Ac~2~, *open circle*; Neu5,7Ac~2~, *closed circle*; Neu5,8Ac~2~, *closed square*. (B) Expected cleavages in the C7--C8--C9 glycerol side chains are indicated with \-\-\-\-\--.Fig. 13Panel (A): Reproduced from Schauer, R. Chemistry and Biology of the Acylneuraminic *Acids. Angew. Chem., Int. Ed. Engl.***1973**, *12*, 127--138. Copyright Wiley-VCH Verlag GmbH & Co. KGaA.

A few years later (1975), a novel technology for the analysis of *N*,*O*-acylneuraminic acids, namely, GLC--EIMS, was introduced by Vliegenthart/Kamerling and coworkers at Utrecht University (the Netherlands).[@bb0135], [@bb0140] To this end, the isolated sialic acids were esterified with diazomethane, followed by trimethylsilylation of the free hydroxy groups. In a later protocol, the sialic acids were pertrimethylsilylated.[@bb0170] Analysis of the mass spectra suggested strongly that all *N*,*O*-acylneuraminic acids with an earlier identified 8-*O*-acetyl group by periodate oxidation, in fact, had to be assigned with an *O*-acetyl group at C9. This change in assignment was based on mass spectrometric fragmentation patterns that originated from the mass spectral analysis of partially methylated alditol acetates.[@bb1370], [@bb1375], [@bb1380] For cleavage of the latter compounds, at the end of the 1960s it had been demonstrated that the charge is preferentially located on an ether oxygen instead of on an ester oxygen atom. Translated to the sialic acid situation, it meant that, in general, cleavage occurs between two trimethylsiloxylated carbon atoms, or between an acetoxylated and a trimethylsiloxylated carbon atom with location of the charge on the ether oxygen, rather than between an acetoxylated and a trimethylsiloxylated carbon atom with location of the charge on the ester oxygen, or between two acetoxylated carbon atoms ([Fig. 14](#f0075){ref-type="fig"}A). The mass spectra obtained for the different sialic acid derivatives gave rise to highly specific fragmentation patterns A--H, both for *N*,*O*-acylneuraminic acids and for *N*-acyl-*O*-alkyl-neuraminic acids ([Fig. 14](#f0075){ref-type="fig"}B).[@bb0035], [@bb0140], [@bb0155], [@bb0170], [@bb1380] Fragments A and B indicate the molecular mass of the sialic acid derivatives, and thus the number and type of substituents. Fragments C--H contain the information concerning the position of the different substituents. Fragment C only has significant abundance if C7 bears an ether group; when an ester group is present at C7, this fragment is absent or hardly observable. The occurrence of fragment D is dependent on the presence of fragment C. Fragment E is not seen if an *O*-acyl group is attached to C4. Fragment F can be readily formed only if an ether group is attached at C8. As an illustration, the mass spectra of Neu5Ac and Neu5,9Ac~2~ are presented in [Fig. 15](#f0080){ref-type="fig"} . Additional mass spectra of various members of the sialic acid family can be found in refs. [@bb0035], [@bb0155], [@bb0170], [@bb0525], as well as in the references included in [Table 1](#t0010){ref-type="table"}. For tables of *m/z* data of the A--H fragments and GLC retention times of various sialic acid derivatives, see refs. [@bb0035], [@bb0135], [@bb0140], [@bb0155], [@bb0170], as well as the references included in [Table 1](#t0010){ref-type="table"}.Fig. 14(A) EI mass spectrometric cleavages in the C7--C8--C9 glycerol side chain of *N*,*O*-acylneuraminic acids. (B) Fragmentation scheme for the analysis of sialic acid derivatives.[@bb0035], [@bb0140]*Ac*, acetyl; *Lt*, lactyl; *Me*, methyl; *TMS*, trimethylsilyl.Fig. 14Fig. 15(A) EI mass spectrum (70 eV) of the per-O-trimethylsilylated methyl ester of β-Neu5Ac. (B) EI mass spectrum (70 eV) of the per-O-trimethylsilylated methyl ester of β-Neu5,9Ac~2~.Fig. 15Reproduced from Kamerling, J. P.; Vliegenthart, J. F. G. Gas-Liquid Chromatography and Mass Spectrometry of Sialic Acids. In *Sialic Acids---Chemistry, Metabolism and Function*; Schauer, R., Ed.; *Cell Biology Monographs*, Vol. 10; Springer-Verlag: Vienna, Austria, 1982; pp 95--125. Copyright Springer-Verlag.

To prove the interpretation of the mass spectra of the 9-O-acetylated sialic acid derivatives, Neu5,9Ac~2~ and Neu9Ac5Gc were incubated with acylneuraminate pyruvate lyase. The products formed were 6-*O*-acetyl-*N*-acetylmannosamine and 6-*O*-acetyl-*N*-glycolylmannosamine, respectively, as proven by GLC--EIMS.[@bb0140] Furthermore, synthetic β-Neu5,9Ac~2~1,2Me~2~ and β-Neu4,5,9Ac~3~1,2Me~2~, of which the structures were confirmed by ^1^H and ^13^C NMR spectroscopy, were subjected to mass spectrometry and periodate oxidation studies. Indeed, both derivatives showed mass spectrometric fragmentation patterns similar to those found for β-Neu5,9Ac~2~ and β-Neu4,5,9Ac~3~, and consumed only \~0.15 mol of periodate/mol of sialic acid within 10 min (β-Neu5Ac1,2Me~2~ consumed 2 mol of periodate/mol sialic acid within 10 min).[@bb1385] An explanation for the resistance of 9-O-acetylated sialic acids to periodate oxidation was stated to originate from the staggered anti orientation of the OH groups at C7 and C8, stabilized by some hydrogen-bonding network, that hampers the formation of a diol--periodate complex (see [Section 6](#s0070){ref-type="sec"}). It seems to take time to create the complex with both OH groups in a *cis* configuration, as over a period of 48 h a higher periodate consumption (85% of their theoretical value) was seen for both compounds, only partially due to O-deacetylation. Neu5Ac9Lt behaved in the same way as Neu5,9Ac~2~ (consumption of only \~0.10 mol of periodate/mol sialic acid within 10 min).[@bb0215] Periodate oxidation of Neu5Ac9P yielded glycolaldehyde phosphate, indicating a splitting of the C7--C8 bond, and a positive thiobarbituric acid color reaction (extinction coefficient 78% of that obtained with free Neu5Ac).[@bb0260] Also Neu5Gc9S turned out to be easily susceptible to periodate oxidation.[@bb0365] In view of the literature protocols followed, it seems that in both cases the oxidation had been carried out for several hours. It should be noted that on treatment of β-Neu5Ac1,2Me~2~ with low amounts of periodate, the C8--C9 diol group is preferentially oxidized, as was shown by the high ratio of the aldehyde of the 8-carbon analogue to the aldehyde of the 7-carbon analogue obtained.[@bb1390] The aldehyde of the 8-carbon analogue, being a 2-hydroxyaldehyde, is further oxidized if the amount of periodate is sufficient. So, the oxidation of the C7--C8 diol group will be hindered if the formation of the mentioned aldehyde is blocked by the presence of an *O*-acetyl group at C9. See also refs. [@bb0035], [@bb0155], [@bb1390], and [@bb1395] for periodate/borohydride degradation studies on the glycoprotein level, generating bound C~8~-α-Neu5Ac, C~7~-α-Neu5Ac, C~8~-α-Neu5Gc, and/or C~7~-α-Neu5Gc.

In later years, several other MS protocols, combined with GLC or high-performance liquid chromatography (HPLC), were explored. Underivatized *N*,*O*-acylneuraminic acids were successfully analyzed by combined HPLC--CIMS (chemical ionization mass spectrometry), although localization of O-substituents based on CIMS data alone was not possible.[@bb1400] Although CIMS of pertrimethylsilylated sialic acid derivatives gave less fragmentation than EIMS, GLC--CIMS also furnished suitable information for identification purposes.[@bb0525], [@bb1405] Furthermore, a methodology based on HPLC, coupled with electrospray-ionization mass spectrometry (ESIMS), has been developed.[@bb0165] To this end fluorescent sialic acid derivatives were prepared by reaction with 1,2-diamino-4,5-methylenedioxybenzene (DMB) (see [Section 7.2](#s0105){ref-type="sec"}). A combination of HPLC retention times and ESI mass spectra allowed the assignment of the type and position of the various substituents.[@bb0165], [@bb0170] A similar approach, but now using matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS), has also been developed.[@bb1410] Analogous to the GLC--EIMS analysis of trimethylsilylated sialic acids, a GLC--EIMS methodology for the analysis of heptafluorobutyrylated (HFB) sialic acid methyl ester derivatives has been worked out.[@bb0100] Here, the EI mass spectra are rather complex; a survey of reporter fragment ions and GLC data of specific members of the sialic acid family can be found in refs. [@bb0100], [@bb0170]. For EI mass spectra of acetylated derivatives, see ref. [@bb0130]. For fast-atom bombardment mass spectrometry (FABMS) studies of sialic acid derivatives, see ref. [@bb0160].

Also ^1^H NMR spectroscopy has been shown to be an excellent tool in the characterization of *N*,*O*-acylneuramic acids.[@bb0035], [@bb0150], [@bb1415] ^1^H chemical shift values of sialic acids are pH dependent. However, the pH of the solution is also important for the stability of the sialic acids under investigation: autohydrolysis in case of bound sialic acids at low pH; O-deacylation at low and high pH; exchange of H3 in D~2~O or tritiated H~2~O at high pH[@bb1420], [@bb1425] (see [Section 7.3](#s0110){ref-type="sec"}), migration of *O*-acyl groups at neutral pH[@bb0195], [@bb9015], [@bb1310] (see [Section 11.5.2](#s0200){ref-type="sec"}). With respect to anomeric α:β ratios, interestingly, the ratio of Neu5,7Ac~2~ and Neu5,7,9Ac~3~ (\~23:77) differed strongly from the ratio of the other *N*(*O*)-acylneuraminic acids (\~7:93); the 5Ac signal of both Neu5,7Ac~2~ anomers resonates at clearly different positions, when compared with the positions of Neu5Ac and Neu5,9Ac~2~.[@bb0150]

6. Different Views on the Conformation of the Glycerol Side Chain {#s0070}
=================================================================

The studies related to the conformational aspects of sialic acids are mainly attributed to the understanding of the hydrogen-bonding network within α- and β-sialic acids that comes to an expression in the interaction between the "flexible" staggered C7--C8--C9 glycerol side chain and the rigid C2--C3--C4--C5--C6--O6 ^2^ *C* ~5~ chair conformation.

6.1. X-ray Diffraction Analysis {#s0075}
-------------------------------

At the beginning of the 1970s, first crystallographic data appeared on β-methoxyneuraminic acid trihydrate (β-Neu2Me·3H~2~O),[@bb1430] β-*N*-acetylneuraminic acid dihydrate (β-Neu5Ac·2H~2~O),[@bb1435] β-*N*-acetylneuraminic acid methyl ester monohydrate (β-Neu5Ac1Me·H~2~O),[@bb1440] and at a later stage α-*N*-acetylneuraminic acid methyl ester methyl glycoside (α-Neu5Ac1,2Me~2~).[@bb1445] All four substances were found to occur in a ^2^ *C* ~5~ chair conformation with equatorial groups at C4 (OH), C5 (NH~2~ or NHAc), and C6 (glycerol side chain). The first three compounds had an axial OR (R = CH~3~ or OH) group at C2 (proof for β-anomer), while the fourth compound had an equatorial OCH~3~ group at C2 (proof for α-anomer). The equatorial glycerol side chain of all four compounds was found to occur in an extended, staggered conformation with the OH groups at C7 and C8 in anti orientation. In general, extensive three-dimensional systems of intermolecular hydrogen bonds, also involving H~2~O molecules, were seen. In the context of the conformation of the glycerol side chain, intramolecular hydrogen bonds are of interest. For β-Neu5Ac1Me·H~2~O, 1 intramolecular hydrogen bond between HO7 and the carbonyl O of NHCOCH~3~ was detected. In the case of α-Neu5Ac1,2Me~2~, intramolecular hydrogen bonds were detected between HO7 and the carbonyl O of the planar NHCOCH~3~ group (trans configuration of the peptide bond), and between HO8 and the carbonyl O of the COOCH~3~ group ([Fig. 16](#f0085){ref-type="fig"} ). Here, the ^2^ *C* ~5~ chair was shown to be somewhat distorted toward a ^6^ *H* ~5~ half-chair conformation.Fig. 16Molecular conformation of crystalline α-Neu5Ac methyl ester methyl glycoside.Fig. 16Reproduced from Kooijman, H.; Kroon-Batenburg, L. M. J.; Kroon, J.; Breg, J. N.; de Boer, J. L. Structure of α-[d]{.smallcaps}-*N*-Acetyl-1-*O*-methylneuraminic Acid Methyl Ester. *Acta Crystallogr. C***1990**, *46*, 407--410. With permission of the International Union of Crystallography.

6.2. NMR Spectroscopy {#s0080}
---------------------

The first 60-MHz ^1^H NMR spectra of Neu5Ac, recorded in D~2~O, were published in 1968,[@bb1450], [@bb1455] but these low-resolution spectra did not contain much information ([Fig. 17](#f0090){ref-type="fig"} ). In fact, the 100-MHz ^1^H NMR spectrum of β-Neu5Ac1Me, already discussed in [Section 4.3](#s0055){ref-type="sec"}, delivered the first useful information with respect to the conformation of sialic acids.[@bb1290] In a first high-resolution study, the 270-MHz ^1^H NMR spectrum of Neu5Ac in D~2~O was completely assigned.[@bb0145] The wrong assignment of the Neu5Ac sample as α-Neu5Ac was corrected in a later report.[@bb1460] In subsequent papers full assignments of various sialic acids were published, as reviewed in refs. [@bb0035], [@bb1415]. As a typical example, [Fig. 18](#f0095){ref-type="fig"} presents the 500-MHz ^1^H NMR spectrum of Neu5Ac, dissolved in D~2~O, at pD 7, whereas [Table 3](#t0020){ref-type="table"} summarizes chemical shifts and coupling constants for α- and β-Neu5Ac (note the ^3^ *J* ~7,8~ value of \~9 Hz, reflecting the staggered anti orientation of H7 and H8, and thus of HO7 and HO8 at the glycerol side chain). The spectrum shows a major and a minor set of protons, related to the subspectra of the β- and α-anomer of Neu5Ac, respectively (β:α = 93:7). The positions of the H3e and H3a signals, being highly pH dependent and resonating outside the proton bulk signal, turned out to be of special interest in the structural analysis of sialoglycan chains (see [Section 8.6](#s0150){ref-type="sec"}).Fig. 1760-MHz ^1^H NMR spectrum of Neu5Ac, dissolved in D~2~O, recorded at ambient temperature.Fig. 17Reproduced from Kimura, A.; Tsurumi, K. Studies on Colominic Acid---IV. Conformation and Configuration of the *N*-Acetyl-neuraminic Acid Moiety of Colominic Acid. *Fukushima J. Med. Sci.***1968**, *15*, 55--60. With permission of the Board.Fig. 18500-MHz ^1^H NMR spectrum of Neu5Ac (β:α = 93:7), dissolved in D~2~O, recorded at pD 7 and 27°C ([Table 3](#t0020){ref-type="table"}), relative to internal acetone in D~2~O (δ 2.225 ppm). The H3e and H3a signals of α-Neu5Ac are enlarged 10-fold.Fig. 18Reproduced from Schauer, R.; Kamerling, J. P. Chemistry, Biochemistry and Biology of Sialic Acids. In *Glycoproteins II*; Montreuil, J.; Vliegenthart, J. F. G.; Schachter, H., Eds.; *New Comprehensive Biochemistry*, Neuberger, A.; van Deenen, L. L. M., Series Eds., Vol. 29b; Elsevier Science B.V.: Amsterdam, The Netherlands, 1997; pp 243--402. Copyright Elsevier Science B.V.Table 3360-MHz ^1^H Chemical Shifts and Coupling Constants of β- and α-Neu5Ac at Different pH Values, in ppm Relative to Internal Acetone in D~2~O (δ 2.225) at 25°C[@bb0035], [@bb0150], [@bb1415]Table 3CompoundpDH3aH3eH4H5H6H7H8H9H9′NAcβ-Neu5Ac1.41.8802.3134.0673.9314.0563.5563.7503.8413.6192.053α-Neu5Ac1.41.7052.718n.d.3.853.6843.533.753.853.622.036β-Neu5Ac7.01.8272.2084.0243.8993.9843.5143.7533.8353.6082.050α-Neu5Ac7.01.6212.730n.d.n.d.n.d.n.d.n.d.n.d.n.d.2.030CompoundpD^2^*J*~3a,3e~^3^*J*~3a,4~^3^*J*~3e,4~^3^*J*~4,5~^3^*J*~5,6~^3^*J*~6,7~^3^*J*~7,8~^3^*J*~8,9~^3^*J*~8,9′~^2^*J*~9,9′~β-Neu5Ac1.4− 13.211.85.010.410.71.29.42.86.4− 12.4α-Neu5Ac1.4− 13.011.54.5n.d.10.51.59.0n.d.6.5− 12.5[^20]

The first 22.6- and 25.2-MHz ^13^C NMR spectra of Neu5Ac (derivatives), recorded in H~2~O or D~2~O, appeared in the 1970s.[@bb0180], [@bb1460], [@bb1465], [@bb1470], [@bb1475] For a review of early ^13^C NMR studies, including chemical shift data, see ref. [@bb1415]. As a typical example, in [Fig. 19](#f0100){ref-type="fig"} the 25.2-MHz ^13^C NMR spectrum of Neu5Ac, dissolved in D~2~O, at pD 2, is depicted.Fig. 19Proton-noise-decoupled 25.2-MHz ^13^C NMR spectrum of Neu5Ac, dissolved in D~2~O, recorded at pD \~2 and 25°C, relative to external TMS (δ 0 ppm). Only the signals stemming from the β-anomer are clearly observable. For a first report on chemical shifts of both α- and β-Neu5Ac, see ref. [@bb1460].Fig. 19Reproduced from Vliegenthart, J. F. G.; Dorland, L.; van Halbeek, H.; Haverkamp, J. NMR Spectroscopy of Sialic Acids. In *Sialic Acids---Chemistry, Metabolism and Function;* Schauer, R., Ed.; *Cell Biology Monographs*, Vol. 10; Springer-Verlag: Vienna, Austria, 1982; pp 127--172. Copyright Springer-Verlag.

Besides the full interpretation of the ^1^H and ^13^C NMR spectra of sialic acids in different solvents, the conformation of the glycerol side chain (average over rotamer states) as part of the whole molecule in D~2~O was studied in more detail and compared with the conformation in crystal structures. In a first study,[@bb0145] taking into account the values of the vicinal coupling constants *J* ~6,7~, *J* ~7,8~, *J* ~8,9~, and *J* ~8,9′~ ([Table 3](#t0020){ref-type="table"}), the lowest energy conformation of the extended C7--C8--C9 side chain was believed to be as depicted in [Fig. 20](#f0105){ref-type="fig"}A. Here, H6 and H7 are placed in a staggered gauche, H7 and H8 in a staggered anti, H8 and H9 in a staggered gauche, and H8 and H9′ in a staggered anti orientation. In this spatial model the H of HO7 can form a hydrogen bond with the ring O, and the H of HO8 a hydrogen bond with the O of HO9 (two five-membered ring interactions). In another study, using hard-sphere, exo-anomeric (HSEA) calculations, the latter model ([Fig. 20](#f0105){ref-type="fig"}A) got support.[@bb1480] Fig. 20NMR Molecular conformations in aqueous solution of (A) β-Neu5Ac according to ref. [@bb0145], (B) β-Neu5Ac according to refs. [@bb1475], [@bb1485], and (C) and (D) α-Neu5Ac according to refs. [@bb1490], [@bb1495]. For both (A) and (B), as measured in D~2~O solution, the H atoms of the OH and NH groups would be replaced by D atoms.Fig. 20

However, the spatial model depicted in [Fig. 20](#f0105){ref-type="fig"}A was not supported by results obtained from a ^13^C spin--lattice relaxation time (*T* ~1~) study of the sodium salts of β-Neu5Ac, β-Neu5Ac1Me, β-Neu5Ac2Me, β-Neu5Fo1,2Me~2~, α-Neu5Ac2Me, β-Neu5Gc, and Neu2en5Ac in D~2~O.[@bb1475], [@bb1485] In this case, a conformational model was postulated, consistent with the ^1^H NMR data and the motional requirements of the *T* ~1~ values ([Fig. 20](#f0105){ref-type="fig"}B). In this model, intramolecular hydrogen bonds occur between the O of HO7 and the acetamido NH and between the H of HO8 and the ring O, keeping HO7 and HO8 in a fixed staggered anti orientation (two six-membered chair-form ring interactions). Furthermore, the model made a third intramolecular hydrogen bond between the acetamido CO and the H of HO4 (seven-membered ring interaction) possible. Apparently, the anomeric center is not involved in any hydrogen bond, leading to the same conformation for α- and β-anomers.

Using a new approach to the NMR study of OH and NH protons in aqueous solution (85% H~2~O/15% (CD~3~)~2~CO), α-Neu5Ac as part of Neu5Ac-containing trisaccharides was investigated.[@bb1490] Careful NOE experiments showed that the strongest NOE was visible between the NH proton and H6. Further NOE contacts were seen between the HO8 proton and H6. Based on a comparison with a study on GM1 ganglioside in (CD~3~)~2~SO,[@bb1495] it was concluded that HO8 was involved in a strong intramolecular hydrogen bond with the carboxylic acid function or the ring O, or both, and explained as the main source of rigidity of the glycerol side chain ([Fig. 20](#f0105){ref-type="fig"}C and D) (note that in case of β-Neu5Ac only a hydrogen bond between HO8 and the ring O is possible). The investigation on GM1 ganglioside mentioned also a hydrogen bond between the H of HO7 and the acetamido CO. Both intramolecular hydrogen bonds are also proposed for crystalline α-Neu5Ac1,2Me~2~ ([Fig. 16](#f0085){ref-type="fig"}).[@bb1445]

For NMR complexation studies of Neu5Ac and Neu5Gc (derivatives) with Ca^2+^, Mn^2+^ or Gd^3+^, see refs. [@bb0335], [@bb1460], [@bb1465], [@bb1500], and [@bb1505].

6.3. Molecular Mechanics, Molecular Dynamics, and Ab Initio Calculations {#s0085}
------------------------------------------------------------------------

First potential energy calculations of the conformation of β-Neu5Ac suggested that in solution the compound might exist preponderantly in two conformations, differing only in the orientation of the terminal CH~2~OH (C9) group of the glycerol side chain.[@bb1510] One of these two energy conformations accorded with the crystal structure of β-Neu5Ac∙2H~2~O.[@bb1435] Although the two generated conformations were consisted with the earlier reported ^1^H and ^13^C NMR data, there is disagreement with the derived NMR models in [Fig. 20](#f0105){ref-type="fig"}A and B. For α-Neu5Ac, two similar minimum energy conformations have been reported.[@bb1515] See also [@bb1520] for theoretical studies on the conformation of mono- and disialogangliosides.

In a more recent study, density functional theory calculations of the conformation of α-Neu5Ac in the gas phase have been carried out.[@bb1525] Out of many possibilities for relatively stable hydrogen bond networks, the most stable structure had an intramolecular hydrogen bond network of O9--H9...O8--H8...OC1--OH/O7--H7...OC--NH--C5, which shows similarity with the earlier reported crystal structure of α-Neu5Ac1,2Me~2~ ([Fig. 16](#f0085){ref-type="fig"}). One of the lower stable structures shows similarity with the model presented in [Fig. 20](#f0105){ref-type="fig"}A (H9--O9...H8--O8/O7--H7...O6 (ring)/O4--H4...OC--NH--C5/O2--H2...OC1--OH). In addition, α-Neu5Ac--H~2~O complexes of the various gas phase conformations were optimized. Here, the following hydrogen bond networks for the optimum complex were seen: O9--H9...OH~2~...O8--H8, O8--H8...OH~2~(...OC1--OH)...OH~2~(...H2--O2)...O6 (ring), O7--H7...OH~2~...OC--NH--C5, and HO--C1O...H~2~O...HO--C1O (compare with [Fig. 20](#f0105){ref-type="fig"}C).

A first molecular dynamics (MD) simulation of α-Neu5Ac was performed both in vacuum and in water.[@bb1530] It was shown that the average conformation of the glycerol side chain was not influenced by the presence of explicit solvent molecules, and the rotation around the C6--C7 and C7--C8 bonds is highly restricted. Hydrogen bond positions were suggested for either O8--H8...OC1--OH or O8--H8...O6 (ring), for either O7--H7...OC--NH--C5 or O7--H7...O6 (ring), and for O4--H4...OC--NH--C5. The C8--C9 bond was found to be more flexible.

Furthermore, also an MD simulation and quantum mechanical (QM) calculations of α-Neu5Ac directed to the whole molecule have been published.[@bb1535] Here, the optimized structure was in good agreement with the crystal structure published for α-Neu5Ac1,2Me~2~.[@bb1445]

Finally, ab initio calculations (gas phase) were carried out on a series of neuraminic acid derivatives: α-Neu5Ac, α-Neu5Ac1,2Me~2~, β-Neu5Ac, β-Neu4,5Ac~2~, β-Neu5,9Ac~2~, β-Neu5Gc, β-Neu4Ac5Gc, and Neu2en5Ac.[@bb1540] The calculations for α-Neu5Ac1,2Me~2~ were in close agreement with those of the crystal structure.[@bb1445] The calculated structure for α-Neu5Ac is depicted in [Fig. 21](#f0110){ref-type="fig"} .Fig. 21Ab initio calculated structure of α-Neu5Ac.Fig. 21Reproduced from van Lenthe, J. H.; den Boer, D. H. W.; Havenith, R. W. A.; Schauer, R.; Siebert, H.-C. *Ab initio* Calculations on Various Sialic Acids Provide Valuable Information About Sialic Acid-Specific Enzymes. *J. Mol. Struct. (Theochem)***2004**, *677*, 29--37. Copyright Elsevier B.V.

6.4. Final Remarks {#s0090}
------------------

First drawings of the conformation of sialic acids, including the glycerol side chain, stem from the end of the 1960s. These drawings, in later years included in the carbohydrate IUPAC/IUBMB Recommendations 1996/1997,[@bb0070] and generally used by many researchers including us, have a glycerol side chain with the H6--C6--C7--C8 part of the chain in an eclipsed conformation. The HO7 and HO8 groups are placed in a staggered anti orientation, whereby the HO7 group points in the direction of the ring O ([Fig. 2](#f0015){ref-type="fig"}/[Fig. 22](#f0115){ref-type="fig"}A).Fig. 22(A, B) Two different drawings of the structure of α-Neu5Ac.Fig. 22

Going through the different reports, discussed in [6.1](#s0075){ref-type="sec"}, [6.2](#s0080){ref-type="sec"}, [6.3](#s0085){ref-type="sec"}, it is evident that, although a discussion about the average conformation of the glycerol side chain is highly complex, the drawing as depicted in [Fig. 22](#f0115){ref-type="fig"}A does not reflect the most favorable conformation. In contrast, especially models with intramolecular hydrogen bonds between the HO7 and the NHCOCH~3~ group, and between the HO8 and the ring O or the COOH function (in case of the α-configuration), leading to a strong hydrogen-bonding network between the glycerol side chain and the ^2^ *C* ~5~ pyranose ring conformation, pop up. Inspection of the literature shows a great variety in drawing the glycerol side chain. Perhaps, one of the better drawings is shown in [Fig. 22](#f0115){ref-type="fig"}B.

7. An Impression of Analytical Techniques as Used in Sialic Acid Analysis {#s0095}
=========================================================================

7.1. Spectrophotometric Assays {#s0100}
------------------------------

In the early days of the sialic acid history, colorimetry played a major role in the unraveling of sialic acid structures. As demonstrated in [Section 2](#s0015){ref-type="sec"}, initially two reagents were applied routinely, namely, Bial\'s reagent (orcinol/concd. HCl/FeCl~3~ mixture) and Ehrlich\'s reagent (*p*-dimethylaminobenzaldehyde/50% HCl). By the 1950s several additional assays were developed; however, the majority of these early methods were found to be unsuitable because of their lack of specificity and/or sensitivity required for sialic acid analysis in biological materials or for enzymatic assays.[@bb0035], [@bb0510], [@bb1350] In the following, a number of spectrophotometric assays, still in use or used for a long time, will be explained in more detail.

In the Bial reaction,[@bb0910], [@bb1545], [@bb1550] the sialic acid sample is mixed with the orcinol/\~30% HCl/FeCl~3~ reagent and heated for 15 min at 96°C, whereafter the formed purple to red--violet chromophore is extracted with isoamyl alcohol, and its absorbance measured at 572 nm (for more details, see refs. [@bb0510], [@bb0525], and [@bb1350]). Because of the strong acidic conditions used, the method is suitable for the quantification of total amounts of free and glycosidically bound sialic acid. Note that *O*-acyl groups are split off. When applied during the fractionation of biological materials, the Bial assay is therefore typically a reaction to monitor the presence of sialic acids. As other carbohydrates (pentoses, hexoses, uronic acids) can strongly disturb the determination of small amounts of sialic acid, quantification usually requires purified samples. To overcome some of the problems, different variants of the Bial reaction have been explored. With a focus on contaminating 2-ketohexoses, a suitable variant reagent to measure total sialic acid, namely, resorcinol/concd. HCl/CuSO~4~, was worked out by Svennerholm. It proved to be 30%--50% more sensitive than the Bial assay.[@bb1555], [@bb1560] Here, free or bound sialic acid samples are mixed with the reagent and heated for 15 min at 110°C, and the formed blue--violet chromophore is extracted with amyl alcohol followed by measurement of the absorbance at 580 nm, and also at 450 nm to correct for 2-ketohexoses (for further information, see refs. [@bb1350], [@bb1565], and [@bb1570]). Note that Kdn gives no color in the orcinol and resorcinol reactions.[@bb1575]

In trying to formulate a reaction mechanism for the Bial and Svennerholm reaction, it was proposed that the strong acidic conditions lead to N-deacetylation, yielding an internal Schiff base formed by the condensation of the free amino group at C5 and the C2 carbonyl group, followed by decarboxylation and dehydration, to yield a pyrrole derivative. The latter chromogen then gives a condensation product with orcinol or resorcinol ([Scheme 11](#sch0060){ref-type="fig"} ).[@bb1570], [@bb1580] When combined with a preceding periodate oxidation step, the sensitivity of the Svennerholm assay can be increased significantly (between three- and sixfold).[@bb1565], [@bb1570] Scheme 11Possible pyrrole chromogen formation \[N-deacetylation, condensation NH~2~(C5) and CO(C2), decarboxylation, dehydration\] in the Bial (orcinol/concd. HCl/FeCl~3~) and Svennerholm (resorcinol/concd. HCl/CuSO~4~) reaction, taking into account the proposals in refs. [@bb1570] and [@bb1580].Scheme 11

In the "direct" Ehrlich reaction (without previous treatment with alkali),[@bb0830], [@bb0910] the sialic acid sample is usually mixed with the *p*-dimethylaminobenzaldehyde/\~18% HCl reagent and heated for 30 min at 100°C, whereafter the absorbance of the formed red--violet chromophore is measured at 565 nm (for more details, see refs. [@bb0445] and [@bb0910]). In the case of the "indirect" Ehrlich reaction, the test material is first incubated with mild alkali, e.g., borate buffer at pH 8.5 (45 min, 100°C), followed by the addition of Ehrlich\'s reagent (20 min, 70°C), whereafter the extinction is determined at 558 nm.[@bb1330] To illustrate the chemical background of the color formation in the Ehrlich\'s test, and taking into account the proposals by different authors, the "direct" and "indirect" Ehrlich pathways for Neu5Ac are presented in [Scheme 12](#sch0065){ref-type="fig"} . Just like in the Bial/Svennerholm assays, N-deacetylation, internal Schiff base formation, and dehydration play a role. For the formulation of the pathway leading to structure A, the earlier scheme of Tuppy and Gottschalk, combined with information of Treibs and Herrmann, is followed.[@bb0505], [@bb1585] For the formulation of the pathway leading to structure B (including a decarboxylation), the earlier scheme of Wirtz-Peitz, combined with information from Alexander and Butler, is followed.[@bb1580], [@bb1590] Note that the "direct" Ehrlich test does not distinguish free from bound sialic acid. It should be mentioned that the Ehrlich assay as a quantitative method has lost its importance.Scheme 12Possible pyrrole derivatives arising from Neu5Ac, following the "direct" Ehrlich (E = *p*-dimethylaminobenzaldehyde/concd. HCl) and the "indirect" Ehrlich (alkali; E = *p*-dimethylaminobenzaldehyde/concd. HCl) reaction, taking into account the proposals in refs. [@bb0505] and [@bb1580], [@bb1585], [@bb1590].Scheme 12

The periodic acid/thiobarbituric acid assay, independently developed at about the same time (1959) by Warren and by Aminoff, grew out to the most widely applied quantitative colorimetric method for measuring free sialic acid.[@bb1335], [@bb1340] The methods differ in two ways from each other: (i) the acidity is that of the initial periodate oxidation step (concd. H~3~PO~4~ [@bb1335] vs 0.06 M H~2~SO~4~ [@bb1330]), and (ii) the use of cyclohexanone[@bb1335] or acidic *n*-butanol[@bb1330] for the extraction of the chromophore. In the periodate oxidation step (followed by an arsenite step), a chromogen is generated, predicted to be β-formylpyruvic acid, which gives a red chromophore with 2-thiobarbituric acid with *λ* ~max~ 549 nm. A proposed reaction mechanism of the assay is presented in [Scheme 13](#sch0070){ref-type="fig"} .[@bb0505], [@bb1345] In contrast to Warren,[@bb1335] it was stated by Paerels and Schut[@bb1345] that a conversion of the *N*-acyl group into a free amino group under the acidic periodate oxidation conditions (room temperature; incubation for a relatively short time) is not obvious, because of the high stability of an amide bond. As sialic acid glycosides did not react in the Warren and Aminoff tests, sialic acid glycosidic linkages are not hydrolyzed under the assay conditions. Furthermore, it was presumed that β-formylpyruvic acid is not a direct product of the periodate oxidation, but the result of an acid-catalyzed C4--C5 aldol splitting of the true oxidation product (for Neu5Ac: formed after consumption of 3 mol of periodate; see the upper part of [Scheme 13](#sch0070){ref-type="fig"}) during the incubation with the acid solution of 2-thiobarbituric acid at 100°C. The red pigment was earlier prepared in the crystalline form from a derivative of β-formylpyruvic acid, and proven to be a condensation product of 2 mol of 2-thiobarbituric acid and 1 mol of β-formylpyruvic acid.[@bb1595] It may be clear that O-substitutions of the glycerol side chain will influence the prechromogen formation (see discussion in [Section 5](#s0065){ref-type="sec"}), and a test after O-deacetylation was advised. In case of Neu4,5Ac~2~, an O-deacetylation at C4 during the reaction with 2-thiobarbituric acid before the aldol splitting was suggested. See the comments on the analysis of Kdn, which directly yields β-formylpyruvic acid.[@bb1575] Scheme 13Proposed reaction mechanisms of the periodic acid/thiobarbituric acid assay.[@bb0505], [@bb1345], [@bb1600], [@bb1605]Scheme 13

However, in the 1980s, a positive periodic acid/thiobarbituric acid test with Neu5Ac4Me initiated a new discussion, wherein the postulated prechromogen was suggested to react directly with 1 mol of 2-thiobarbituric acid, followed by an acid-catalyzed reaction (cleavage of the C4--C5 bond) to yield the β-formylpyruvic acid derivative.[@bb1600] This derivative can then react with a second mol of 2-thiobarbituric acid to give the final chromophore (lower part [Scheme 13](#sch0070){ref-type="fig"}). The latter pathway, stating that free β-formylpyruvic acid is not an intermediate, was suggested in the 1970s to explain the positive Warren reaction for 3-deoxy-5-*O*-methyloctulosonic acid.[@bb1605] However, in view of the positive Warren reaction for Neu5Ac4Me, a chromophoric 1:1 condensation product should be expected.

So, applying the periodic acid/thiobarbituric acid methodology on biological samples before and after mild acid hydrolysis, and eventually saponification, the levels of free, bound, and total sialic acid can be determined (for experimental details, see refs. [@bb0510], [@bb0525], and [@bb1350]).

In attempts to lower the detection limits of sialic acid, since the 1960s a number of fluorimetric assays have also been developed (for reviews, see refs. [@bb0035], [@bb0510], [@bb0515], [@bb1350], and [@bb1350]). In the following, some typical examples will be presented. Reaction of sialic acid with 3,5-diaminobenzoic acid dihydrochloride in hot dilute HCl yields an intense green fluorescent condensation product (405 nm excitation, 510 nm emission) (free and bound sialic acids react equally).[@bb1610] Reaction of sialic acid with pyridoxamine in the presence of zinc acetate and pyridine/methanol for 45 min at 70°C yields a highly fluorescent chelate (395 nm excitation, 470 nm emission; [Scheme 14](#sch0075){ref-type="fig"} ) (free sialic acids).[@bb1615], [@bb1620] The fluorescence of the chromophoric product, obtained from sialic acid in the periodate/2-thiobarbituric acid assay ([Scheme 13](#sch0070){ref-type="fig"}), is readily detected by excitation at 550 nm and analysis of the emission at 570 nm. Here, special attention has been paid to contamination with 2-deoxyribose.[@bb1625] Finally, a different approach has been worked out, whereby free or glycosidically bound sialic acid was subjected to mild periodate oxidation. This method also allowed the discrimination between sialic acids with or without *O*-acyl groups at the glycerol side chain by O-deacetylation of a parallel sample (for a discussion of the mild periodate oxidation of sialic acids, see [Section 5](#s0065){ref-type="sec"}). The released formaldehyde, derived from C9 in the case of nonsubstituted HO9 and HO8 functions, is derivatized with acetylacetone in the presence of ammonium acetate, yielding the slightly yellow chromophore 3,5-diacetyl-1,4-dihydro-2,6-dimethylpyridine,[@bb1630] of which the fluorescence can be detected by excitation at 410 nm and analysis of the emission at 510 nm ([Scheme 15](#sch0080){ref-type="fig"} ).[@bb1635] Using this methodology, it could be demonstrated that rapid O-deacetylation of Neu5,9Ac~2~ occurred only at pH values below 2 and above 11. When incubated for 10 min at 58°C, no significant loss of *O*-acetyl groups were seen in the range of pH 2--11.[@bb1640] Scheme 14Proposed reaction mechanism for the transamination of sialic acid with pyridoxamine in the presence of zinc acetate and pyridine/methanol, yielding the fluorescent Zn-chelate.[@bb1620]Scheme 14Scheme 15Reaction of formaldehyde with acetylacetone in the presence of ammonium acetate, yielding the fluorigen 3,5-diacetyl-1,4-dihydro-2,6-dimethylpyridine.[@bb1630], [@bb1635]Scheme 15

Based on the finding of the acylneuraminate pyruvate lyase (or aldolase)-catalyzed cleavage and synthesis of Neu5Ac with ManNAc and pyruvic acid as counter compounds by Roseman and coworkers ([Section 4.1](#s0045){ref-type="sec"}; [Scheme 5](#sch0030){ref-type="fig"}),[@bb1160], [@bb1165] indirect quantification protocols for sialic acids, via estimation of ManNAc or pyruvate, were also developed.[@bb1350], [@bb1645], [@bb1650] The most sensitive method turned out to be a pyruvate assay, based on the lactic acid dehydrogenase-catalyzed interconversion of pyruvate and lactic acid with the concomitant interconversion of NADH and NAD^+^. Coupling of the aldolase-catalyzed cleavage reaction of *N*-acylneuraminic acids to the lactate dehydrogenase/NADH-catalyzed reduction of pyruvate to lactate drives the lyase reaction, otherwise an equilibrium reaction, to completion. Initially, the amount of pyruvate (and thus the amount of sialic acid) was calculated from the amount of oxidized NADH, measured spectrophotometrically by the change in absorbance at 340 nm.[@bb1650] In the course of time, various commercial colorimetric and fluorimetric assays have been developed for the estimation of oxidized NADH. Note that the reaction rate of the cleavage by aldolase is influenced by the sialic acid O-substitution pattern, e.g., it has been found that *O*-acyl groups at the sialic acid glycerol side chain lead to a reduction in the reaction rate of 30%--50%, while O-acetylation at C4 gives 90% reduction.[@bb0210], [@bb1655], [@bb1660]

Originally, acetyl determinations for sialic acids were described using a protocol that included hydrolysis with *p*-toluenesulfonic acid, subsequent distillation to collect acetic acid, conversion into barium acetate, and determination of the Ba^2+^ content.[@bb0120], [@bb1665] In the case of glycolyl groups, sialic acids were treated with 1 M NaOH at 100°C, and the glycolic acid that formed was quantified as crystalline calcium glycolate.[@bb0120] At a later stage, among the different colorimetric methods to quantify the *O*-acyl content of sialic acids, the Hestrin assay, as modified by Ludowieg and Dorfman, played an important role.[@bb1360], [@bb1670] Incubation of *N*,*O*-acylneuraminic acids with alkaline hydroxylamine affords acylhydroxamates that form red chromophores with Fe(ClO~4~)~3~, the absorbance of which are measured at 520 nm.[@bb1675] *O*-Glycolyl (but also *N*-glycolyl) groups can be quantified using a protocol that includes treatment with ethanolic *p*-toluenesulfonic acid (8 h, 95°C), affording ethyl glycolate, which is collected via distillation in vacuo. After saponification, the amount of sodium glycolate is estimated colorimetrically using the Eegriwe\'s reagent, 2,7-dihydroxynaphtalene/concd. H~2~SO~4~.[@bb0325], [@bb1355], [@bb1675], [@bb1680], [@bb1685] The reddish chromophore that is formed (20 min, 100°C), represents the condensation product of 1 mol of formaldehyde (oxidative decarboxylation of glycolic acid) and 2 mol of 2,7-dihydroxynaphtalene, and yields an absorption at *λ* ~max~ 546 nm. Finally, the configuration and the amount of *O*-lactyl groups in *N*,*O*-acylneuraminic acids can be measured as lactic acid with [l]{.smallcaps}-lactate dehydrogenase and [d]{.smallcaps}-lactate dehydrogenase after release with NaOH (1 h, room temperature) and neutralization.[@bb0215], [@bb0220] So far, only *O*-[l]{.smallcaps}-lactyl groups have been found.

7.2. Chromatographic Techniques {#s0105}
-------------------------------

Just as with structural investigations of many other natural products, in the early days paper chromatography played an important role in the analysis of sialic acids.[@bb0445], [@bb1320], [@bb1350]

However, at the end of the 1950s, thin-layer chromatography (TLC) on cellulose and silica gel plates slowly surpassed the use of paper. The greater resolution, combined with improved reproducibility, made TLC for many years the technique of choice for screening and (tentative) assignments of sialic acids. Especially, Schauer and coworkers at the Ruhr-Universität Bochum, and later at the Christian-Albrechts-Universität zu Kiel, contributed greatly to the development of TLC technologies. Although several solvents were developed, the most popular flow systems turned out to be propan-1-ol/butan-1-ol/0.1 M HCl (2:1:1, v/v/v) for cellulose sheets ([Fig. 23](#f0120){ref-type="fig"} ), and propan-1-ol/water (7:3, v/v) for silica gel sheets. For *R* ~f~ values of different sialic acids, see refs. [@bb0035] and [@bb1350]. For the visualization of the sialic acid members, in most cases, the Bial reagent (orcinol/concd. HCl/FeCl~3~) was used, yielding typical purple--blue bands. Periodate combined with resorcinol/CuSO~4~ and periodate combined with arsenite and thiobarbituric acid sprays were also developed. For a further differentiation between *N*,*O*-acylneuraminic acids with similar *R* ~f~ values in one direction, a two-dimensional TLC method with intermediate saponification, carried out on cellulose sheets with the solvent system mentioned earlier, was developed. The intermediate exposure to an atmosphere of ammonia vapor over a 5 M NH~4~OH solution (2 h, room temperature) generates Neu5Ac and Neu5Gc from their *O*-acyl derivatives.[@bb0210], [@bb1675] A two-dimensional technique on cellulose sheets was also developed for *O*-acyl group identifications. After a separation in the first dimension using propan-1-ol/butan-1-ol/0.1 M HCl (2:1:1, v/v/v), the lane of migrated sialic acids is sprayed with Hestrin\'s alkaline hydroxylamine reagent and left for 60 min. Then, the plate is developed in the second dimension using propan-1-ol/10% aq (NH~4~)~2~CO~3~/5 M NH~4~OH (6:2:1, v/v/v). Visualization of the acylhydroxamates is carried out with a 10% FeCl~3~ spray.[@bb0210], [@bb1675] Fig. 23TLC patterns of sialic acids on a cellulose plate, developed with propan-1-ol/butan-1-ol/0.1 M HCl (2:1:1, v/v/v), and stained with Bial\'s reagent. Lane 1: sialic acid mixture, released from bovine submandibular gland mucin. Lane 2: standard Neu5Ac and Neu5Gc.Fig. 23

Around the 1970s, GLC (in combination with EIMS) of volatile sialic acid derivatives was introduced.[@bb0035], [@bb0155], [@bb0170] Major protocols that were explored are based on trimethylsilylation,[@bb1305], [@bb1690], [@bb1695], [@bb1700], [@bb1705], [@bb1710], [@bb1715] trifluoroacetylation,[@bb1720] and methylation (in case of partial methylation, followed by trimethylsilylation or acetylation).[@bb1725], [@bb1730], [@bb1735], [@bb1740], [@bb1745] For the application of GLC--EIMS in studying sialic acid O-substitution patterns, see [Section 5](#s0065){ref-type="sec"}. The partially methylated derivatives of sialic acids play a role in methylation/linkage analysis studies (GLC--EIMS) of glycan chains with internal sialic acid residues.

As already mentioned in [Section 5](#s0065){ref-type="sec"}, the introduction of serial anion-exchange and cellulose column chromatography at the end of the 1960s was a real step forward in the isolation of sialic acid family members on a preparative scale.[@bb0125] However, at a later stage the introduction of HPLC using different column materials, elution protocols, and detection techniques replaced this original approach. So, rapid screening of sialic acids in biological materials, affording assignments based on retention times, whereby contaminating substances (e.g., other monosaccharides) did not interfere, could be developed. Also the monitoring of fast transitions between members of the sialic acid family due to migration of substituents, the introduction of substituents, the cleavage of substituents, or other (enzymatic) modifications became possible.

First reports on the application of HPLC for the separation and quantitative analysis of sialic acids stem from the mid-1970s onward. Initially, methods for Neu5Ac were developed using an anion-exchange resin combined with a periodate/arsenite/thiobarbituric acid colorimetric detection assay,[@bb1750] a cation-exchange resin combined with UV detection at 206 nm,[@bb1755] and an amino column combined with UV detection at 195 nm.[@bb1760] Chromophores, obtained by treatment of Neu5Ac and Neu5Gc with periodate/arsenite/thiobarbituric acid, were analyzed on a reversed-phase C~18~ column, monitored at 549 nm.[@bb1765] As it was realized that analysis of complex mixtures of sialic acids should require other approaches, the focus was switched to generally applicable methods (for a review, see ref. [@bb0035]). A first report proposed the use of an anion-exchange resin in borate buffer (pH 8.55), whereby nonderivatized sialic acids were separated as sugar--borate complexes. For the detection, the effluent was mixed with 4,4′-dicarboxy-2,2′-biquinoline disodium salt/CuSO~4~ (5.4 min, 100°C), and the chromophores (Cu^+^/4,4′-dicarboxy-2,2′-biquinoline complexes) that formed were monitored at 570 nm.[@bb1770], [@bb1775], [@bb1780] At the same time a different anion-exchange chromatography method was reported, making use of sodium sulfate as mobile phase and UV detection at 195 or 215 nm.[@bb1785] Great progress in HPLC approaches was made by the combination of reversed-phase HPLC with fluorometric detection systems and, in a later stage, with additional coupling to MS. To this end fluorescent sialic acid derivatives were prepared by reaction with DMB (373 nm excitation; 448 nm emission) ([Scheme 16](#sch0085){ref-type="fig"} )[@bb1790], [@bb1795], [@bb1800] or *o*-phenylenediamine (OPD) (232 nm excitation; 420 nm emission).[@bb1805] In an evaluation of seven different HPLC methods, including high-performacnce anion-exchange chromatography with pulsed amperometric detection (HPAEC--PAD) (see ref. [@bb1810]), it turned out that no single method is adequate to completely separate and quantitate complex mixtures of sialic acids.[@bb1815] For a quantification protocol of Neu5Ac and Neu5Gc by a stable isotope dilution assay using HPLC coupled with ESIMS, see ref. [@bb1820]. For a more detailed overview of HPLC procedures, see ref. [@bb0035].Scheme 16Reaction of Neu5Ac with 1,2-diamino-4,5-methylenedioxybenzene (DMB) to yield the corresponding fluorescent derivative.[@bb1790], [@bb1795]Scheme 16

Around the turn of the century, also capillary electrophoresis (CE) was introduced for the analysis of derivatized and nonderivatized Neu5Ac and Neu5Gc.[@bb1825], [@bb1830], [@bb1835], [@bb1840], [@bb1845], [@bb1850]

7.3. Instrumental Techniques {#s0110}
----------------------------

As indicated at several other places in this chapter, since the 1970s, mass spectrometry and NMR spectroscopy have played important roles in the further development of the sialic acid world, and detailed reviews are available.[@bb0035], [@bb0155], [@bb1415]

In the context of this section, attention will be paid to some NMR studies of sialic acids. As shown in [5](#s0065){ref-type="sec"}, [11.5.2](#s0200){ref-type="sec"}, the value of ^1^H NMR spectroscopy for the characterization of *N*,*O*-acylneuraminic acids and for the migration of *O*-acetyl groups along the glycerol side chain was clearly demonstrated. NMR spectroscopy also proved to be of great value for unraveling of the mechanism of the release of bound sialic acid and for the assignment of the type of glycosidic linkage \[e.g., (α2→3), (α2→6), (α2→8); see also [Section 8.6](#s0150){ref-type="sec"}\]. Following the incubation of Neu5Ac(α2→3 or 6) conjugates with bacterial (*C. perfringens*, *Arthrobacter ureafaciens*, *V. cholerae*, *Bifidobacterium*) and viral (fowl plague virus) sialidases in an NMR tube, NMR spectroscopy showed in a fast process at first instance the formation of free α-Neu5Ac in high amounts, which then mutarotates in a slower process to the equilibrium α-Neu5Ac:β-Neu5Ac = 8:92. The anomerization could be followed easily via the intensities of the H3e, H3a, and *N*-acetyl signals of both anomers (see [Section 6.2](#s0080){ref-type="sec"}; [Table 3](#t0020){ref-type="table"}).[@bb1855], [@bb1860], [@bb1865] Fortunately, the initial high concentration of α-Neu5Ac made it now possible to follow the mutarotation in more detail than described in [Section 4.3](#s0055){ref-type="sec"}. But it should be said that the rapidity of the α-Neu5Ac → β-Neu5Ac mutarotation depends on the pH. At pD 5.4, being the pH for an optimal cleavage of 2-azido-α-Neu5Ac with *C. perfringens* sialidase, the process turned out to be rather slow, but at higher and lower pD values a more rapid establishment of the equilibrium of mutarotation was observed. At pD 1.3 and pD 11.7 the mutarotation was too fast to be measured (no indications for open-chain structures or lactones).[@bb1870] For GLC--EIMS studies on the release of Neu5Ac from substrates by sialidases in the presence of H~2~\[^18^O\], see ref. [@bb1875]. The fact that the cleavage by these sialidases passed with retention of anomeric configuration received support in a later mechanistic study with the sialidase from influenza virus.[@bb1880] These results were in contradiction with an earlier report that Neu5Ac, liberated by the enzymatic cleavage of the α-linked Neu5Ac, leaves the catalytic site of *V. cholerae* sialidase as the β-anomer, which meant an inversion of anomeric configuration in the mechanism.[@bb1240] However, such a mechanism was later proposed in case of *Salmonella typhimurium* sialidase.[@bb1885], [@bb1890] With the ability to generate α-Neu5Ac in situ, the aldolase-catalyzed degradation of Neu5Ac to pyruvate and ManNAc (in fact α-ManNAc, followed by a fast mutarotation to α,β-ManNAc) could also be investigated in more detail using ^1^H NMR spectroscopy.[@bb1895], [@bb1900]

In alkaline D~2~O solutions of Neu5Ac at pD 9.0, H3a was completely replaced by D3a, which led to the disappearance of the H3a signal in the ^1^H NMR spectrum and simpler splitting patterns for the H3e and H4 signals.[@bb1425] Further increase of the pD to 12.4 also caused the exchange of H3e for D3e.[@bb1420] When using tritiated H~2~O, tritium-labeled sialic acids could be prepared. A ^13^C NMR study of aqueous solutions of Neu5Ac, labeled with ^13^C at C1, C2, and/or C3 at varying pHs, made the detection and quantification of its acyclic forms possible. Thus, at pH 2 anomerization of β-Neu5Ac leads to α-pyranose:β-pyranose:keto:enol:keto hydrate (gem-diol) = 5.8:91.2:0.7:0.5:1.9.[@bb1905]

The importance of different MS techniques in the structural analysis of sialic acids and sialoglycans is discussed in [Sections 5](#s0065){ref-type="sec"} and [8.6](#s0150){ref-type="sec"}, respectively.

7.4. Histological Methods {#s0115}
-------------------------

Histochemistry is a most important area of glycobiology research, enabling insight into the chemical architecture of a cell, and especially its surface, the glycocalyx. For this purpose, the cell or tissue remains intact and can be investigated mostly in sliced form by different forms of microscopy. Nowadays, histological experiments are also possible with viable cells. This means that cell biological studies, during which the function of a cell varies, can now be visualized.

Histochemistry has a long history, and the methods applied are manifold. In a short note from 1946 in *Nature*, McManus from the University Museum in Oxford, UK, described the staining of mucins by Schiff\'s reagent following the action of 0.5% periodic acid.[@bb1910] Originally, Schiff\'s reagent was defined as "a solution of fuchsine decolorized by treatment with sulfur dioxide that gives a useful test for aldehydes because they restore the dye\'s color." Examples of the staining comprised mucins of goblet cells of the human intestine and bronchus, and also various other tissues from rat and man. A few years later, in 1950 and 1952, Leblond and coworkers used the technology in combination with light microscopy.[@bb1915], [@bb1920] After periodate oxidation, tissues of different animals were stained with fuchsine--sulfurous acid, a technique developed by Hotchkiss.[@bb1925] At these times, the nature of the molecules in tissues, oxidized by periodic acid, was not yet known.

Interestingly, in 1957, in a report by Leblond and coworkers[@bb1930] describing the staining of glycogen by the periodic acid--Schiff (PAS) technique, sialic acid also came into play as the probable molecule responsible for periodate staining (sialic acid was found in various tissues along with galactose, fucose, and hexosamine). In subsequent years, the PAS technique developed into a powerful technique of sialic acid staining, because of the sensitivity of its glycerol side chain to mild periodate oxidation, thereby generating aldehyde functions. Typical examples are the detection of vicinal hydroxy groups (mostly of sialic acids) in plasma membranes by electron microscopy.[@bb1935], [@bb1940] In an early review,[@bb1945] the periodate acid--Schiff technique, together with other methods for the detection of acidic groups/acidic glycoproteins of plasma membranes, e.g., using cationic compounds such as colloidal iron, thorium hydroxide, Alcian blue, and ruthenium red, used earlier for light or electron microscopy, is summarized. The studies confirmed that all cell surfaces seem to be covered by a carbohydrate-rich coat. In a thorough investigation on complex carbohydrates (glycoproteins) in the Golgi apparatus of rat cells, two electron microscopy visualization methods, based on (1) successive treatment of sections with periodic acid, chromic acid, and silver methenamine, and (2) brief treatment of sections with a mixture of chromic acid and phosphotungstic acid, were compared with the PAS technique using light microscopy, and the staining results obtained were shown to be identical/similar.[@bb1950]

Soon after the beginning of the use of periodate for histological sialic acid determinations, it was noticed that pretreatment with alkali (0.5% KOH) increased the periodic acid--Schiff (1% PAS) reactivity of, e.g., certain mucins,[@bb1955] and the authors confirmed the hypothesis that this KOH--PAS effect was due to the presence of O-acetylated sialic acids.[@bb1960], [@bb1965] It should be noted that ester groups, which prevent aldehyde formation by periodate, were assumed to be located at C8 of the glycerol side chain of sialic acid. Until the mid-1970s, 9-O-acetylated sialic acids were believed to be cleavable between C7 and C8 (see fig. 1 of ref. [@bb1960]). However, as discussed in [Section 5](#s0065){ref-type="sec"}, in the same period (1974), this assumption turned out to be incorrect.[@bb1385] So, PAS-resistant sialic acids can be substituted at C9 and not necessarily at C8. Neu4,5Ac~2~ is fully PAS positive (but sialidase resistant). The specificity of this sialic acid-staining technique can be increased by previous sialidase or acid treatment of tissue slices. The difference of staining intensity with and without alkali treatment enables a rough estimation of the degree of O-acetylation in the glycerol side chain.

In the following years, staining of sialic acid by periodic acid and Schiff or thionine reagents, respectively, was carried out in numerous studies. For an early review by Culling and Reid that describes many details of the histochemical methodologies available for the location and identification of members of the sialic acid family in tissue sections, see ref. [@bb1970]. It should be mentioned that the Hungarian G. Romhány developed in the 1970s a polarization optical electron microscopic analysis of the spatial arrangement of sialylated cell membrane components by periodate oxidation with the aldehyde bisulfite toluidine blue reaction ("anisotropic ABT reaction"), summarized by Makovitzky and Richter.[@bb1975] Also new reagents for staining, making use of periodate oxidation as a first step, were developed, as illustrated by the two following examples. First, a light microscopic histochemical localization of sialic acids (sialoglycoconjugates) in tissue sections of eccrine glands of porcine snout skin could be carried out by employing a method that includes a selective periodate oxidation--phenylhydrazine blockade and a thiocarbohydrazide--silver protein sequence, followed by a physical development procedure.[@bb1980], [@bb1985] Second, for the in situ imaging by confocal laser microscopy and flow cytometric quantification of sialylated glycoproteins on living human gastric normal and cancer cells, the cell lines were treated by mild periodate oxidation (1 mM, 4°C, up to 20 min), and the aldehyde functions generated on the glycoproteins were ligated with the fluorescence tag, fluorescein-5-thiosemicarbazide.[@bb1990] Note that the chosen periodate oxidation conditions only introduce aldehyde groups into the sialic acid glycerol side chains of the glycoproteins on the living cell surface.

In the 1990s, staining of sialic acids in tissues or cells also became possible with lectins and antibodies. The specificities of the methods, developed for sialic acid linkage analysis, were higher than those developed using the periodate reaction.[@bb1995] Especially, the sialyl(α2→3)-specific *Maackia amurensis* agglutinin (MAA) and the sialyl(α2→6)-specific *Sambucus nigra* agglutinin (SNA) found wide application \[and more rarely *Limax flavus* agglutinin (LFA)\] in the lectin histochemical localization of glycoconjugates containing Neu5Ac in (α2→3) and (α2→6) linkage, respectively, to Gal and GalNAc. Wheat germ agglutinin (WGA) also interacts with Neu5Ac (not Neu5Gc), but according to a discussion with Jürgen Roth (University of Zurich, Switzerland), the lectin is not suited for sialic acid analysis. For the detection of sialic acid with these lectins, for example, a peroxidase--antibody--peroxidase complex (PAPS), which can be visualized, is in use. In the same period, the labeling of lectins and immunoglobulins with ferritin, and especially colloidal gold particles, used in both light and electron microscopy, got wide attention. Jürgen Roth ("Immunogold Master," "Mr. Compartment"[@bb2000]) and collaborators developed, most elegantly and frequently applied, the lectin--gold technique for human and animal tissues, including the Golgi complex.[@bb2005], [@bb2010], [@bb2015] Typical examples of staining of normal human colonic mucosa and colon carcinoma with MAA and SNA are shown in [Fig. 24](#f0125){ref-type="fig"} . Before these studies, the same research group had developed cationic (poly-[l]{.smallcaps}-lysine-coated) colloidal gold particles, which allow the detection of anionic, sialidase-sensitive, sites on erythrocytes.[@bb2020] Fig. 24Detection of sialic acid residues in human colon by silver-intensified lectin--gold labeling of sections from paraffin-embedded tissues. (A) Normal colonic surface (*arrowhead*) and crypt epithelium (*asterisks*) are reactive for (α2→3)-linked sialic acid residues, as detected with the *Maackia amurensis* lectin. (B) In contrast, (α2→6)-linked sialic acid residues are undetectable in the colonic surface (*arrowhead*) and crypt epithelium (*asterisks*) with the *Sambucus nigra* lectin. Note the positive labeling of capillary endothelia (*arrows*). In two adjacent serial sections of a colon carcinoma, both (α2→3)-linked sialic acid residues (C) and (α2→6)-linked sialic acid residues (D) can be detected. Scale bar: 20 μm (A, B), 50 μm (C, D).Fig. 24Photos courtesy of Prof. Dr. Jürgen Roth.

In more recent years, virolectins have shown to be also powerful reagents for histochemical detection of sialic acids. For example, influenza C viruses bind to 9-O-acetylated sialic acid in tissue slices from rat liver or human colon and are immunologically detected by incubation with rabbit antiserum, followed by treatment with fluorescent anti-rabbit IgG antibody for visualization.[@bb2025] Staining is also possible by the esterase activity of the bound viruses. In a similar way, such staining has also been done with a soluble form of influenza C virus hemagglutinin-esterase, wherein the C-terminal transmembrane and cytoplasmic domains are replaced by the Fc portion of human IgG. This complex (CHE-Fc) retains both its recognition and enzymatic function. It is detected on the cryosections with alkaline phosphatase-conjugated goat antihuman IgG.[@bb2030] Great progress in the identification of 4-mono-, 9-mono, and 7,9-di-O-acetylated sialic acids (Neu5Ac and Neu5Gc) in tissue slices or cells of man and mouse was recently achieved with hemagglutinin-esterase (HE) envelope proteins of nidoviruses (toro- and coronaviruses) and influenza C virus (HEF).[@bb2035] For this purpose, HE and HEF ectodomains were fused with the C-terminal domain of human IgG1 or of mouse or bovine IgG2a. The authors showed that O-acetylated sialoglycans occur in a species-, organ-, tissue-, and cell-type-specific way, and that their expression is regulated at the level of the individual cell. They also observed that in several key tissues, especially in the brain, mice and humans share similar 9-*O*-acetyl-sialic acid expression profiles, which suggests an evolutionary and functional conservation. In a similar way, this method with the recombinant soluble virolectins was applied to various tissues of many kinds of animals, including humans, and demonstrated an astonishing variability of the occurrence of the three O-acetylated sialic acids in the tissues studied. While Neu4,5Ac~2~, for example, was prevalent in horse and guinea pig respiratory tissue, Neu5,9Ac~2~ and Neu5,7,9Ac~3~ were found especially in the same tissue of man and mouse.[@bb2040] In an early study using a monoclonal antibody bound to gold particles against the *Meningococci* group B capsular polysaccharide, \[→ 8)Neu5Ac(α2 →\]~*n*~, this polymer was detected in a human Wilms tumor ([Fig. 25](#f0130){ref-type="fig"} ).[@bb2045], [@bb2050], [@bb2055] Treatment with endo-neuraminidase N as control abolished staining. Furthermore, in an immunocytochemical study on ganglioside expression in human breast cancer cells, specific monoclonal antibodies and antimouse IgM or antimouse IgG labeled with Alexa 488 showed the accumulation of gangliosides on the tumor cell surfaces in confocal microscopy.[@bb2060] Fig. 25Reexpression of (α2→8)-linked polysialic acid in human Wilms tumor. (A) Silver-intensified immunogold staining with mAb 735 of a section of paraffin-embedded tissue shows intense labeling in the Wilms tumor (WT). The adjacent normal kidney (NK) is unlabeled. (B) Immunolabeling in a consecutive serial section for (α2→8)-linked polysialic acid is abolished by section pretreatment with endoneuraminidase N (Endo N). (C) Immunogold labeling for (α2→8)-linked polysialic acid of an ultrathin frozen section from a Wilms tumor is very intense at cell-surface regions with a *thick surface coat*. (D) In contrast, immunogold labeling is sparse and patchy in regions of close contact of tumor cells. Scale bar: 300 μm (A, B), 300 nm (C), 150 nm (D).Fig. 25Photos courtesy of Prof. Dr. Jürgen Roth.

Finally, at the end of this short overview of the history of histological methods in sialobiology, attention will be paid to some new fluorescence microscopy investigations that allow the manipulation of glycans within their native environment, i.e., to study living cells and the localization, mobility, and lifetime of glycans. Since some sialyltransferases tolerate such large groups as fluorescein at C5 or C9, it was possible to incorporate fluorescent probes via suitably modified CMP-sialic acid donors into cell-surface glycoconjugates[@bb2065] (for a general review, see ref. [@bb2070]) or even enabled the kinetic analyses of the rates of different sialyltransferases within cells.[@bb2075] So, it was possible to localize sialyltransferases in the Golgi compartments in rat liver with the CMP-9-fluoresceinyl-Neu5Ac donor substrate.[@bb2080] Furthermore, Bertozzi and coworkers introduced the Staudinger ligation for covalent tagging of azido sugars, incorporated biosynthetically into cell-surface glycans. In case of sialic acid, cells are treated with per-O-acetylated *N*-azidoacetyl-[d]{.smallcaps}-mannosamine (ManNAz). After entering the cells, the product is O-deacetylated, transformed into the corresponding *N*-azidoacetylneuraminic acid (Neu5Az), subsequently converted into the activated CMP sugar, and finally incorporated into cell-surface glycans on human or other cells.[@bb2085] Interestingly, the various biosynthetic enzymes, normally involved in the conversion of ManNAc into bound Neu5Ac (see [Section 11.1](#s0170){ref-type="sec"}), tolerate the unnatural substrates. The bound Neu5Az can be visualized using a copper-free click chemistry reaction with, for instance, a difluorinated cyclooctyne (DIFO) reagent, conjugated to an imaging probe, e.g., Alexa Fluor 488. This staining procedure is not toxic and can be carried out in cultured cells and in live mice. Here, a typical example is the study of the sialome during zebrafish development, which showed that the biosynthesis of cell-surface sialosides starts as early as 8.5 h postfertilization.[@bb2090] In another example, Neu5Az(α2→3)Lac or Neu5Az(α2→3)Gal was incubated with live trypomastigotes, resulting in Neu5Az(α2→3)Gal-glycoconjugates by means of the parasite *trans*-sialidase (see [Section 11.7](#s0220){ref-type="sec"}). For visualization use was made of, for instance, the phosphine--FLAG conjugate, identified by anti-FLAG antibodies. It was learned from this approach that the transfer of sialic acid is mainly to the mucins of the parasites.[@bb2095]

8. Sialic Acids as a Part of Glycoproteins, Glycolipids, Oligosaccharides, and Polysaccharides {#s0120}
==============================================================================================

Although some members of the sialic acid family only occur in free form (see [Section 1](#s0010){ref-type="sec"}; [Table 1](#t0010){ref-type="table"}), most members are constituents of glycoproteins, glycolipids, capsular polysaccharides, lipopolysaccharides, and (lipo)oligosaccharides. But also glycosylphosphatidylinositol membrane anchors and keratan sulfates have been shown to contain sialic acid. In the following sections a summary of sialic acid-containing structural elements will be given, as found in first/early reports.

8.1. Glycoprotein N- and O-Glycans {#s0125}
----------------------------------

In most eukaryotic glycoproteins the N- and O-glycans are terminated with Neu5Ac or Neu5Gc, or both. First indications stem from the late 1950s. Over the years, the two sialic acids have been found to be attached to [d]{.smallcaps}-galactose (Gal) via (α2→3)[@bb2100], [@bb2105], [@bb2110], [@bb2115], [@bb2120] or (α2→6)[@bb2120], [@bb2125], [@bb2130] linkages, to *N*-acetyl-[d]{.smallcaps}-galactosamine (GalNAc) via (α2→3)[@bb2135], [@bb2140], [@bb2145] or (α2→6)[@bb2110], [@bb2150], [@bb2155], [@bb2160], [@bb2165] linkages, and to *N*-acetyl-[d]{.smallcaps}-glucosamine (GlcNAc) via an (α2→6) linkage.[@bb2170] At the end of the 1970s, mid-1980s, terminal *N*-acylneuraminic acids were also discovered to be (α2→8)-linked[@bb2175], [@bb2180], [@bb2185] or (α2→9)-linked[@bb2190], [@bb2195] with internal *N*-acylneuraminic acids, a phenomenon that was already seen in the 1960s for glycolipids (see [Section 8.2](#s0130){ref-type="sec"}). Incidentally, terminal Neu5Ac(α2→4)Gal(β1 →[@bb2200], [@bb2205], [@bb2210] and terminal Neu5Ac(α2→4)GlcNAc(β1→[@bb2215] sequences have been published, but discussion about these results does exist. Furthermore, an internal →)Fuc(1→4)Neu5Gc(2→ sequence is known.[@bb2220]

Although a long list of naturally occurring *N*,*O*-acylneuraminic acids is known ([Table 1](#t0010){ref-type="table"}), only for a few glycoproteins, intact glycans with such sialic acids have been published. In short, the terminal sequences comprise Neu4,5Ac~2~(α2→3)Gal(β1→,[@bb2225], [@bb2230] Neu4,5Ac~2~(α2→6)Gal(β1→,[@bb2230], [@bb2235], [@bb2240], [@bb2245], [@bb2250] Neu5,9Ac~2~(α2→3)Gal(β1→,[@bb2255], [@bb2260], [@bb2265], [@bb2270], [@bb2275] and Neu5,7,9Ac~3~(α2→3)Gal(β1 → .[@bb2265], [@bb2270] But also (α2→3) linkages with Gal have been reported for Neu5,7Ac~2~, Neu5,8Ac~2~, Neu5,7,8Ac~3~, and Neu5,8,9Ac~3~.[@bb2265] Furthermore, \[Neu5Ac(α2→8)\]~*n*~, \[Neu5Gc(α2→8)\]~*n*~, and \[Neu5Ac/5Gc(α2→8)\]~*n*~ sequences with 4Ac, 7Ac, 9Ac, or 9Lt substituents,[@bb2280] a Neu5Ac8S(α2→9)\[Neu5Ac(α2→9)\]~*n*~ sequence,[@bb2285] and the \[Neu5Gc(α2→O5)\]~*n*~ sequence (linkage between Neu5Gc C2 and the *N*-glycolyl OH function of the next Neu5Gc residue; [Fig. 26](#f0135){ref-type="fig"} ) should be mentioned.[@bb2290] The latter sequence can also be terminated with Neu5Gc9S, i.e., Neu5Gc9S(α2→O5)\[Neu5Gc(α2→O5)\]~*n*~.[@bb0365] Fig. 26A terminal Neu5Gc(α2→O5)Neu5Gc sequence.Fig. 26

The N- and O-glycans can also be terminated by Kdn, and first reports are from the late 1980s and early 1990s. The sialic acid can be (α2→3)-linked with Gal[@bb2295], [@bb2300] and (α2→3)- or (α2→6)-linked with GalNAc.[@bb2295], [@bb2305] Furthermore, Kdn occurs in polysialyl sequences: \[Kdn(α2→8)\]~*n*~ (eventually with 4Ac, 7Ac, or 9Ac substituents),[@bb2295], [@bb2310] and Kdn(α2→8)\[Neu5Ac(α2→8)\]~*n*~, Kdn(α2→8)\[Neu5Gc(α2→8)\]~*n*~, Kdn(α2→8)\[Neu5Ac/5Gc(α2→8)\]~*n*~, and Kdn9Ac(α2→8)\[Neu5Gc(α2→8)\]~*n*~.[@bb0385], [@bb0405], [@bb2310] Of interest are the disubstituted internal Kdn units in Fuc(α1→4)\[Fuc(α1→5)\]Kdn(α2→3)Gal(β1→[@bb2315] and in Fuc(α1→4)\[Fuc(α1→5)\]Kdn(α2→6)GalNAc(α1→,[@bb2315], [@bb2320] and the double Kdn-termination in Kdn(α2→3)\[Kdn(α2→6)\]GalNAc(α1→,[@bb2325] all three occurring in O-glycans.

For extensive reviews of established sialic acid-containing glycoprotein glycan structures, see, e.g., refs. [@bb0035], [@bb2330], [@bb2335], [@bb2340], [@bb2345]. For sialylation of glycosylphosphatidylinositol membrane anchors and keratan sulfates, see ref. [@bb2350] and ref. [@bb2355], respectively.

8.2. Glycolipids {#s0130}
----------------

As in glycoprotein glycans, in glycolipids/gangliosides (first reports from the early 1960s), terminal Neu5Ac and/or Neu5Gc can be coupled with Gal via (α2→3)[@bb2360], [@bb2365], [@bb2370], [@bb2375] or (α2→6)[@bb2380], [@bb2385] linkages, with GalNAc via (α2→3)[@bb2390] or (α2→6)[@bb2395] linkages, with GlcNAc via an (α2→6)[@bb2400], [@bb2405] linkage, and with other *N*-acylneuraminic acids via (α2→8)[@bb2370], [@bb2410], [@bb2415] or (α2→9)[@bb2420] linkages. Also Neu5Gc(α2→4)Neu5Gc, Neu5Gc(α2→4)Neu5Ac, Neu5Ac(α2→6)Glc, and Neu5Gc(α2→6)Glc (Glc =  [d]{.smallcaps}-glucose) elements have been reported.[@bb0245], [@bb2425], [@bb2430], [@bb2435] Furthermore, terminal sequences with Neu itself have been identified: Neu(α2→3)Gal(β1→[@bb0085], [@bb0090], [@bb2440], [@bb2445] and Neu(α2→8)Neu5Ac(α2→3)Gal(β1→.[@bb0095] In the mid-1960s, it was predicted that gangliosides could occur in the lactonic form (inner esters),[@bb2450], [@bb2455] which a few years later was supported by IR spectroscopy.[@bb2460] Besides the inner ester formation between sialic acids (see [Section 8.5](#s0145){ref-type="sec"}), such lactone formation was also seen for the Neu5Ac(α2→3)Gal sequence.[@bb2465] Here, Neu5Ac(α2→3,1→2)Gal and/or Neu5Ac(α2→3,1→4)Gal elements could be proven by NMR spectroscopy and shown not to be artifacts.[@bb2470] More recently, both lactone forms were prepared from sialoglycopeptides (treatment with glacial acidic acid).[@bb2475]

In addition to the Neu5Ac/Neu5Gc-glycolipids, from the 1970s onward, intact glycan structures with O-acetylated and O-methylated *N*-acylneuraminic acid residues have been published. Established terminal sequences showNeu5,9Ac~2~(α2→3)Gal(β1→,[@bb2480]Neu4Ac5Gc(α2→3)Gal(β1→ (or Neu5GcAc),[@bb2485], [@bb2490]Neu9Ac5Gc(α2→3)Gal(β1→,[@bb2495]Neu4,9Ac~2~5Gc(α2→3)Gal(β1→,[@bb2500]Neu5Ac8Me(α2→3)Gal(β1→,[@bb2505], [@bb2510]Neu5Gc8Me(α2→3)Gal(β1→ (or Neu5GcMe),[@bb0375], [@bb2505]Neu5Gc8Me(α2→3)GalNAc(β1→,[@bb2515]Neu5Ac9Me(α2→6)Glc(β1→,[@bb2520]Fuc(α1→O5)Neu5Gc(α2→6)Glc(β1→,[@bb2525]Neu4,5Ac~2~(α2→8)Neu5Ac(α2→3)Gal(β1→,[@bb0175]Neu5,7Ac~2~(α2→8)Neu5Ac(α2→3)Gal(β1→,[@bb2530]Neu5,9Ac~2~(α2→8)Neu5Ac(α2→3)Gal(β1→,[@bb2530], [@bb2535], [@bb2540]Neu5,7,9Ac~3~(α2→8)Neu5Ac(α2→3)Gal(β1→,[@bb2530]Neu5Ac8Me(α2→O5)Neu5Gc(α2→3)Gal(β1→,[@bb2545]\[Neu5Gc9Me(α2→O5)\]~*n*~.[@bb0355], [@bb2550]

Also sequences containing terminal sulfated sialic acid residues have been characterized:Neu5Ac8S(α2→3)Gal(β1→ and Neu5Gc8S(α2→3)Gal(β1→,[@bb2555]Neu5Ac4S(α2→6)Glc(β1→,[@bb0245]Neu5Ac8S(α2→6)Glc(β1→,[@bb0250]Neu5Gc8S(α2→6)Glc(β1→,[@bb0250], [@bb0360]Neu5Ac8S/5Gc8S(α2→8)Neu5Ac/5Gc(α2→3)Gal(β1→,[@bb0255]Neu5Ac8S(α2→8)Neu5Ac(α2→6)Glc(β1→.[@bb2560]

Furthermore, terminal and internal (branched) elements with sialic acid became known from the late 1970s onward:Neu5Ac(α2→3)\[Neu5Ac(α2→6)\]Gal(β1→,[@bb2565]Neu5Ac(α2→3)\[Neu5Ac(α2→4)\]Gal(β1→8)Neu5Ac(α2→3)GalNAc(β1→,[@bb2570]Neu5Gc8Me(α2→3)\[Neu5Gc8Me(α2→6)\]GalNAc(β1→,[@bb2420]→6)Gal(β1→4)\[Gal(β1→8)\]Neu5Gc(α2→3)Gal(β1→,[@bb2575]→6)Gal(β1→4)Neu5Gc(α2→3)Gal(β1→,[@bb2580]→6)Gal(β1→4)Neu5Gc8Me(α2→3)Gal(β1→,[@bb2580]→3/4)Gal(α1→4)Neu5Ac(α2→3)Gal(β1→ \[earlier reported with an (α2→4) linkage\],[@bb2585], [@bb2590], [@bb2595]→3)Gal(α1→4)Neu5Ac(α2→6)Gal*f*(β1→3)Gal(α1→4)Neu5Ac(α2→3)Gal(β1→,[@bb2600]→3)Gal(α1→4)Neu5Ac8Me(α2→3)Gal(β1→,[@bb2510]→3)Gal(α1→9)Neu5Ac(α2→3)Gal(β1→,[@bb2510]→6)Glc(β1→8)Neu5Gc(α2→6)Glc(β1→,[@bb2605]Fuc(α1→8)Neu5Gc(α2→4)Neu5Ac(α2→,[@bb0245]Fuc(α1→4)Neu5Ac(α2→O5)Neu5Gc(α2→4)Neu5Ac(α2→,[@bb2610]Fuc(α1→O5)Neu5Gc(α2→4)Neu5Ac(α2→ .[@bb2615]

Finally, the \[Neu5Gc8Me(α2→O5)\]~*n*~ [@bb0235], [@bb0345] and the Neu5Gc8Me(α2 → O5)\[Neu5Gc(α2 → O5)\]~*n*~ [@bb2620] sequences, and the Kdn-containing sequences Kdn(α2 → 3)Gal(β1 →,[@bb2625] Kdn9Ac(α2 → 3)Gal(β1→,[@bb2630] and Kdn(α2 → 6)GalNAc(β1→[@bb2635] have been established.

In fact, the large variety in sialylated structural elements found so far among glycolipid glycans is certainly influenced by the interest of researchers in the glycolipids of lower animals, such as starfish, sea urchins, sea cucumbers, brittle stars, and feather stars.

For extensive reviews of established sialic acid-containing glycolipid structures, see, e.g., refs. [@bb0035], [@bb2640], [@bb2645], [@bb2650].

8.3. Milk Oligosaccharides {#s0135}
--------------------------

Since the late 1950s, neutral and acidic milk oligosaccharides of a large variety of animals have been studied. The ensembles of oligosaccharides differ from species to species, and in the case of human milk over 200 different compounds are expected to be present, of which at the moment 163 have been characterized (up to tridecasaccharides), including 54 sialyloligosaccharides.[@bb2655], [@bb2660], [@bb2665], [@bb2670], [@bb2675], [@bb2680]

The established terminal sequences with sialic acid are similar to those found in glycoprotein and glycolipid glycans:Neu5Ac(α2 → 3)Gal(β1 →,[@bb1040], [@bb1255], [@bb1260], [@bb2685]Neu5Ac(α2 → 6)Gal(β1 →,[@bb2685], [@bb2690]Neu5Ac(α2 → 6)GalNAc(β1 →,[@bb2695]Neu5Ac(α2 → 3)GlcNAc(β1 →,[@bb2700]Neu5Ac(α2 → 4)GlcNAc(β1 →,[@bb2705], [@bb2710]Neu5Ac(α2 → 6)GlcNAc(β1 →,[@bb2685]Neu5Ac(α2 → 6)Glc,[@bb2715]Neu5Gc(α2 → 3)Gal(β1 →,[@bb2685]Neu5Gc(α2 → 6)Gal(β1 →,[@bb2720]Neu5Ac/5Gc(α2 → 8)Neu5Ac/5Gc(α2 → 3)Gal(β1 →,[@bb2685], [@bb2695], [@bb2700]Neu4,5Ac~2~(α2 → 3)Gal(β1 →,[@bb2725], [@bb2730]Neu4,5,*x*Ac~3~(α2 → 3)Gal(β1 → with *x*  = 7, 8, or 9,[@bb2735]Neu4,5Ac~2~(α2 → 6)Gal(β1 →,[@bb2740] andNeu5,*y*Ac~2~(α2 → 3)Gal(β1 → with *y*  = probably 9.[@bb1040], [@bb2700]

For Neu5,9Ac~2~ data in human and cow milk carbohydrates, see also ref. [@bb2745]. Interestingly, besides Neu5Ac and Neu5Gc, porcine milk oligosaccharides (and also glycoproteins and gangliosides) contain very small amounts of Kdn as the building block.[@bb2750]

8.4. Urinary Oligosaccharides and Glycopeptides {#s0140}
-----------------------------------------------

In normal human urine of different biological origin only small ensembles of sialylated oligosaccharides have been demonstrated to occur, e.g.:Neu5Ac(α2 → 3)Gal(β1 → 4)Glc/GlcNAc/GlcNAc(α1 → P/GalNAc(α1 → P,[@bb2755], [@bb2760], [@bb2765], [@bb2770]Neu5Ac(α2 → 6)Gal(β1 → 4)Glc/GlcNAc/GlcNAc(α1 → P,[@bb2755], [@bb2765], [@bb2770]Neu5Ac(α2 → 3)Gal(β1 → O)inositols,[@bb2770]Neu5Ac(α2 → 3)Gal(β1 → 3)\[Neu5Ac(α2 → 6)\]GalNAc,[@bb2765] andNeu5Ac(α2 → 3)Gal(β1 → 3)\[Neu5Ac(α2 → 6)\]GalNAc(α1 → O)Ser.[@bb2765]

A disialylated hexasaccharide was found in human pregnancy urine, Neu5Ac(α2 → 3)Gal(β1 → 3)\[Neu5Ac(α2 → 6)\]GlcNAc(β1 → 3)Gal(β1 → 4)Glc.[@bb2775]

Studies on rat urine revealed the presence of Neu5Ac/Neu5Gc/Neu5,9Ac~2~(α2 → 3)Gal(β1 → 4)Glc.[@bb2255], [@bb2760], [@bb2780]

Several carbohydrate-related inborn errors of metabolism can lead to the accumulation of oligosaccharides in the body (see [Sections 13.3](#s0290){ref-type="sec"} and [13.4](#s0295){ref-type="sec"}). In case of sialidosis/galactosialidosis, (α2 → 3)- and (α2 → 6)-sialylated (Neu5Ac) glycoprotein N-glycans (nearly only the expected endo-β-*N*-acetylglucosaminidase-cleaved oligosaccharides) and O-glycans (glycopeptides) are accumulated in the patient\'s urine, blood serum, amniotic fluid, and ascitic fluid, stored in the placenta, and shown to be present in fibroblasts.[@bb2785], [@bb2790], [@bb2795], [@bb2800], [@bb2805], [@bb2810], [@bb2815], [@bb2820], [@bb2825], [@bb2830], [@bb2835], [@bb2840], [@bb2845], [@bb2850] In a more recent study also relatively small Neu5Ac- and Neu5Ac--Neu5Ac-containing oligosaccharides with a reducing-end hexose were identified. It was suggested that they were derived from glycosphingolipids, whereby the existence of a hitherto unknown endoglycosylceramidase involved in an alternative glycosphingolipid catabolic pathway was assumed. Unexpectedly, also related sialylated C1-oxidized (aldohexonic acid) versions were detected.[@bb2850]

Interestingly, Neu5Ac(α2 → 6)Man(β1 → 4)GlcNAc was isolated from the urine of a patient with β-mannosidosis.[@bb2855]

Furthermore, in the urine of patients with aspartylglucosaminuria, a series of neutral and acidic glycoasparagines, including Neu5Ac(α2 → 3/6)Gal(β1 → 4)GlcNAc(β1 → N)Asn, Neu5Ac(α2 → 3/6)Gal(β1 → 4)GlcNAc(β1 → 3)Gal(β1 → 4)GlcNAc(β1 → N)Asn, and Neu5Ac(α2 → 8)Neu5Ac(α2 → 3)Gal(β1 → 4)GlcNAc(β1 → N)Asn, are accumulated.[@bb2845] Note that the history of elucidating aspartylglucosaminuria carbohydrates showed, besides GlcNAc(β1 → N)Asn, initially several proposals for structures, including compounds with terminal Neu5Ac(α2 → 4)Gal(β1 →, Neu5Ac(α2 → 7)Neu5Ac(α2 → 3)Gal(β1 →, and Neu5Ac(α2 → 9)Neu5Ac(α2 → 3)Gal(β1 → elements, that were found to be incorrect in later studies.[@bb2860], [@bb2865], [@bb2870], [@bb2875], [@bb2880]

Patients with Schindler disease type I, type II (Kanzaki), and type III, having an α-*N*-acetylgalactosaminidase deficiency, excrete relatively high concentrations of mono- and disialylated O-glycopeptides and related oligosaccharides in their urine.[@bb2845], [@bb2885], [@bb2890], [@bb2895], [@bb2900]

In this context, also pathological abnormalities of (i) lysosomal sialic acid transport (Salla disease) and (ii) a biosynthetic defect in the sialic acid metabolism (CMP-Neu5Ac overproduction; sialuria), described for the first time in 1979 and 1967, respectively, should be mentioned. Depending on the defect, the urinary excretions of Neu5Ac vary from (i) 5- to 10-fold (Salla disease[@bb2905], [@bb2910]) and 200-fold (infantile free sialic acid storage disease[@bb2915]) to (ii) 10,000-fold (sialuria; hypersialylation of glycoprotein O-glycans[@bb2920], [@bb2925], [@bb2930], [@bb2935], [@bb2940]) over the normal values, and increased levels in tissues and cells (for further information, see [Sections 13.1](#s0280){ref-type="sec"} and [13.2](#s0285){ref-type="sec"}).

8.5. Capsular Polysaccharides, Lipopolysaccharides, and Lipooligosaccharides {#s0145}
----------------------------------------------------------------------------

With the first characterized polysialic acid, called colominic acid, in the late 1950s, over the years a continuous flow of structures of sialic acid-containing microbial polysaccharides has appeared. Colominic acid is an (α2 → 8)-linked homopolymer of Neu5Ac, \[→ 8)Neu5Ac(α2 → 8)Neu5Ac(α2 →\]~*n*~, isolated from *Escherichia coli* K235.[@bb0590], [@bb2945], [@bb2950], [@bb2955] Such a homopolymer, isolated from *E. coli* K1, can also be partially acetylated at Neu5Ac O7 and/or O9.[@bb0185] A polysialic acid from *Neisseria meningitidis* Group C was identified as \[→ 9)Neu5Ac(α2 → 9)Neu5Ac(α2 →\]~*n*~ (partly Neu5,7,8Ac~3~ and Neu5,7Ac~2~ or Neu5,8Ac~2~).[@bb0180], [@bb2960] Note that in the late 1950s this homopolymer was suggested to be built up from hexosamine and sialic acid residues.[@bb2965] A \[→ 8)Neu5Ac(α2 → 9)Neu5Ac(α2 →\]~*n*~ polysialic acid was reported to be present in the *E. coli* K92 strain.[@bb2970] In several heteropolysaccharides and core regions of lipopolysaccharides (lipooligosaccharides), the (O-acetylated) Neu5Ac(α2 → 3/6) unit was found in the terminal (side-chain) position.[@bb0035], [@bb2975], [@bb2980] Interestingly, a microbial decasaccharide revealed the presence of a terminal Neu5,9Ac~2~(α2 → 6)Gal(β1 → sequence.[@bb2985] Also heteropolysaccharide structures with internal sialic acid, e.g., → 4)Neu5Ac(α2 →; → 4)Neu5,7/9Ac~2~(α2 →; → 4)Neu5,9Ac~2~(α2 →; → 4)Neu5,7/8,9Ac~3~(α2 →; and → 7)Neu5Ac(α2 → units, were established.[@bb0035], [@bb2980], [@bb2990] Typical examples are \[→ 4)Neu5Ac(α2 → 6)Gal(α1 →\]~*n*~,[@bb2995] \[→ 3)GalNAc(β1 → 4)Gal(α1 → 4)Neu5,9Ac~2~(α2 → 3)Gal(β1 →\]~*n*~,[@bb0200], [@bb3000] and {→ 3)GalNAc(β1 → 7)Neu5Ac(α2 → 3)\[Glc(α1 → 2)\]Glc(β1 →}~*n*~,[@bb3005] and, as core region oligosaccharide of a lipopolysaccharide, Gal(α1 → 6)Glc(β1 → 7)Neu5Ac.[@bb3010] For Kdn-containing capsular polysaccharides, terminal \[Kdn(α2 →\] and internal \[→ 9)Kdn5Me(α2 →\] units have been shown. In case of teichulosonic acids, containing Kdn residues, (β2 → 4)-linked Kdn backbones, decorated with single monosaccharide side-chain units, have been determined, e.g., {→ 4)\[Glc(β1 → 8)\]Kdn(β2 →}~*n*~, {→ 4)\[Gal(β1 → 9)\]Kdn(β2 →}~*n*~, and {→ 4)\[Glc(β1 → 8)\]\[Glc(β1 → 9)\]Kdn(β2 →}~*n*~, as well as tetrasaccharides with two Kdn residues, which are (α2 → 4)-interlinked, e.g., Gal(β1 → 9)Kdn(α2 → 4)\[Gal(β1 → 9)\]Kdn.[@bb2980], [@bb3015] The Kdn residues in the tetrasaccharide can be acetylated at O7 and O8.[@bb3020]

In polysialyl sequences intramolecular lactone formation between sialic acids has been observed.[@bb0035] In the case of a Neu5Ac(α2 → 8)Neu5Ac sequence, lactonization yields a Neu5Ac(α2 → 8,1 → 9)Neu5Ac element, whereby the COOH group of one residue reacts with HO9 of an adjacent residue to give a six-membered ring. In a similar way, Neu5Ac(α2 → 9)Neu5Ac can be converted into Neu5Ac(α2 → 9,1 → 8)Neu5Ac.

8.6. General Remarks About the Structural Analysis of Glycans {#s0150}
-------------------------------------------------------------

In the late 1960s and early 1970s, the protocols for the structural analysis of carbohydrates underwent a great change. At first instance, GLC combined with EIMS, developed for the linkage analysis on the monomer level (methylation analysis), caused a revolution in polysaccharide and glycoconjugate characterization.[@bb1370], [@bb1380] And with the introduction of high-resolution ^1^H and ^13^C NMR spectroscopy in the mid-1970s, the analysis of glycoprotein glycans, glycolipids, and polysaccharide-derived oligosaccharides came within reach.[@bb1380], [@bb2330], [@bb2335], [@bb2345] Concerning sialoglycans, the chemical shifts of H3e and H3a of sialic acids (and other non-2-ulosonic acids) turned out to be highly indicative for the anomeric configuration, the type of linkage with neighboring residues, and the further microenvironment of these acids. Note that the pH of the solution can influence these values ([Table 3](#t0020){ref-type="table"}). For illustration, a few examples at pH 7 will be given. α-Neu5Ac: H3e, δ 2.730/H3a, δ 1.621; β-Neu5Ac: H3e, δ 2.208/H3a, δ 1.827; Neu5Ac(α2 → 6)Gal(β1 → 4): H3e, δ 2.67/H3a, δ 1.71--1.72; Neu5Ac(α2 → 3)Gal(β1 → 4): H3e, δ 2.75--2.76/H3a, δ 1.80; Neu5Gc(α2 → 6)Gal(β1 → 4): H3e, δ 2.69--2.70/H3a, δ 1.73--1.74; Neu5Gc(α2 → 3)Gal(β1 → 4): H3e, δ 2.77--2.78/H3a, δ 1.81--1.82; Neu4,5Ac~2~(α2 → 6)Gal(β1 → 4): H3e, δ 2.67--2.68/H3a, δ 1.85; Neu4,5Ac~2~(α2 → 3)Gal(β1 → 4): H3e, δ 2.77/H3a, δ 1.93; Neu5Ac(α2 → 6)\[R → 3\]GalNAc-ol: H3e, δ 2.72--2.74/H3a, δ 1.69--1.71. For complete tables of H3e/H3a structure--reporter-group NMR data of Neu5Ac/Neu5Gc/Neu4,5Ac~2~/Neu5,9Ac~2~-containing structural elements, see refs. [@bb2335], [@bb2345].

Fortunately, the discovery of softer ionization techniques than electron-impact (EIMS) also made mass spectrometry suitable for the analysis of glycoprotein glycans, glycolipids, and (polysaccharide-derived) oligosaccharides. This revolution started with the introduction of fast-atom-bombardment mass spectrometry (FABMS) in the 1980s. However, today, MALDI-TOFMS and ESIMS play the main roles in carbohydrate analysis (for recent reviews, see refs. [@bb1380] and [@bb3025], [@bb3030], [@bb3035], [@bb3040], [@bb3045], [@bb3050], [@bb3055]). Even intact glycoproteins can be unraveled now by ESIMS.[@bb3060] For a series of papers, specifically focused on mass spectrometry of intact sialoglycans, including information about the stabilization of sialic acid, see refs. [@bb3065], [@bb3070], [@bb3075], [@bb3080], [@bb3085], [@bb3090], [@bb3095]. For the differentiation between (α2 → 3) and (α2 → 6) linkages several elegant protocols have been developed. For instance, treatment of Neu5Ac(α2 →  *x*)Gal(β1 → 4)-glycans (*x*  = 3 or 6) with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (carboxylic acid activator) in methanol yielded methyl ester derivatives for (α2 → 6)-linked Neu5Ac and lactone derivatives for (α2 → 3)-linked Neu5Ac \[Neu5Ac(α2 → 3,1 → 2)Gal(β1 → and/or Neu5Ac(α2 → 3,1 → 4)Gal(β1 →\], providing a difference of 32 Da in mass between both glycosidic linkage types.[@bb3090] A very recent example comprises the treatment of Neu5Ac(α2 →  *x*)Gal(β1 → 4)-glycans (*x*  = 3 or 6) with dimethylamine, 1-ethyl-3-(3-dimethylamino)propyl)carbodiimide (activator)/1-hydroxybenzotriazole (catalyst) in dimethyl sulfoxide, affording dimethylamidate derivatives for (α2 → 6)-linked Neu5Ac and lactone derivatives for (α2 → 3)-linked Neu5Ac (difference in mass: 45 Da).[@bb3100] Subsequent treatment with ammonium hydroxide had only effect on the lactone ring of the (α2 → 3)-linked Neu5Ac, resulting in the formation of an amidate derivative (difference in mass: 28 Da).[@bb3105]

9. Growing Interest From the Organic and Enzymatic Chemistry {#s0155}
============================================================

As has been described in [Section 4.1](#s0045){ref-type="sec"}, first reports on the organic and enzymatic synthesis of Neu5Ac date from the 1960s, in a period that questions around the different chiralities were still not completely solved. The protocols comprised chemical coupling of oxaloacetic acid (or its di-*tert*-butyl ester) and either [d]{.smallcaps}-GlcNAc or [d]{.smallcaps}-ManNAc, followed by decarboxylation ([Scheme 6](#sch0035){ref-type="fig"}),[@bb1145], [@bb1180], [@bb1185], [@bb1190] and enzymatic coupling of pyruvic acid and [d]{.smallcaps}-ManNAc in the presence of Neu5Ac aldolase (*N*-acylneuraminate pyruvate lyase) ([Scheme 5](#sch0030){ref-type="fig"}).[@bb1160], [@bb1165] For the preparation of Neu5Gc, [d]{.smallcaps}-ManNAc was replaced by [d]{.smallcaps}-ManNGc. Next routes to prepare Neu5Ac enzymatically were the condensation of [d]{.smallcaps}-ManNAc with phosphoenolpyruvic acid catalyzed by Neu5Ac synthase (rat liver extract) in the presence of ATP, or by Neu5Ac synthase using nonphosphorylated ManNAc (meningococcal extract).[@bb1200], [@bb3110], [@bb3115] In the following years, different routes and improvements to obtain higher yields (even at the multikilogram level) were reported.[@bb0035], [@bb0505], [@bb3120], [@bb3125], [@bb3130], [@bb3135] In this context, [d]{.smallcaps}-ManNAc was frequently generated from the cheaper [d]{.smallcaps}-GlcNAc in an alkaline epimerization process. Note that an excellent biological source for the isolation of large amounts of Neu5Ac was initially the urine of sialuria patients (see [Sections 8.4](#s0140){ref-type="sec"} and [13.1](#s0280){ref-type="sec"}),[@bb2925] and later edible bird\'s nest mucin[@bb0770], [@bb2745] and hen\'s egg.[@bb3140] For the isolation of large amounts of Neu5Gc from holothuroidea gumi, *Cucumaria echinata*, see ref. [@bb3145]. With the characterization of a long series of *N*,*O*-acylneuraminic acids in the late 1970s and early 1980s ([Section 5](#s0065){ref-type="sec"}), synthetic activities in this direction were also started. Via organic synthesis, several free O-acetylated sialic acids became available, e.g., Neu4,5Ac~2~, Neu5,9Ac~2~, Neu9Ac5Gc, Neu4,5,9Ac~3~, and Neu5,7,8,9Ac~4~.[@bb3150], [@bb3155], [@bb3160], [@bb3165] Additionally, a large series of *N*,*O*-acetylneuraminic acid alkyl/aryl ester α-alkyl/α-aryl glycosides were synthesized: Neu4,5Ac~2~, Neu5,7Ac~2~, Neu5,8Ac~2~, Neu5,9Ac~2~, Neu5,7,8Ac~3~, Neu5,7,9Ac~3~, Neu5,8,9Ac~3~, Neu4,5,9Ac~3~, Neu4,5,8,9Ac~4~, and Neu5,7,8,9Ac~4~.[@bb3170], [@bb3175], [@bb3180] Enzymatic protocols using Neu5Ac aldolase were developed for the synthesis of Neu5,9Ac~2~ and Neu5Ac9Lt.[@bb3185], [@bb3190] A number of other naturally occurring sialic acids have also been synthesized along organic chemical or aldolase-catalyzed routes. Examples are as follows: Neu2en5Ac,[@bb3195] Neu2en5Gc,[@bb0380], [@bb3195] Neu2en5,9Ac~2~,[@bb0285] Neu2en5,7,9Ac~3~,[@bb0285] Neu2en9Ac5Gc,[@bb0285] Neu2en5GcAc,[@bb0285] Kdn,[@bb3200], [@bb3205], [@bb3210] Kdn2en,[@bb3215] Neu2,7an5Ac,[@bb3220], [@bb3225] Neu5Ac8Me,[@bb3230] Neu5Ac9P,[@bb0260] Neu5Ac1,7lactone,[@bb3235], [@bb3240], [@bb3245] Neu5Gc1,7lactone,[@bb3240] and Kdn1,7lactone.[@bb3240] See also refs. [@bb0035] and [@bb1265]. More recently, a highly efficient, one-pot, three-enzyme system with flexible substrate specificity was developed, whereby sialic acid family members are generated as intermediates from corresponding *N*,*O*-acyl-[d]{.smallcaps}-mannosamines and *O*-acyl/*O*-alkyl-[d]{.smallcaps}-mannoses (catalyst: a sialic acid aldolase) in a protocol that leads via CMP-sialic acids (catalyst: a CMP-sialic acid synthetase) to sialic acid-containing glycosides or sialyl(α2 → 3 or α2 → 6)galacto-glycans (catalyst: a bacterial sialyltransferase).[@bb3250], [@bb3255], [@bb3260], [@bb3265] Reported examples of intermediates comprise Neu5Ac, Neu5,9Ac~2~, Neu5Ac9Lt, Neu5Gc, Neu9Ac5Gc, Neu5GcAc, Neu5GcMe, Kdn, Kdn5Ac, Kdn5Me, Kdn9Ac, and Kdn5,9Ac~2~. For the study of biochemical pathways and to understand interactions at the molecular level, isotopically labeled and (stereochemically) modified sialic acids (at C1 and C3 to C9) were also prepared; for reviews, see refs. [@bb0035], [@bb0535], [@bb0545], [@bb1265], [@bb3135], and [@bb3135], [@bb3270], [@bb3275], [@bb3280], [@bb3285], [@bb3290], [@bb3295], [@bb3300], [@bb3305].

The scientific interest in the synthesis of sialo-oligosaccharides dates from the end of the 1960s. The first synthetic compounds comprised two disaccharides with Neu5Ac in a reducing position, i.e., Glc(β1 → 9)Neu5Ac1Me and Gal(β1 → 9)Neu5Ac1Me.[@bb3310] Furthermore, a series of reducing disaccharides with Neu5Ac in a nonreducing position were synthesized, although in low yields: Neu5Ac(α2 → 3)Glc, Neu5Ac(α2 → 3)GlcNAc, Neu5Ac(α2 → 6)Glc, Neu5Ac(α2 → 6)Gal, and Neu5Ac(α2 → 6)GlcNAc.[@bb3315] Other interesting disaccharides were nonreducing Neu5Ac(α2↔2α)Neu5Ac and Neu5Ac(α2↔2β)Neu5Ac.[@bb3320] Higher yields for Neu5Ac(α2 → 6)Gal were obtained in the early 1980s,[@bb3325] but efforts to synthesize Neu5Ac(α2 → 6)GlcNAc in larger amounts failed, as mainly Neu5Ac(β2 → 6)GlcNAc was formed.[@bb3330]

It was soon realized that stereoselective chemical sialylation leading to α-glycosidic linkages is one of the most difficult glycosylation reactions in carbohydrate chemistry. First, a neighboring participating group is missing to direct the stereochemical outcome of the coupling (C3 is a deoxy group). Second, the coupling reaction takes place at a sterically hindered, tertiary oxocarbenium-ion intermediate. Third, the deoxy moiety in combination with the electron-withdrawing carboxylic acid group (C1) at the anomeric center (C2) makes sialic acid donors prone to glycal formation. Because it was realized that the availability of labeled sialic acids, sialic acid derivatives, sialic acid O-, N-, C-, and S-glycosides, sialo-analogues, and sialo-oligosaccharides was of the utmost importance for unraveling the secrets of the sialobiology and sialomedicine, the interest in sialochemistry grew enormously. In this context, the creation of a great variety of suitable sialic acid donors and catalysts for organic chemical approaches was developed.[@bb0035], [@bb0540], [@bb0690], [@bb3305], [@bb3335], [@bb3340], [@bb3345], [@bb3350], [@bb3355], [@bb3360], [@bb3365] Furthermore, the progress in the biotechnology of carbohydrate enzymes led also to the generation of suitable amounts of stereoselective sialyltransferases/CMP-Neu5Acyl and *trans*-sialidases, which made enzymatic approaches attractive.[@bb0540], [@bb0635], [@bb0690], [@bb0700], [@bb0715], [@bb3305], [@bb3350], [@bb3370], [@bb3375], [@bb3380], [@bb3385]

In this way, growing activities focused on a further exploration of the properties of modified sialic acids, the preparation of substrates and inhibitors for sialidases, sialyltransferases, *trans*-sialidases, or sialic acid-converting enzymes, the synthesis of sialo-glycans, and to make compounds accessible for analytical purposes or for studies related to metabolism or biological functions of sialic acids. Over the years, several detailed reviews, describing different aspects of sialic acid organic and enzymatic synthesis, were published (see references in the foregoing paragraphs of this section).

10. Structural Variants of the Sialic Acid Backbone {#s0160}
===================================================

A series of naturally occurring nonulosonic acids (NulOs), which do not belong to the classical sialic acid (Sia) family, contain a terminal methyl group as C9 and aminodeoxy functions at C5 and C7, and compared with neuraminic acid (Neu), may exhibit differences in the configuration of the chiral centers at C4, C5, C7, and C8 ([Fig. 27](#f0140){ref-type="fig"} ). According to IUPAC recommendations, these structural variants of the sialic acid backbone are systematically named 5,7-diamino-3,5,7,9-tetradeoxynon-2-ulosonic acids. In the early days of their discovery, the mid-1980s, they have sometimes been called "bacterial sialic acids." They were found specifically in bacterial lipopolysaccharides and capsular polysaccharides, and since the turn of the century, also in bacterial glycoproteins. Over the years, a number of reviews about these nonulosonic acids have appeared.[@bb0575], [@bb2980], [@bb3390], [@bb3395], [@bb3400], [@bb3405], [@bb3410] Fig. 27^2^*C*~5~ Chair conformations of α-Pse, β-Leg, β-4eLeg, β-8eLeg, α-Aci, and α-8eAci. Note the difference in orientation of the COOH and OH groups at the anomeric C2 atom.Fig. 27

The first data about the occurrence of these "sialic acid-like" monosaccharides as components of lipopolysaccharides are from 1984 and reported by Knirel and coworkers at the N.D. Zelinsky Institute of Organic Chemistry, Moscow (Russia).[@bb3415] In view of the date of their first discovery, it may not be surprising that, in contrast to all the approaches used in the development of the sialic acid field, the analytical techniques had completely changed. Now, from the beginning onward, ^1^H and ^13^C NMR spectroscopy and mass spectrometry played major roles in their characterization. Since 2017, six subclasses (six isomers) have been identified, namely,(i)5,7-diamino-3,5,7,9-tetradeoxy-[l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*manno*-non-2-ulosonic acid, called pseudaminic acid (Pse);(ii)5,7-diamino-3,5,7,9-tetradeoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid, called legionaminic acid (Leg);(iii)5,7-diamino-3,5,7,9-tetradeoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*talo*-non-2-ulosonic acid, called 4-*epi*-legionaminic acid (4eLeg);(iv)5,7-diamino-3,5,7,9-tetradeoxy-[l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid, called 8-*epi*-legionaminic acid (8eLeg);(v)5,7-diamino-3,5,7,9-tetradeoxy-[l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*altro*-non-2-ulosonic acid, called acinetaminic acid (Aci); and(vi)5,7-diamino-3,5,7,9-tetradeoxy-[d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*altro*-non-2-ulosonic acid, called 8-*epi*-acinetaminic acid (8eAci).

It should be noted that during the starting period of this research field, some tentative structures were published with misassignment of the chiral configurations. Therefore, to solve these problems, at the end of the 1990s 5,7-di-*N*-acetyl derivatives with the [d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*, [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*, [d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*talo*, [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*talo*, [d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*manno*, [l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*manno*, [d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*altro*-, [l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*altro*, and [l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*gluco* configuration were synthesized by condensation of suitable 2,4-diacetamido-2,4,6-trideoxyhexoses with oxalacetic acid under basic conditions.[@bb3420], [@bb3425], [@bb3430] In contrast to reports from the time of their discovery, presently, the earlier chosen trivial names Pse, Leg, 4eLeg, and 8-Leg have been directly related to the nonsubstituted mother molecules with free amino functions,[@bb2980] and the same system was followed for the recently established Aci and 8eAci,[@bb3435], [@bb3440] in a similar way as usual for the Sia family (Neu). As in the case of neuraminic acid, in the full names C7 is the anomeric reference atom. The free sugars exist in the ^2^ *C* ~5~ pyranose form as mixtures of α- and β-anomers with a predominance of the thermodynamically more stable anomer having an equatorial carboxyl group. Substitutions of the amino groups at C5 and C7 comprise acetyl (Ac), formyl (Fo), (*R*)-3-hydroxybutyryl (3~*R*~Hb), (*S*)-3-hydroxybutyryl (3~*S*~Hb), 4-hydroxybutyryl (4Hb), 3,4-dihydroxybutyryl (3,4Hb), acetimidoyl (Am), *N*-methyl-acetimidoyl (AmMe), *N*,*N*-dimethyl-acetimidoyl (AmMe~2~), methyl (Me), [d]{.smallcaps}-alanyl (Ala), *N*-acetyl-[d]{.smallcaps}-alanyl (AlaNAc), *N*-methyl-5-glutamyl (GluNMe), [l]{.smallcaps}-glyceryl (Gr), and/or 2,3-di-*O*-methyl-glyceryl (Me~2~Gr) groups. Note that only N-acylated derivatives are known; there are no derivatives with free NH~2~5 or free NH~2~7 groups. Furthermore, acetyl, *N*-acetyl-glutaminyl (GlnNAc), and glycyl (Gly) groups have been detected at O8, and acetyl groups at O4.

A survey of over 45 known structures[@bb0400], [@bb3015], [@bb3415], [@bb3425], [@bb3435], [@bb3440], [@bb3445], [@bb3450], [@bb3455], [@bb3460], [@bb3465], [@bb3470], [@bb3475], [@bb3480], [@bb3485], [@bb3490], [@bb3495], [@bb3500], [@bb3505], [@bb3510], [@bb3515], [@bb3520], [@bb3525], [@bb3530], [@bb3535], [@bb3540], [@bb3545], [@bb3550], [@bb3555], [@bb3560], [@bb3565], [@bb3570], [@bb3575], [@bb3580], [@bb3585], [@bb3590], [@bb3595], [@bb3600], [@bb3605], [@bb3610], [@bb3615], [@bb3620], [@bb3625], [@bb3630], [@bb3635], [@bb3640], [@bb3645], [@bb3650], [@bb3655] of naturally occurring 5,7-diamino-3,5,7,9-tetradeoxynon-2-ulosonic acid derivatives, together with some related 9-deoxynon-2-ulosonic acids, is presented in [Table 4](#t0025){ref-type="table"} . The symbolic abbreviations for the various derivatives of the 5,7-diamino-3,5,7,9-tetradeoxynon-2-ulosonic acids have been chosen in accordance with the Sia recommendations. The constituents can occur in homo- and heteropolysaccharides, as terminal and internal units, with (α2 → or (β2 → glycosidic linkages. In case of internal residues, the HO4 or HO8 functions can be substituted by another monosaccharide. The same holds for the hydroxy groups of the 3- or 4-hydroxybutyramido substituents at C7. In flagellins, the nonulosonic acids are directly connected to Ser or Thr, e.g., Pse5,7Ac~2~(α2→O)Ser.[@bb3450] For pilins, an O-linked trisaccharide with Pse7Fo5(3Hb) as the terminal unit has been demonstrated to occur,[@bb3520] whereas Leg7Ac5Fo was found to be a terminal unit of an N-linked pentasaccharide of a haloarchaeal virus glycoprotein.[@bb3550] For further biochemical information, see [Section 11.5.3](#s0205){ref-type="sec"}.Table 4Survey of Reported Structures of Naturally Occurring 5,7-Diamino-3,5,7,9-tetradeoxynon-2-ulosonic Acid Derivatives, and Some Related Structures, Which Are Terminal or Internal Units of Bacterial Homo- and Hetero-polysaccharides and Glycoprotein Glycans[@bb2980], [@bb3390], [@bb3400], [@bb3410]Table 4NameAbbreviationReferences*\*5,7-Diamino-3,5,7,9-tetradeoxy-[l]{.smallcaps}-*glycero-*[l]{.smallcaps}*-manno*-non-2-ulosonic acid/pseudaminic acid (Pse)*5,7-Di-*N*-acetyl-pseudaminic acidPse5,7Ac~2~[@bb3445], [@bb3450]5,7-Di-*N*-acetyl-8-*O*-acetyl-pseudaminic acidPse5,7,8Ac~3~[@bb3450]5,7-Di-*N*-acetyl-8-*O*-glycyl-pseudaminic acidPse5,7Ac~2~8Gly[@bb3455]5,7-Di-*N*-glyceryl-pseudaminic acidPse5,7Gr~2~[@bb3450]5-*N*-Acetimidoyl-7-*N*-acetyl-pseudaminic acidPse7Ac5Am[@bb3450], [@bb3460]5-*N*-Acetimidoyl-7-*N*-acetyl-8-*O*-acetyl-pseudaminic acidPse7,8Ac~2~5Am[@bb3465]5-*N*-Acetimidoyl-7-*N*-acetyl-8-*O*-(*N*-acetyl-glutaminyl)-pseudaminic acidPse7Ac5Am8GlnNAc[@bb3455]5-*N*-Acetyl-7-*N*-formyl-pseudaminic acidPse5Ac7Fo[@bb3415], [@bb3470]5-*N*-Acetyl-7-*N*-[l]{.smallcaps}-glyceryl-pseudaminic acidPse5Ac7Gr[@bb3475]5-*N*-Acetyl-7-*N*-\[(*R*)-3-hydroxybutyryl\]-pseudaminic acidPse5Ac7(3~*R*~Hb)[@bb3415], [@bb3480], [@bb3485]5-*N*-Acetyl-7-*N*-\[(*R*)-3-hydroxybutyryl\]-4-*O*-acetyl-pseudaminic acidPse4,5Ac~2~7(3~*R*~Hb)[@bb3490]5-*N*-Acetyl-7-*N*-\[(*S*)-3-hydroxybutyryl\]-pseudaminic acidPse5Ac7(3~*S*~Hb)[@bb3485]5-*N*-Acetyl-7-*N*-(4-hydroxybutyryl)-pseudaminic acidPse5Ac7(4Hb)[@bb3495]5-*N*-Acetyl-7-*N*-(3,4-dihydroxybutyryl)-pseudaminic acidPse5Ac7(3,4Hb)[@bb3015]7-*N*-Acetimidoyl-5-*N*-acetyl-pseudaminic acidPse5Ac7Am[@bb3500]7-*N*-Acetimidoyl-5-*N*-(2,3-di-*O*-methyl-glyceryl)-pseudaminic acidPse7Am5Me~2~Gr[@bb3505]7-*N*-Acetyl-5-*N*-(3-hydroxybutyryl)-pseudaminic acidPse7Ac5(3Hb)[@bb3510]7-*N*-Acetyl-5-*N*-(2,3-di-*O*-methyl-glyceryl)-pseudaminic acidPse7Ac5Me~2~Gr[@bb3505]7-*N*-Formyl-5-*N*-\[(*R*)-3-hydroxybutyryl\]-pseudaminic acidPse7Fo5(3~*R*~Hb)[@bb3415], [@bb3515], [@bb3520]*\*5,7-Diamino-3,5,7,9-tetradeoxy-[d]{.smallcaps}-*glycero-*[d]{.smallcaps}*-galacto*-non-2-ulosonic acid/legionaminic acid (Leg)*5,7-Di-*N*-acetyl-legionaminic acid[a](#tf0095){ref-type="table-fn"}Leg5,7Ac~2~[@bb3425], [@bb3525], [@bb3530]5-*N*-Acetimidoyl-7-*N*-acetyl-legionaminic acid[a](#tf0095){ref-type="table-fn"}Leg7Ac5Am[@bb3425], [@bb3530]5-*N*-Acetimidoyl-7-*N*-acetyl-8-*O*-acetyl-legionaminic acid[b](#tf0100){ref-type="table-fn"}Leg7,8Ac~2~5Am[@bb3425], [@bb3535]5-*N*-Acetimidoyl-7-*N*-acetyl-5-*N*-methyl-legionaminic acidLeg7Ac5Am5Me[@bb3540]5-*N*-(*N*-Methyl-acetimidoyl)-7-*N*-acetyl-legionaminic acidLeg7Ac5AmMe[@bb3530], [@bb3540]5-*N*-(*N*,*N*-Dimethyl-acetimidoyl)-7-*N*-acetyl-legionaminic acidLeg7Ac5AmMe~2~[@bb3540]5-*N*-Acetimidoyl-7-*N*-acetyl-8-*O*-acetyl-5-*N*-methyl-legionaminic acidLeg7,8Ac~2~5Am5Me[@bb3535]5-*N*-(*N*,*N*-Dimethyl-acetimidoyl)-7-*N*-acetyl-8-*O*-acetyl-legionaminic acidLeg7,8Ac~2~5AmMe~2~[@bb3535]5-*N*-Acetyl-7-*N*-(*N*-acetyl-[d]{.smallcaps}-alanyl)-legionaminic acidLeg5Ac7AlaNAc[@bb3525]5-*N*-Acetyl-7-*N*-([d]{.smallcaps}-alanyl)-legionaminic acidLeg5Ac7Ala[@bb3545]7-*N*-Acetyl-5-*N*-formyl-legionaminic acidLeg7Ac5Fo[@bb3550]7-*N*-Acetyl-5-*N*-\[(*S*)-3-hydroxybutyryl\]-legionaminic acid[c](#tf0105){ref-type="table-fn"}Leg7Ac5(3~*S*~Hb)[@bb3425]7-*N*-Acetyl-5-*N*-(*N*-methyl-5-glutamyl)-legionaminic acidLeg7Ac5GluNMe[@bb3555]*\*5,7-Diamino-3,5,7,9-tetradeoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*talo*-non-2-ulosonic acid/4*-epi*-legionaminic acid (4eLeg)*5,7-Di-*N*-acetyl-4-*epi*-legionaminic acid4eLeg5,7Ac~2~[@bb3560]5,7-Di-*N*-acetyl-8-*O*-acetyl-4-*epi*-legionaminic acid[d](#tf0110){ref-type="table-fn"}4eLeg5,7,8Ac~3~[@bb3425]5-*N*-Acetimidoyl-7-*N*-acetyl-4-*ep*i-legionaminic acid4eLeg7Ac5Am[@bb3565]5-*N*-Acetimidoyl-7-*N*-acetyl-8-*O*-acetyl-4-*ep*i-legionaminic acid4eLeg7,8Ac~2~5Am[@bb3565]*\*5,7-Diamino-3,5,7,9-tetradeoxy-[l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid/8-*epi*-legionaminic acid (8eLeg)*5,7-Di-*N*-acetyl-8-*epi*-legionaminic acid[e](#tf0115){ref-type="table-fn"}8eLeg5,7Ac~2~[@bb3570], [@bb3575], [@bb3580]5,7-Di-*N*-acetyl-8-*O*-acetyl-8-*epi*-legionaminic acid8eLeg5,7,8Ac~3~[@bb3585]5-*N*-Acetimidoyl-7-*N*-acetyl-8-*epi*-legionaminic acid8eLeg7Ac5Am[@bb3590]7-*N*-Acetimidoyl-5-*N*-acetyl-8-*epi*-legionaminic acid8eLeg5Ac7Am[@bb0400]7-*N*-Acetimidoyl-5-*N*-acetyl-8-*O*-acetyl-8-*epi*-legionaminic acid8eLeg5,8Ac~2~7Am[@bb0400]7-*N*-Acetyl-5-*N*-\[(*R*)-3-hydroxybutyryl\]-8-*epi*-legionaminic acid[e](#tf0115){ref-type="table-fn"}8eLeg7Ac5(3~*R*~Hb)[@bb3425], [@bb3570], [@bb3575]7-*N*-Acetyl-5-*N*-(4-hydroxybutyryl)-8-*epi*-legionaminic acid[e](#tf0115){ref-type="table-fn"}8eLeg7Ac5(4Hb)[@bb3425]*\*5,7-Diamino-3,5,7,9-tetradeoxy-[l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*altro*-non-2-ulosonic acid/acinetaminic acid (Aci)*5,7-Di-*N*-acetyl-acinetaminic acidAci5,7Ac~2~[@bb3435]*\*5,7-Diamino-3,5,7,9-tetradeoxy-[d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*altro*-non-2-ulosonic acid/8-*epi*-acinetaminic acid (8eAci)*5,7-Di-*N*-acetyl-8-*epi*-acinetaminic acid8eAci5,7Ac~2~[@bb3440]*\*Some related 9-deoxynon-2-ulosonic acids*5- or 7-Acetamido-,7- or 5-(3-hydroxybutyramido)-5,7,9-trideoxynon-2-ulosonic acid[@bb3595]5-Acetamido-7-\[(*S*)-3-hydroxybutyramido\]-8-amino-3,5,7,8,9-pentadeoxy-[l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*manno*- or [d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*manno*-non-2-ulosonic acid[@bb3600]5-Acetamidino-3,5,9-trideoxy-[l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*gluco*-non-2-ulosonic acid (tentatively assigned chirality; trivial name: fusaminic acid)[@bb3605]5,7-Diacetamido-8-amino-3,5,7,8,9-pentadeoxy-[d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*-non-2-ulosonic acid[@bb3610][^21][^22][^23][^24][^25][^26]

11. Unraveling the Metabolism of Sialic Acids {#s0165}
=============================================

First observations on the metabolism of sialic acids were made at the beginning of the 1940s when sialic acid (at that time an unknown low-molecular-weight substance) was released from cells by a viral or bacterial enzyme, termed the *RDE* (see [Section 2.1](#s0020){ref-type="sec"}). This catabolic enzyme was later called neuraminidase or sialidase. Another catabolic enzyme, the acylneuraminate--pyruvate lyase (*N*-acetylneuraminic acid aldolase) from bacteria, was shown to split *N*-acetylneuraminic acid into pyruvate and *N*-acetylmannosamine (see [Section 4.1](#s0045){ref-type="sec"}). This serendipitous discovery by the group of Saul Roseman[@bb1160], [@bb1165] at the end of the 1950s turned out to be a milestone in (sialo)glycobiology, leading to Roseman being named "Dr. Saul Serendipity Roseman."[@bb1155] The finding of *N*-acetylmannosamine instead of *N*-acetylglucosamine also played a major role in the elucidation of the final structure of *N*-acetylneuraminic acid."In a detailed personal letter handed over to Yuan C. Lee, and recently published by Schnaar and Lee,[@bb3660] Roseman describes the full GlcNAc vs ManNAc story, wherein Don Comb played such a great role. With respect to the quantification of *N*-acetylhexosamine using the Morgan--Elson color reaction, he memorized that this assay was used for the acylneuraminate--pyruvate lyase degradation of *N*-acetylneuraminic acid. Although the amounts of *N*-acetylneuraminic acid (consumed) and pyruvate (formed) were equal, the amount of formed *N*-acetylhexosamine was only half of the expected amount (reaction time, 3 min). Citing Roseman: "There are two ways to run the Morgan--Elson reaction; one involves heating for 3 min, while the other requires 12 min. There was no way that Don would waste time and heat for 12 min when 3 min was sufficient. But the incredible thing, however, is that both of these sugars \[ManNAc and GlcNAc (R.S.)\] give the same color when they are heated for 12 min. In other words, the stoichiometry results would have been perfect if he had heated for 12 min and not 3 min. I have often wondered where we would be if Don had heated for 12 min. Would we still think that the Gottschalk structure is correct?" Note that up to this time, *N*-acetylneuraminic acid was thought to be the condensation product of pyruvate and GlcNAc (see [Section 4.1](#s0045){ref-type="sec"})."

For the biosynthesis of sialic acid, it was believed in the beginning that the process is reversibly catalyzed by an enzyme, first observed in extracts of *V. cholerae*, which degrades *N*-acetylneuraminic acid to an *N*-acetylhexosamine and pyruvate.[@bb1140] The enzyme also occurred in mammalian tissues and was purified 1700-fold from hog kidney cortex.[@bb1645] As said (see [Section 4.1](#s0045){ref-type="sec"}), Comb and Roseman found the same enzyme in *C. perfringens* and identified the *N*-acetylhexosamine product as *N-*acetylmannosamine.[@bb1160], [@bb3665] Three arguments, however, were not in favor of this acylneuraminate--pyruvate lyase to be responsible for sialic acid synthesis: (i) in cells, the reaction equilibrium of this enzyme is largely in favor of sialic acid degradation; (ii) the enzyme does not exist in tissues producing large quantities of sialylated mucins[@bb1645]; and (iii) the bacteria *V. cholerae* and *C. perfringens* do not contain sialic acid, but express the sialic acid aldolase. Thus, this aldolase is a degradative enzyme, although the reaction is reversible. For an earlier proposed reaction mechanism of the catalysis by this *N*-acetylneuraminic acid lyase, as well as a recent proposal based on crystallography, QM/MM simulation, and mutagenesis, see ref. [@bb0035] and ref. [@bb3670], respectively.

At this time, at the end of the 1950s, the "golden" and laborious time of the study of the metabolism of sialic acids began.

11.1. The Biosynthesis of *N*-Acetylneuraminic Acid {#s0170}
---------------------------------------------------

The biosynthesis of sialic acids, both in animals and in microorganisms, is linked to glycolysis. This central metabolic pathway provides both fructose-6-phosphate and phosphoenol pyruvate as basic substances for the biosynthesis of sialic acids. The chemical steps involved were primarily elucidated in the laboratories of Roseman[@bb3675] and Warren.[@bb3680] It had been shown in the 1950s by several researchers (see, e.g., refs. [@bb3685], [@bb3690]) that radioactive [d]{.smallcaps}-glucose is converted into [d]{.smallcaps}-glucosamine. Moreover, the precursor of [d]{.smallcaps}-glucosamine-6-phosphate was investigated in microorganisms[@bb3695], [@bb3700] and in mammals (rat liver).[@bb3700], [@bb3705] Here, the biosynthetic route comprised an amination of [d]{.smallcaps}-fructose-6-phosphate (not [d]{.smallcaps}-glucose-6-phosphate) with the amido group of [l]{.smallcaps}-glutamine catalyzed by [l]{.smallcaps}-glutamine-[d]{.smallcaps}-fructose-6-phosphate aminotransferase (glucosamine-6-phosphate synthetase), to give [d]{.smallcaps}-glucosamine-6-phosphate and [l]{.smallcaps}-glutamate.[@bb3700] The product [d]{.smallcaps}-glucosamine-6-phosphate is then acetylated by an *N*-acetyltransferase, which occurs in many animals and microorganisms, and was first isolated 254-fold from *Neurospora crassa*.[@bb3710]

The next step is the transformation of *N*-acetylglucosamine-6-phosphate into *N*-acetylglucosamine-1-phosphate, catalyzed by a phosphoacetylglucosamine mutase, isolated from different sources.[@bb3715], [@bb3720], [@bb3725] The sialic acid biosynthesis continues with the formation of UDP-*N*-acetylglucosamine from *N*-acetylglucosamine-1-phosphate and UTP, and the liberation of pyrophosphate by a pyrophosphorylase.[@bb3730] UDP-*N*-acetylglucosamine (UDP-GlcNAc) was first detected in rat liver extracts and in yeast.[@bb3735] This sugar nucleotide could then, in 1955, be synthesized in extracts of yeast and Rous sarcoma tumors.[@bb3740]

The epimerization of *N*-acetylglucosamine (GlcNAc) to *N*-acetylmannosamine (ManNAc) is a key step in sialic acid biosynthesis. In this reaction, the acetylamino group at C2 is epimerized, and the linkage between UDP and the amino sugar is hydrolyzed (UDP-ManNAc could not be detected) ([Fig. 28](#f0145){ref-type="fig"}A). It should be noted that this reaction was discovered in rat liver in 1957, but erroneously the reaction product was described as GalNAc.[@bb3745] The rectification to ManNAc followed one year later[@bb3665]; the responsible enzyme was isolated from rat liver in 1966.[@bb3750] The reaction was shown to be irreversible, and the enzyme occurred widely in vertebrate tissues; however, it was not found in bacteria.Fig. 28Metabolism of non-2-ulosonic acids having the [d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto* configuration. (A) *N*-Acetylneuraminic acid (Neu5Ac) in vertebrates[@bb0575]; (B) *N*-acetylneuraminic acid (Neu5Ac) in bacteria[@bb3305]; (C) ketodeoxynononic acid (Kdn) in vertebrates[@bb0065]; and (D) 5,7-di-*N*-acetyllegionaminic acid (Leg5,7Ac~2~) in bacteria.[@bb2980]*[d]{.smallcaps}-6dManNAc4NAc*, 2,4-diacetamido-2,4,6-trideoxy-[d]{.smallcaps}-mannose; *GDP-α-[d]{.smallcaps}-6dGlcNAc4NAc*, GDP-2,4-diacetamido-2,4,6-trideoxy-α-[d]{.smallcaps}-glucose; *Kdn9P*, ketodeoxynononic acid 9-phosphate; *[d]{.smallcaps}-ManNAc6P*, *N*-acetyl-[d]{.smallcaps}-mannosamine 6-phosphate; *[d]{.smallcaps}-Man6P*, [d]{.smallcaps}-mannose 6-phosphate; *Neu5Ac9P*, *N*-acetylneuraminic acid 9-phosphate; *PEP*, phosphoenolpyruvate; *P*~*i*~, phosphate; *PP*~*i*~, diphosphate. In case of CMP-β-Leg5,7Ac~2~, also another route, going from UDP-α-[d]{.smallcaps}-GlcNAc, via UDP-α-[d]{.smallcaps}-6dGlcNAc4NAc to [d]{.smallcaps}-6dManNAc4NAc, has been formulated.[@bb2980]Fig. 28

For the biosynthesis of sialic acid in vertebrates, ManNAc had to be converted into *N*-acetylmannosamine-6-phosphate (ManNAc6P), and a corresponding kinase was detected in mammalian liver and submandibular glands (see, e.g., ref. [@bb3755]), as summarized in ref. [@bb3760]. It can use both ManNAc and *N*-glycolylmannosamine (ManNGc). Many years later (1990s), it was shown by the group of Werner Reutter at the Freie Universität Berlin (Germany) that the conversion of UDP-GlcNAc into ManNAc6P is catalyzed by one bifunctional enzyme, the UDP-*N*-acetylglucosamine 2-epimerase (GNE)/*N*-acetylmannosamine kinase (MNK), a crucial step often discussed between Reutter and one of the authors (R.S.). This enzyme, purified from rat liver, both epimerizes UDP-GlcNAc under release of UDP and phosphorylates the resulting ManNAc by its kinase activity.[@bb3765] In the same study, also feedback inhibition of the UDP-*N*-acetylglucosamine 2-epimerase part of the enzyme by CMP-Neu5Ac was demonstrated. In a parallel report, the molecular cloning and functional expression of the GNE/MNK enzyme were published.[@bb3770] A selective loss of either the epimerase or the kinase activity was established, via site-directed mutagenesis based on sequence alignments. This technique also enabled the localization of the 2-epimerase activity in the N-terminus and the kinase activity in the C-terminus of the protein.[@bb3775] GNE, the root of which is in the Bilateria, was found to have a complex evolutionary origin.[@bb3780] It is encoded in the genomes of deuterostomes, acoelomorphs, and *Xenoturbella*, but is absent in protostomes and nonbilaterians.

In order to study the inhibition of the sialic acid biosynthesis, a search for inhibitors of human *N*-acetylmannosamine kinase by high-throughput screening of drug-like small molecules was carried out,[@bb3785] and a few promising compounds binding to the ATP-binding pocket of the enzyme were found. 3-*O*-Methyl-*N*-acetylmannosamine inhibited the same enzyme and correspondingly affected the sialic acid concentration in cells.[@bb3790]

In vertebrate tissues, the formation of sialic acid as its 9-phosphate ester (Neu5Ac9P) (Roseman--Warren pathway, [Fig. 28](#f0145){ref-type="fig"}A) occurs by condensation of ManNAc6P and phosphoenolpyruvate in an irreversible manner. A synthesizing, anabolic "sialic acid-9-phosphate synthetase" responsible for this reaction was discovered in the early 1960s by the Warren and Roseman groups.[@bb0260], [@bb3110], [@bb3680] The first sources were rat liver and bovine submandibular gland. The enzyme reaction favors the production of sialic acid.

Before the activation of Neu5Ac by CMP, the 9-phosphate group must be removed. This is achieved by a specific Neu5Ac-9-phosphate phosphatase,[@bb3680] first seen in rat liver, and later isolated 800-fold from human erythrocytes ([Fig. 28](#f0145){ref-type="fig"}A).[@bb3795] This enzyme, completing the Neu5Ac biosynthesis, only occurs in animals. It does not exist in bacteria, where Neu5Ac is formed from nonphosphorylated ManNAc and phosphoenolpyruvate under release of phosphate ([Fig. 28](#f0145){ref-type="fig"}B).[@bb3800], [@bb3805]

In summary, at the end of these challenging studies in the 1950s and 1960s, three pathways were described as leading to Neu5Ac:(i)The Neu5Ac aldolase (lyase) route, which condenses ManNAc and pyruvate and occurs in both animals and bacteria;(ii)The sialic acid-9-phosphate synthetase route, which condenses ManNAc6P with phosphoenolpyruvate and exists only in animal tissues;(iii)The bacterial sialic acid synthetase route, condensing ManNAc with phosphoenolpyruvate.

11.2. The Activation of Sialic Acids {#s0175}
------------------------------------

The sialylation of glycan chains (see [Section 8](#s0120){ref-type="sec"} for structural elements) requires in general an activated Neu5Ac donor substrate, which is obtained by reaction of Neu5Ac with CTP, resulting in the nucleotide sugar CMP-Neu5Ac and pyrophosphate ([Fig. 28](#f0145){ref-type="fig"}A) (for *trans*-sialidases, see [Section 11.7](#s0220){ref-type="sec"}). The glycosidic linkage between Neu5Ac and CMP has the β-configuration.[@bb3810], [@bb3815], [@bb3820] The responsible enzyme, CMP-sialic acid synthetase, a pyrophosphorylase (EC 2.7.7.43), was first detected in bacteria and purified from *N. meningitidis*.[@bb3825] At the same time, it was also found in animal tissues[@bb3830], [@bb3835] and was first purified from pig submandibular glands,[@bb3840] as reviewed in ref. [@bb3845]. The enzyme from different sources was found to react with Neu5Ac, Neu5Gc, and O-acetylated sialic acids, and some of them also with Kdn.[@bb0035] Remarkably, in contrast to the other sialic acid-synthesizing enzymes, CMP-Neu5Ac synthetase is located in cell nuclei, first observed by Ed Kean[@bb3850] at Case Western Reserve University (Cleveland, USA). From the nucleus, CMP-Neu5Ac is transported into the Golgi, using a carrier-mediated transport system to penetrate liver microsomal vesicles (mice studies).[@bb3855] For the cloning and expression of this CMP-sialic acid transporter, see ref. [@bb3860]. Kean, who devoted most of his scientific life to the investigation of sialic acid activation, discovered also a CMP-Neu5Ac hydrolase in the plasma membranes of rat liver. Its activity was low in other tissues.[@bb3865] The role of this hydrolase is still a subject of speculation. Especially in liver, with its most active sialic acid metabolism, the membrane-bound CMP-Neu5Ac hydrolase may regulate the extent of attachment of sialic acid residues to cell membrane glycoconjugates by membrane sialyltransferases.

In the Golgi, CMP-Neu5Ac is used as the substrate for sialyltransferases, which are responsible for sialic acid polymerization (polySia) and sialylation of oligo/polysaccharides, glycoproteins, and glycolipids (see [Section 11.3](#s0180){ref-type="sec"}). It additionally serves as a substrate for the *N*-acetyl-hydroxylation reaction leading to Neu5Gc (see [Section 11.5.1](#s0195){ref-type="sec"}) and for the O-acetylation of sialic acids (see [Section 11.5.2](#s0200){ref-type="sec"}). These modified CMP-sialic acids are also transferred to glycoconjugates in the Golgi. For the synthetic production of CMP-Neu5Ac, see, e.g., refs. [@bb3820], [@bb3870], and [@bb3875].

11.3. Sialic Acid Transfer to Glycans {#s0180}
-------------------------------------

Studies of the group of sialyltransferases comprise one of the largest and most important fields in sialobiology, and a wealth of papers during the last decades deals with their occurrence, properties, structure, and function. The enzymes are mostly Golgi-membrane-bound. Since several excellent reviews cover this subject, here only some of the milestones will be reported, and the reader is referred to refs. [@bb0035], [@bb0635], [@bb0695], [@bb3880], and [@bb3885].

In 1963, the first sialyltransferase activities were observed in studies on the biosynthesis of colominic acid[@bb2950] and the sialylation of lactose.[@bb3890] In the latter case in which details were worked out in Roseman\'s laboratory, a particulate preparation from the rat mammary gland was incubated with lactose and CMP-\[1-^14^C\]Neu5Ac to yield radiolabeled Neu5Ac(α2 → 3)lactose. In the field of glycolipids, the biosynthesis of GM3 ganglioside was shown from an incubation of lactosyl-ceramide, CMP-\[1-^14^C\]Neu5Ac, and a particulate preparation from a 9-day-old embryonic chicken brain.[@bb3895] In Roseman\'s laboratory the period between 1963 and 1970 was most fruitful, and the detection of four different sialyltransferases for the biosynthesis of glycoproteins and four different sialyltransferases for the biosynthesis of gangliosides was reported by various coworkers (summarized in refs. [@bb1155], [@bb3900], and [@bb3905]). These studies suggested that the different sialyltransferases were responsible for the formation of a variety of sialyl glycosidic linkages. The first purification of a sialyltransferase from bovine colostrum by affinity chromatography on CDP-hexanolamine agarose was achieved by the group of Robert Hill at Duke University Medical Center (Durham, NC, USA).[@bb3905] The specific activity increased 440,000 times when compared with whole colostrum. The enzyme was pure and consisted of two bands of 43 and 56 kDa, respectively. The enzyme turned out to be a β-[d]{.smallcaps}-galactoside α2,6-sialyltransferase.[@bb3910] The enzyme was cloned[@bb3915] and is cleaved in a whole or post-Golgi compartment.[@bb3920] The expression of this ST6Gal-I, regulated by multiple transcriptional promotors, is tissue specific.

Meanwhile, 20 distinct sialyltransferases, which are Golgi type II transmembrane glycosyltransferases, have been identified in murine and human genomes. This superfamily comprises four main sialyltransferase families: (i) an ST3 Gal family with six members (ST3Gal I--VI), whereby sialic acid is (α2 → 3)-linked to galactose (Gal); (ii) an ST6 family with two members (ST6Gal I--II), whereby sialic acid is (α2 → 6)-linked to Gal; (iii) an ST6GalNAc family with six members (ST6GalNAc I--VI), whereby sialic acid is (α2 → 6)-linked to *N*-acetylgalactosamine (GalNAc); and (iv) an ST8Sia family with six members (ST8Sia I--VI), which mediates the transfer of Neu5Ac residues to other Neu5Ac residues of glycoproteins and glycolipids via (α2 → 8) linkages.[@bb3880] In the latter reference, a phylogenetic approach to animal sialyltransferases and the related genes was undertaken. In this excellent analysis the architecture of these enzymes, which is similar in all vertebrate sialyltransferases, is discussed. Also the precursor genes for animal sialyltransferases are suggested, e.g., for ST6Gal from insects (*Drosophila melanogaster*).[@bb0055] There are also over 25 subfamilies in lower vertebrates, orthologs of the 20 mammalian subfamilies, as well as additional subfamilies in fish genomes.[@bb0695] For the interesting evolutionary history of the ST8Sia gene family since the early deuterostomes, see ref. [@bb3925]. Recently, it was shown that the cellular availability of sialic acids regulates the expression of various sialyltransferases at the level of transcription.[@bb3930]

Since sialyltransferases are the final enzymes of sialic acid anabolism, they are responsible for the physiologically correct sialylation of glycans in cells, and their activity should be decreased by inhibitors of cellular development or of aberrant oversialylation, such as that which may occur in cancer (see [Section 12.3](#s0245){ref-type="sec"}). A natural inhibitor was first purified in 1988 from the 100,000 ×  *g* supernatant of a rat-brain homogenate.[@bb3935] It is a small, heat-stable protein composed of two components of 14.8 and 22.4 kDa, which inhibits brain α2,6-sialyltransferase noncompetitively. Inhibitory activity was also found in brains from other mammals and in nonbrain tissues. A similar, potent inhibitor was isolated from calf brain, which inhibited (95% by 4 μg of inhibitor) the α2,6-sialyltransferase from ovine submandibular glands.[@bb3940] Experiments to chemically modify CMP-Neu5Ac in either its nucleotide or sialic acid moiety in order to gain effective sialyltransferase inhibitors were not successful. Instead, cytidine nucleotides inhibited rat liver α2,6-sialyltransferase (α2,6-ST) and porcine submandibular gland α2,3-sialyltransferase (α2,3-ST) well and at similar rates. The *K* ~i~-values of 5′-CMP, 5′-CDP, and 5′-CTP varied between 0.13 and 0.05 mM for α2,6-ST.[@bb3945] Probably the strongest sialyltransferase inhibitor presently known is 3-fluoro~ax~-*N*-acetylneuraminic acid (3F~ax~-Neu5Ac), which is supplied to cells or tissues in per-O-acetylated methyl ester form.[@bb3950] The hydrophobic molecules penetrate into cells, where they are O-deacetylated. The liberated free 3F~ax~-Neu5Ac more efficiently inhibits α2,3-sialyltransferases and, consequently, hypersialylation of cancer cells. In vivo, delayed growth of inhibitor-treated melanoma cells was observed.

11.4. The Regulation of Sialic Acid Biosynthesis {#s0185}
------------------------------------------------

Such an important biochemical pathway as that of sialic acid synthesis, which results in a great variety of bioactive compounds, must be regulated, since the amount of CMP-sialic acids in a cell may be critical, and influences the level of the sialylation grade in glycoconjugates. The first hint came from studies by Kean.[@bb3850] The fact that CMP-sialic acid synthetase is located in cell nuclei of various prominent mammalian tissues suggested that this location is an important control mechanism. Furthermore, two feedback inhibition mechanisms of key enzymes of sialic acid synthesis were detected, i.e., (i) UDP-GlcNAc efficiently inhibits the [l]{.smallcaps}-glutamine-[d]{.smallcaps}-fructose-6-phosphate aminotransferases, and (ii) CMP-Neu5Ac inhibits UDP-*N*-acetylglucosamine 2-epimerase (GNE).[@bb3955] Newer views on the latter enzyme (GNE/MNK) have been discussed in [Section 11.1](#s0170){ref-type="sec"}. An example of the lack of the feedback inhibition by CMP-Neu5Ac, required for a physiologically controlled sialic acid metabolism, came from studies of the metabolism of a sialuria patient[@bb2920] (see [Section 13.1](#s0280){ref-type="sec"}). This young patient excreted gram quantities of free Neu5Ac in urine, as well as Neu2en5Ac, 2-acetamidoglucal, ManNAc, and GlcNAc.[@bb0265], [@bb2930] 2-Acetamidoglucal represents the putative transition state between UDP-GlcNAc and ManNAc.

11.5. Modified Sialic Acids Different From *N*-Acetylneuraminic Acid {#s0190}
--------------------------------------------------------------------

The most frequent natural sialic acid in Nature is Neu5Ac, as is understandable from its biosynthetic pathway. However, from the survey in [Table 1](#t0010){ref-type="table"} it is also evident that there exist a large number of other sialic acids, variously substituted at the amino and/or hydroxy groups as well as dehydro and anhydro forms. In the following subsections, various derivatives of Neu5Ac will be discussed.

### 11.5.1. *N*-Glycolylneuraminic Acid {#s0195}

Leonard Warren, then at the National Institutes of Health, Bethesda, USA, described in 1963 the occurrence of Neu5Gc in different animals.[@bb0015] Neu5Gc belongs to the group of the most frequently encountered sialic acids, and it is widely distributed in Nature. Although it has never been found in microorganisms (with the exception of *Trypanosoma cruzi* cultivated in Neu5Gc-containing medium[@bb3960]), it is often expressed in species ranging from echinoderms to mammals.[@bb0030], [@bb0035], [@bb0040] However, exceptions are known, such as sauropsides (birds and reptiles), and the monotremes, such as platypus and echidna,[@bb3965] as well as ferrets, New World monkeys, and man. Very recently, a study appeared about the phylogenetic distribution of the CMP-Neu5Ac hydroxylase (CMAH) gene in 322 deuterostome genomes. It was found that the gene has been lost or inactivated at least 31 times during deuterostome evolution.[@bb3970]

Since humans frequently consume Neu5Gc (mainly with red meat), they incorporate a small portion of this sialic acid into their tissues.[@bb3975] Neu5Gc is a xeno-antigen and may cause the production of anti-Neu5Gc antibodies. Evidence exists that this can lead to inflammations and tumors, e.g., in the colon.[@bb3980] African Great Apes regularly synthesize Neu5Gc in contrast to man.[@bb3985] Not much is known about the function of Neu5Gc.[@bb0035] Some aberrations in behavior and physiology like retarded wound healing and hearing loss, similar to human pathologies, were observed in Neu5Gc-knockout mice.[@bb3990] Neu5Gc may even be toxic. Remarkably, in mammalian brains Neu5Gc exists in only very small amounts. This may be of physiological significance, since experiments leading to a higher expression of Neu5Gc in mouse brain resulted in some neuronal disturbancies.[@bb3995] On the other hand, as far as it has been investigated, fetal tissues express more Neu5Gc than adult tissues, as shown in calf and pig.[@bb4000], [@bb4005]

Neu5Gc was first isolated and structurally analyzed by Blix and coworkers,[@bb0120] and later it was chemically synthesized by Faillard and Blohm.[@bb4010] Elucidation of the biosynthesis of Neu5Gc was a tedious procedure; first attempts go back to 1967.[@bb1355], [@bb4015] Theoretically, the origin of the *N*-glycolyl group is a glycolic acid residue, e.g., from coenzyme A, or it is generated by a direct oxidation of the *N-*acetyl group of the sialic acid precursors GlcNAc and ManNAc, or Neu5Ac itself. Evidence for the formation of glycolyl-CoA from hydroxypyruvate was demonstrated in porcine liver.[@bb4020] However, glycolyl-CoA seemed to be a less likely *N*-glycolyl precursor \[only traces of O-glycolylated sialic acids have been detected in bovine and equine submandibular glands ([Table 1](#t0010){ref-type="table"})\]. Furthermore, radioactively labeled 3-hydroxypyruvate and serine were not precursors of (radioactive) Neu5Gc.[@bb4025] Thus, a transfer of glycolyl groups during Neu5Gc biosynthesis was largely excluded. The following two studies were in agreement with a direct oxidation of the *N*-acetyl group, as had been (theoretically) proposed 10 years earlier[@bb4030]: (i) direct hydroxylation of *N*-acetyl anilids to *N*-glycolyl anilids in liver microsomes[@bb4035]; (ii) oxidation of UDP-*N*-acetylmuramic acid to UDP-*N*-glycolylmuramic acid before incorporation into the peptide glycan of the bacterial cell wall.[@bb4040]

With respect to the suggestion of a direct oxidation of the *N*-acetyl group in the case of Neu5Gc, first experiments with homogenates of porcine submandibular glands did not show the formation of *N*-glycolylglucosamine (GlcNGc) from the sialic acid precursor GlcNAc.[@bb1355], [@bb4015] This pointed to a sialic acid modification at a higher biosynthetic step. Incubation of surviving slices of porcine submandibular glands with *N*-\[1-^14^C\]acetyl-glucosamine led to labeling of sialic acids, including Neu5Gc having a radioactive glycolyl group (for analysis of glycolyl groups, see [Section 7.1](#s0100){ref-type="sec"}). The direct incorporation of ^18^O from ^18^O~2~ gas, resulting in *N*-\[^18^O\]glycolyl groups in Neu5Gc, was also shown.[@bb4045] Further incubations with \[1-^14^C\]acetate, *N*-\[1-^14^C\]acetyl-mannosamine, and *N*-\[1-^14^C\]acetyl-neuraminic acid led in each case to the identification of *N*-\[1-^14^C\]glycolyl-neuraminic acid.[@bb4050], [@bb4055], [@bb4060] All these results led to the claim of the existence of an *N*-acetylhydroxylase, involved in Neu5Gc biosynthesis. Most of the newly formed, radioactive Neu5Gc was within the tissue still free and not yet incorporated into glycoconjugates. As shown by the group of one of the authors (R.S.), CMP-Neu5Gc (and CMP-Neu5Ac) is formed in porcine submandibular glands and can act as the donor for the transfer of Neu5Gc to nascent glycoproteins by sialyltransferases.[@bb4065] This led to the assumption that Neu5Gc was formed before the transfer to glycoconjugates in the Golgi.

In the same period, using particle-free homogenates from porcine submandibular glands, it was found that the hydroxylation of the *N*-acetyl group of Neu5Ac required, besides of oxygen, the addition of NADPH or ascorbic acid as cofactors.[@bb4060] The responsible enzyme was denominated *N*-acetyl-neuraminate:O~2~-oxidoreductase, and later Neu5Ac monooxygenase (EC 1.14.18.2). Although activities were found both in the cytosol and in microsomes, they were generally low, whereas glycan-bound Neu5Ac as a substrate was inactive. A later reevaluation of experiments, however, made clear that the positive tissue fractions were contaminated with CMP-Neu5Ac.

Then, in 1988, CMP-Neu5Ac was found to be the real and only substrate for the monooxygenase in porcine submandibular glands, exhibiting highest activity in the soluble protein fraction.[@bb4070] The same activity was also detected in the high-speed supernatant fraction of mouse liver.[@bb4075] The renamed enzyme, CMP-*N*-acetylneuraminate hydroxylase, was purified from porcine submandibular glands[@bb4080] and mouse liver.[@bb4085] The molecular weight of the monomeric enzyme from both sources was determined to be 65 kDa. In the same years, the group of Akemi Suzuki at Tokyo Metropolitan Institute of Medical Science (Japan) elucidated the complex mechanism of electron transport required for hydroxylase activity, in which NADH, cytochrome *b*5,[@bb4090] and cytochrome *b*5 reductase[@bb4095] in mouse liver cytosol were involved. This cytochrome *b*5-dependent electron transport chain is soluble or membrane-bound.[@bb4100] The enzyme activity can be stimulated by the addition of iron and is inhibited by iron-binding agents, which suggested the existence of an iron-containing prosthetic group.[@bb4105] Electron paramagnetic resonance (EPR) spectroscopy of the primary structure of the hydroxylase revealed that this enzyme is an iron--sulfur protein of the Rieske type (2Fe--2S). Interestingly, it was the first example of such an enzyme found in the cytosol in Eukarya.[@bb4110] The Rieske center is located close to the N-terminus of the enzyme protein. For a first molecular cloning of the CMP-Neu5Ac hydroxylase (CMAH) gene of mouse liver, see ref. [@bb4115]. As the CMAH gene is defective in humans, it became clear why Neu5Gc cannot be synthesized in man.[@bb4120] Finally, the group of Ajit Varki at the University of California (San Diego, USA) discovered that the Rieske sulfur--iron center is missing, which is due to an *Alu*-mediated inactivation of the human CMP-Neu5Ac hydroxylase gene.[@bb9025], [@bb4125]

### 11.5.2. O-Acetylated Sialic Acids {#s0200}

The existence of O-acetylated sialic acids was assumed very early, when Blix, in 1936, isolated and crystallized sialic acids from bovine submandibular gland mucin under mild acid conditions and found more than one acetyl group per sialic acid molecule ("Kohlenhydrat I")[@bb0830] (see [Section 2.1](#s0020){ref-type="sec"}). And in a report from 1956, more information about "7-O- and 7,8(9)-O-acetylated *N*-acetylneuraminic acids" after periodate oxidation studies was provided[@bb0120], [@bb1320] (see [Section 5](#s0065){ref-type="sec"}). In the same period, O-acetylated sialic acids were also isolated from bovine mucin by incubation with sialidase (*V. cholerae* receptor-destroying enzyme)[@bb1325] (see [Section 5](#s0065){ref-type="sec"}). Larger quantities of various O-acetylated sialic acids from bovine submandibular gland were obtained by a combination of anion-exchange and cellulose chromatography.[@bb0125] The challenges and problems of analyzing O-acetylated sialic acids ([Table 1](#t0010){ref-type="table"}) have already been worked out in [Section 5](#s0065){ref-type="sec"}. A turning point in the history of assigning *O*-acyl substitution patterns was a report from the laboratories of both authors (J.P.K. and R.S.) in 1975, describing the determination of "8-*O*-acetyl-*N*-acetylneuraminic acid" as 9-*O*-acetyl-*N*-acetylneuraminic acid (Neu5,9Ac~2~). An unexpected misinterpretation of periodate oxidation data[@bb0125] was rectified by EIMS[@bb0140] (see [Section 5](#s0065){ref-type="sec"}). And over the years it became clear that Neu5,9Ac~2~ is the most frequent O-acetylated sialic acid occurring in Nature.

The newer analytical techniques made also the study of *O*-acyl migration in sialic acids possible, and Neu4,5Ac~2~, Neu5,7Ac~2~, Neu5,9Ac~2~, Neu5,7,9Ac~3~, and Neu5,8,9Ac~3~ were subjected to such analyses.[@bb9015], [@bb0195], [@bb0510], [@bb1310] TLC, HPLC, and GLC--EIMS experiments showed that Neu5,7Ac~2~, dissolved in pH 7.5 buffer, was almost completely converted into Neu5,9Ac~2~ after 30 h at 37°C (only 10% O-deacetylation). At pH 5.0 the substance was relatively stable. This migration phenomenon was studied in more detail by 360-MHz ^1^H NMR spectroscopy.[@bb0195] Using the peak intensities of the *N*-acetyl signals of α,β-Neu5,7Ac~2~ and α,β-Neu5,9Ac~2~, [Fig. 29](#f0150){ref-type="fig"}A illustrates the decrease of Neu5,7Ac~2~ and the increase of Neu5,9Ac~2~ as a function of the time of incubation in 0.1 M phosphate buffer/D~2~O (pD 7.2) at 37°C. In the migration process Neu5,8Ac~2~ could not be traced as an intermediate. This could mean that a direct intramolecular transfer Ac7 (secondary ester group) → Ac9 (primary ester group) occurs. But note that so far, an Ac7 → Ac8 → Ac9 mechanism has not been excluded. In [Fig. 29](#f0150){ref-type="fig"}B a similar plot is depicted for the conversion of Neu5,7,9Ac~3~ to Neu5,8,9Ac~3~ (0.1 M phosphate buffer/D~2~O, pD 7.5), yielding a molar equilibrium of approximately 1:1. A transient distortion of the anti orientation of the functional groups at C7 and C8 seems to be necessary to explain the migration of the *O*-acetyl group between the two secondary OH groups (see [Section 6](#s0070){ref-type="sec"}). For 4-*O*-acetyl-*N*-acetylneuraminic acid no migration of the *O*-acetyl group was observed.Fig. 29Time plots for the migration of *O*-acetyl groups in (A) Neu5,7Ac~2~ (α:β = 23:77) → Neu5,9Ac~2~ (α:β = 9:91) and (B) Neu5,7,9Ac~3~ (α:β = 22:78) → Neu5,8,9Ac~3~ (α:β = 3:97) in 0.1 M phosphate, pD 7.2--7.5, at 37°C, as monitored by 360-MHz ^1^H NMR spectroscopy. As a result of the migration, an anomerization process will also occur.Fig. 29Reproduced from Kamerling, J. P.; Schauer, R.; Shukla, A. K.; Stoll, S.; van Halbeek, H.; Vliegenthart, J. F. G. Migration of *O*-Acetyl Groups in *N,O*-Acetylneuraminic Acids. *Eur. J. Biochem.***1987**, *162*, 601--607. Copyright Wiley.

Application of HPLC and MS techniques revealed that O-acylated sialic acids are most widely distributed, much more than Neu5Gc. They occur in various bacterial species and in vertebrates and invertebrates, from echinoderms to mammals, including those species lacking Neu5Gc, such as monotremes, sauropsides, and humans. For extensive reviews, see refs. [@bb0030], [@bb0035], [@bb0040], [@bb3965], [@bb4130], and [@bb4135]. In these references, the great variety of biological functions of O-acetylated sialic acids is also described.

The *O*-acetyl groups render the respective sialic acid in most cases completely resistant, as in Neu4,5Ac~2~, or partially resistant, as in Neu5,7Ac~2~ or Neu5,9Ac~2~, toward the action of sialidases or sialate lyases. They act as differentiation and tumor antigens, suppress apoptosis, and strongly influence receptor interactions, which also leads to modulation of the immune system. Note that 9-O-acetylation of Neu5Ac and Neu5Gc interferes with the binding of sialoadhesin.[@bb9030], [@bb4140], [@bb4145] Increase of virulence by O-acetylation was early observed in *E. coli* K1.[@bb0185] Sialic acids, O-acetylated at C4 or at the side chain, are also ligands for some viruses,[@bb4135] first studied with influenza C virus. It took some time to demonstrate that the RDE of this virus is a sialate-*O*-acetylesterase, which O-deacetylates Neu5,9Ac~2~.[@bb4150] In contrast, O-acetylation of the sialic acids of mouse erythrocytes inhibits binding of the malaria parasite *Plasmodium falciparum* and infection of the red blood cells.[@bb4155]

For a long time, O-acetylated sialic acids appeared as enigmatic molecules in glycobiology, and they were treated as Cinderella molecules, because of their lability, the difficulties in purification, and characterization of the underlying O-acetylating enzyme proteins, as well as the elucidation of their molecular biology. So, it was difficult in the beginning to convince researchers that it may be rewarding to invest time and effort in the study of sialate *O*-acetyltransferases (SOATs), which were rather reluctant to reveal their secrets.

The experiments to gain first insight into the biosynthesis of the O-acetylation of sialic acids were methodologically similar and carried out at about the same time as the study on the Neu5Gc biosynthesis. When surviving slices of submandibular glands from cow and horse were incubated with \[1-^14^C\]acetate at various times at 37°C in an atmosphere of oxygen, the radioactivity was almost exclusively incorporated into the *O*-acetyl groups (and *N*-acetyl and *N*-glycolyl groups) of sialic acids within the time of incubation of maximum 4 h.[@bb4160] Similar to the Neu5Gc synthesis, the highest specific radioactivity of O-acetylated sialic acids was found in the fraction of free sialic acids, followed by that in the microsomal fractions, and the cytosolic sialic acid of the mature glycoproteins, which were least labeled. These findings were interpreted as O-acetylation also occurs before the sialic acid transfer, either at the hexosamine level (which would not be possible for the horse 4-O-acetylated sialic acid) or at the "free sialic acid" level. In the latter case, free Neu5Ac, Neu5Ac-9-phosphate, or CMP-Neu5Ac were candidates of *O*-acetyltransferase substrates. Indeed, incubation of homogenates of bovine submandibular gland with *N*-\[1-^14^C\]acetyl-neuraminic acid and acetyl-CoA led to *N*-\[1-^14^C\]acetyl-7- and -8-*O*-acetylneuraminic acid, as shown by radio-TLC analysis and based on our knowledge of sialic acid derivatives at that time (at the end of the 1960s). Hints for the existence of O-acetylated *N*-acetylhexosamines were never obtained, and O-acetylation of mature mucin-bound cytosolic sialic acids did not occur.[@bb4165] Therefore, a systematic name for the enzyme was proposed: "acetyl-CoA:*N*-acetylneuraminate-7(8)-*O*-acetyltransferase." As mentioned earlier, the 8-*O*-acetyl position was later corrected to be a 9-*O*-acetyl position, and correspondingly the enzyme was denoted as a 7(9)-*O*-acetyltransferase ([Fig. 30](#f0155){ref-type="fig"} ). In equine submandibular gland and guinea pig liver, a corresponding acetyl-CoA:sialate-4-*O*-acetyltransferase (EC 2.3.1.44) was detected. Kinetic and other properties of the enzyme were studied in microsomes, prepared from equine submandibular glands, and in an enzyme solubilized from guinea pig liver, respectively.[@bb4170], [@bb4175] In the years that followed, 7(9)-*O*-acetyltransferase activity was seen in some bacteria and various tissues and cells, ranging from starfish to man.[@bb4135] Fig. 30Metabolism of sialic acid O-acetylation (here Neu5Ac), including a survey of enzymes involved in the transfer and removal of *O*-acetyl groups. The *flowers* indicate the hydroxy groups found to be O-acetylated. The *hands* symbolize the position specificity of the *O*-acetyltransferase activities discovered: sialate-4-*O*-acetyltransferase, sialate-7-*O*-acetyltransferase, and sialate-9-*O*-acetyltransferase. The *scissors* represent the sialate-4-*O*-acetylesterase and sialylate-9-*O*-acetylesterase, involved in the hydrolysis of the ester groups. The *O*-acetyl group at the sialic acid glycerol side chain can migrate between C7 and C9 (via C8?), whereas the 4-*O*-acetyl group seems to be immobile.Fig. 30

If sialic acid is modified before the transfer to nascent glycoconjugates, the enzymatic coupling of various sialic acids to CMP should be possible. Indeed, this was shown to be the case for the CMP-sialate synthetase from bovine submandibular glands, which activates Neu5Ac, Neu5Gc, Neu5,7Ac~2~, and Neu5,8Ac~2~ (in fact Neu5,9Ac~2~; see above).[@bb4180] Sialyltransferases were also shown to be not absolutely strict toward the kind (structure) of activated sialic acid.[@bb4185] Only in 2007, it was established that CMP-Neu5Ac was the correct substrate for *O*-acetyltransferase, and CMP-Neu5,7Ac~2~ was identified as the primary reaction product. Accordingly, the enzyme\'s name was then modified into AcCoA-CMP-Neu5Ac 7-*O*-acetyltransferase (EC 2.3.1.45).[@bb4190] Interestingly, ab initio calculations gave information concerning possible roles of the different functional groups occurring on sialic acids.[@bb1540] Here, the relatively negative charge on the sialic acid side chain O7 supports the hypothesis that in *O*-acetyltransferase reactions this position is the primary insertion site of the acetyl group, and not the less negative oxygen at C9 ([Fig. 30](#f0155){ref-type="fig"}). Afterward, the *O*-acetyl group migrates to O9, and the participation of a "migrase" was discussed.[@bb4195] Before the 2007 Kiel report,[@bb4190] much effort had been undertaken by the group of Ajit Varki to elucidate the mechanism of sialic acid O-acetylation in rat liver.[@bb4200], [@bb4205] A transmembrane transfer of acetyl groups was observed for which histidine and lysine residues were essential. And it was hypothesized that the *O*-acetyltransferase activity might be associated within a membrane-bound complex composed of the acetyl-CoA transporter, the *O*-acetyltransferase, and sialyltransferase activities, and possibly an acetylated intermediate.[@bb4210] The same group solubilized acetyl-CoA:polysialic acid *O*-acetyltransferase from K1-positive *E. coli* and studied its basic properties.[@bb4215] Unfortunately, it was not possible, in spite of a lot of effort in various laboratories, to isolate and characterize the transferase from this subcellular location, and to get molecular genetic insight on the basis of the amino acid sequence of the enzyme.

However, between 2005 and 2009 several bacterial sialic acid-*O*-acetyltransferase genes from *E. coli* and *Neisseria meningitides* were identified.[@bb4220], [@bb4225] These genes and their encoded proteins do not exhibit significant similarities to animal genes and gene products. *Campylobacter jejuni* also expresses a sialate-*O*-acetyltransferase, which transfers the acetyl groups directly to the O9 position of terminal (α2→8)-linked sialic acids, as shown by NMR spectroscopy ([Fig. 30](#f0155){ref-type="fig"}).[@bb4230]

Great progress was achieved by using a rational approach to identify the mammalian sialate-*O*-acetyltransferase (EC 2.3.1.45).[@bb4235] To this end, the human genome database was screened for genes that are predicted to possibly encode acetyltransferases and are potentially located in the Golgi membrane. The candidate gene turned out to be CasD1 (capsule structure1 domain containing 1), which is similar to a gene of the fungus *Cryptococcus neoformans* (this yeast contains O-acetylated mannose). Various experiments were described indicating a direct involvement of the human Cas1 including siRNA protein (Cas1p) in the O-acetylation of sialic acids. Expression of this protein and characterization as *O*-acetyltransferase were achieved more recently.[@bb4240] CMP-Neu5Ac as substrate of the enzyme was confirmed.

### 11.5.3. Other Natural Sialic Acids {#s0205}

In addition to the *N*-glycolyl group and *O*-acetyl groups in various positions of the neuraminic acid molecule, other, partially rare substituents were also found, as well as dehydro, anhydro, and lactone derivatives. Since the various functions are often combined, nowadays, over 80 sialic acid derivatives have been identified in Nature (see [Table 1](#t0010){ref-type="table"}; [Fig. 31](#f0160){ref-type="fig"} ).Fig. 31Survey of naturally occurring substituents of the sialic acid backbone. For a full survey of structures, see [Table 1](#t0010){ref-type="table"}.Fig. 31

A first example is the 9-O-phosphorylated form of Neu5Ac (Neu5Ac9P). This sialic acid only occurs in free form in very low concentrations with high turnover rate as intermediate of the Neu5Ac biosynthesis (see [Section 11.1](#s0170){ref-type="sec"}; [Fig. 28](#f0145){ref-type="fig"}A). The 9-O-[l]{.smallcaps}-lactylation of sialic acids was first seen in 1976, by the identification of Neu5Ac9Lt in bovine submandibular gland mucin[@bb0215] and in human serum and saliva.[@bb0220] Strikingly, in the latter sources Neu5Ac9Lt was quite often the main *N*,*O*-acylneuraminic acid. 9-O-Lactylation of sialic acid was also found in horse and trout (see [Table 1](#t0010){ref-type="table"}). The function of this sialic acid is not yet known, but it seems to be formed enzymatically, as was studied with a particulate fraction from horse liver.[@bb4245]

So far, O-methylated sialic acids in significant quantities have been found only in echinoderms, in various starfish species. The first sialic acid of that type, 8-O-methylated Neu5Gc (Neu5Gc8Me), was seen in the starfish *Asterias forbesi*.[@bb0340] The Neu5Ac analogue was later traced.[@bb0130] For O-acetylated derivatives of both Neu5Ac8Me and Neu5Gc8Me, see [Table 1](#t0010){ref-type="table"}. *S*-Adenosyl-[l]{.smallcaps}-methionine:*N*-acetylneuraminate 8-*O*-methyltransferase (EC 2.1.1.78), involved in the sialic acid methylation, was detected in *Asterias rubens* [@bb0235] and purified 22,000-fold from this source.[@bb4250] This enzyme methylates both free and bound sialic acids. More recently, a 9-O-methylated variant of Neu5Ac, Neu5Ac9Me, was also found.[@bb0240]

In the period between 1976 and 1990 much attention was paid to 8-O-sulfated sialic acids (see [Table 1](#t0010){ref-type="table"}) being present in glycoproteins (see [Section 8.1](#s0125){ref-type="sec"}) and glycolipids (see [Section 8.2](#s0130){ref-type="sec"}). Here, the group of Kochetkov and coworkers at the Academy of Sciences in Moscow (Russia), working on sialoglycolipids of sea urchin species (Neu5Ac8S, Neu5Gc8S; e.g., ref. [@bb0250]), was quite active. Neu5Ac8S was also described for a sialoglycosphingolipid from bovine gastric mucosa.[@bb0255] With newly developed chemical and immunological techniques, the distribution of Neu5Ac8S and Neu5Gc8S in various cellular sites of sea urchin sperm and eggs was recently shown.[@bb4255] Note also the occurrence of Neu5Ac4S in a ganglioside from the sea cucumber *Holothuria pervicax* [@bb0245] (see [Section 8.2](#s0130){ref-type="sec"}) and Neu5Gc9S in a ganglioside from the sea urchin *Hemicentrotus pulcherrimus* [@bb0365] (see [Section 8.2](#s0130){ref-type="sec"}). The enzyme responsible for the sulfation of sialic acid is not yet known.

2-Keto-3-deoxynononic acid (Kdn) is a sialic acid in which the amino function at C5 of neuraminic acid (Neu) is substituted by a hydroxy group ([Fig. 31](#f0160){ref-type="fig"}). As mentioned in [Section 4.4](#s0060){ref-type="sec"}, this substance was discovered in 1986 in cortical alveolar polysialoglycoproteins of rainbow trout eggs,[@bb1300] composed mainly of Neu5Gc as sialic acid residue.[@bb0385] These sialoglycoproteins were identified 10 years earlier as a novel class of glycoproteins in the unfertilized eggs of rainbow trout.[@bb4260] Meanwhile, Kdn is found in all types of glycoconjugates of bacteria and vertebrates, including mammals, in various linkages like Neu5Ac, and in free form in tissues, including cancer tissue. A recent study on the occurrence of free sialic acids in head and neck cancers of the throat revealed relatively high levels of Kdn (2 μg/g tissue) when compared with Neu5Ac and also Neu5Gc. Thus, Kdn was discussed to be of prognostic value, as a biomarker, for detecting some early-stage cancers at biopsy.[@bb4265] The occurrence of Kdn in bacteria was first reported in 1989, namely, in the acidic capsular polysaccharide from *Klebsiella ozaenae*, which causes respiratory diseases in man.[@bb0390] Kdn was also detected in trout gangliosides[@bb2625] and in different organs of the pig, although in smaller amounts than Neu5Ac and Neu5Gc.[@bb4005]

For a review from 2006, describing 20 years of history of biological studies on deaminated neuraminic acid, see ref. [@bb0065]. Focusing here on the metabolism ([Fig. 28](#f0145){ref-type="fig"}C), a Kdn-9-phosphate synthase, which condenses mannose-6-phosphate and phosphoenol pyruvate to yield Kdn-9-phosphate, was identified in rainbow trout ovaries and in testes. Thus, the biosynthesis of Kdn is similar to that of Neu5Ac, using Man as the hexose precursor instead of ManNAc. After dephosphorylation, the Kdn that is formed can be linked to CMP (CMP-Kdn synthetase[@bb4270]) and transferred to glycans. There exist some enzymes specific for Kdn, including a KDNase (see [Section 11.7](#s0220){ref-type="sec"}), but there are also enzymes of the Neu5Ac metabolism that can react with (CMP-)Kdn. For example, a sialyltransferase activity, which catalyzes the transfer of Kdn from CMP-Kdn to the nonreducing termini of the polysialyl chains of polysialoglycoproteins, was found in rainbow trout ovary[@bb4275] (see [Section 8.1](#s0125){ref-type="sec"}). This capping with Kdn of the polysialyl chains prevents their further elongation.

Information about structural variants of the sialic acid backbone, i.e., the 5,7-diamino-3,5,7,9-tetradeoxynon-2-ulosonic acids pseudaminic acid (Pse), legionaminic acid (Leg), 4-*epi*-legionaminic acid (4eLeg), 8-*epi*-legionaminic acid (8eLeg), acinetaminic acid (Aci), and 8-*epi*-acinetaminic acid (8eAci), has been given in [Section 10](#s0160){ref-type="sec"} and [Table 4](#t0025){ref-type="table"}. For data about homologous biosynthetic pathways for sialic acids and 5,7-diamino-3,5,7,9-tetradeoxynon-2-ulosonic acid derivatives, see refs. [@bb2980], [@bb3400], [@bb3405], [@bb3410], [@bb3435], [@bb3500], [@bb3530], [@bb3545], [@bb3585], [@bb4280], and [@bb4285]. As an example, the biosynthetic pathway of 5,7-di-*N*-acetyllegionaminic acid (Leg5,7Ac~2~),[@bb4285] having also the [d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto* configuration, has been included in [Fig. 28](#f0145){ref-type="fig"}D. The biosynthetic pathway of 5,7-di-*N*-acetylpseudaminic acid ([l]{.smallcaps}-*glycero*-[l]{.smallcaps}-*manno*-configuration) has also been unraveled.[@bb4290], [@bb4295] Here, UDP-α-[d]{.smallcaps}-GlcNAc is converted via UDP-β-[l]{.smallcaps}-6dAltNAc4NAc and [l]{.smallcaps}-6dAltNAc4NAc into Pse5,7Ac~2~, and then into CMP-α-Pse5,7Ac~2~ ([l]{.smallcaps}-6dAltNAc4NAc = 2,4-diacetamido-2,4,6-trideoxy-[l]{.smallcaps}-altrose). For reviews dealing with biological/immunological functions of non-2-ulosonic acids, other than sialic acids, see refs. [@bb2980], [@bb3400], [@bb3410], and [@bb4280].

### 11.5.4. Nonnatural Sialic Acids {#s0210}

The study of the metabolism and biological functions of sialic acids with hexosamine precursors substituted at the amino group with nonnatural functions, inaugurated by Werner Reutter in a visionary way,[@bb4300] opened a new area in chemical sialobiology, referred to as metabolic glycoengineering. By the end of the 1960s, Reinhard Brossmer at the Max-Planck-Institut für medizinische Forschung (Heidelberg, Germany) had synthesized, among others, *N*-formyl- and *N*-succinyl-neuraminic acid and had studied the influence of these foreign substituents on sialidase activity[@bb4305] (see [Section 11.7](#s0220){ref-type="sec"}). At the beginning of the 1980s, the group of Reutter reported that *N*-propionylglucosamine (GlcNProp) and *N*-propionylmannosamine (ManNProp) inhibited the Neu5Ac biosynthesis in a cell-free system of rat liver,[@bb4310] and the formation of *N*-propionylneuraminic acid (Neu5Prop) was demonstrated. Following these studies, the uptake of *N*-propionylhexosamines was studied in more detail.[@bb4315], [@bb4320] In rat liver, Neu5Prop biosynthesized from ManNProp was found back in the membrane and serum glycoproteins, as well as in gangliosides. Although some *N*-acetylmannosamine analogues exhibited a degree of toxicity to cells, with this glycoengineering, various modulations of cell functions became possible. For example, human peripheral blood mononuclear cells could be immunomodulated by the replacement of about 10% of their sialic acids with Neu5Prop, after incubation with ManNProp. The cells proliferated faster, produced more IL-2, upregulated their receptor CD25, and expressed the transferrin receptor.[@bb4325] Modified sialic acids were found to stimulate the proliferation of astrocytes and microglia cells in the rat central nervous system[@bb4330] and modulate virus--receptor interactions.[@bb4335] Growth of diploid human fibroblasts with ManNProp, *N*-butyrylmannosamine (ManNBut), and *N*-valerylmannosamine (ManNVar) destroyed their sensitivity to contact inhibition of growth.[@bb4340] *N*-Acyl modification of sialic acids seems to be promising in cancer therapy. Treatment of human neuroblastoma cells with ManNProp or ManNVar reduced their sialylation and metastatic potential and increased their sensitivity toward radiation and chemotherapeutics. Furthermore, ManNPent inhibited polysialylation.[@bb4345] The formation of cell membrane *N*-azidoacetylneuraminic acid (Neu5Az) after the application of per-O-acetylated *N*-azidoacetylmannosamine (ManNAz) also offers many possibilities for cell biological, including histochemical (see [Section 7.4](#s0115){ref-type="sec"}), experiments.[@bb2070] Recently, this rapidly growing area of the metabolic glycan labeling strategy was excellently and thoroughly reviewed.[@bb4350], [@bb4355] It reports many more applications than mentioned here, and it summarizes that mannosamines with modified aliphatic *N*-acyl functions, like ManNProp, can be used for the investigation of Neu5Ac-dependent biological processes. In contrast, mannosamines with bio-orthogonal modified *N*-acyl groups, like ManNAz, are mainly used to visualize sialylation and sialic acid metabolism in vitro and in vivo*.*

11.6. The De-esterification of O-Acetylated Sialic Acids {#s0215}
--------------------------------------------------------

The discovery of more than 20 different naturally occurring O-acetylated sialic acids (see [Table 1](#t0010){ref-type="table"}) implies the necessity of *O*-acetylesterases for the catabolism of these substances, especially, since sialidases and sialate--pyruvate lyases, the next enzymes in the catabolic reaction sequence of bound sialic acids, are strongly influenced in their activity by *O*-acetyl groups. Although 4-O-acetylated sialic acids are resistant toward the action of the latter enzymes \[an exception is the fowl plague virus sialidase (see [Section 11.7](#s0220){ref-type="sec"})\], no accumulation of sialoglycoconjugates in corresponding tissues, like in the horse, leading to storage diseases, was observed. A first hint for the existence of a "missing link" in the catabolism of O-acetylated sialic acids was obtained in the 1980s when the ganglioside Neu4Ac5Gc-GM3, isolated from horse erythrocytes, was incubated with partially purified equine liver sialidase.[@bb4360] Unexpectedly, non-O-acetylated Neu5Gc was slowly released, which was later explained by the possible presence of a 4-*O*-acetylesterase activity in the sialidase preparation.[@bb4365] More recently, two esterases could be isolated from the 100,000 ×  *g* supernatant of horse liver by isoelectric focusing, one O-deacetylating both Neu4,5Ac~2~ and Neu5,9Ac~2~, and the other only Neu5,9Ac~2~.[@bb4370] Both enzymes were inactive with 7-O-acetylated sialic acids, as was also observed for other sialate esterases.

Sialate-*O*-acetylesterases (EC 3.1.1.53) were studied in bacteria,[@bb0630] in mammalian tissues, for example, rat liver,[@bb4210] bovine brain,[@bb4375] and horse liver,[@bb4370] in corona and toro viruses,[@bb4380] and in influenza C viruses. For a summary of the enzyme tests available, see ref. [@bb4385]. The sialate-*O*-acetylesterase in influenza C virus was one of the first esterases discovered. Although an enzyme destroying the virus receptor had been demonstrated to exist on influenza C viruses in 1950,[@bb4390] the specificity of this enzyme and the nature of the cellular receptor for this virus have remained puzzling ever since. Then, in the 1980s, it was found that sialic acid is involved in the receptor function for the virus, because sialidase destroyed a potent hemagglutination inhibitor present in rat serum, i.e., α~1~-macroglobulin.[@bb4395] The nature of this sialidase-susceptible sialic acid was found to be Neu5,9Ac~2~, which lost its *O*-acetyl group by incubation of rat α~1~-macroglobulin or bovine submandibular gland mucin with influenza C virus.[@bb4150] This pointed to the presence of an esterase in the virus, which was thereafter isolated and denoted as sialate 9(4)-*O*-acetylesterase, because it hydrolyzed both Neu4,5Ac~2~ and Neu5,9Ac~2~.[@bb4400] For a further characterization and molecular cloning, see ref. [@bb4405]. In additional studies, the group of José Cabezas at the Universidad de Salamanca (Spain) found that the influenza C virus esterase had broad substrate specificity, hydrolyzing not only natural substrates containing Neu5,9Ac~2~ (e.g., bovine submandibular gland mucin) but also many nonsialic acid *O*-acetyl-containing compounds.[@bb4410] This esterase turned out to be part of the hemagglutinin-esterase-fusion (HEF) protein complex of influenza C virus, the crystal structure of which has been elucidated in 1998.[@bb4415] In the same period, the HEF protein complex from mouse hepatitis virus strain S was shown to contain a sialate 4-*O*-acetylesterase part.[@bb4420] It should be noted that, due to steric hindrance, all these esterases never can act on sialic acid 7-*O*-acetyl groups. Therefore, for O-deacetylation, the 7-*O*-acetyl group must first migrate to position 9 ([Fig. 30](#f0155){ref-type="fig"}) in order to get access to the catalytic center of the enzyme.[@bb4195] In further investigations, the human sialate-9-*O*-acetylesterase, the gene of which is located on chromosome 11, gained much interest, since it was shown to play a key role in the regulation of B-cell response and the level of O-acetylation in human colon mucosa,[@bb4425] and to be involved in immune and autoimmune events.[@bb4430], [@bb4435], [@bb4440] In a thorough study of the human sialic acid acetylesterase, including a genomic and phylogenetic analysis, the size of the enzyme and its subcellular localization, the composition of the active center, and other properties have been addressed.[@bb4445] One of the most interesting target molecules of this 9-*O*-acetylesterase is the ganglioside 9-O-acetylated GD3, which influences a variety of biological functions, from apoptosis to the growth and metastasis of tumor cells.[@bb4135] Its elevated concentration in a variety of tumors was described.

11.7. exo-, endo-, and *trans*-Sialidases {#s0220}
-----------------------------------------

Sialidases are involved in the catabolism of sialic acids. As is clear from the foregoing, sialidases were discovered much earlier than the enzymes involved in the biosynthesis of these sugars (see [Section 11.1](#s0170){ref-type="sec"}). In 1942, George Hirst, in the Walter and Eliza Hall Institute of Research in Melbourne (Australia), directed by Frank Macfarlane Burnet (1899--1985), observed a factor eluting influenza viruses from erythrocytes, to which they were bound, resulting in agglutination of the red cells after a period of incubation.[@bb4450] Some years later, in the same institute, it was discovered that culture filtrates of various *Clostridia* species made erythrocytes nonagglutinable by influenza virus.[@bb4455] They had lost the ligand for virus binding by an enzyme-like activity. In the same year, similar reactions were described with *V. cholerae* filtrates.[@bb0880] Additionally, the enzyme-like agent, in the meantime called RDE, was found in various viruses of the mumps influenza group,[@bb4460] and later also in pneumococci.[@bb1140] As discussed in [Section 2.1](#s0020){ref-type="sec"}, the released low-molecular-weight substances turned out to be sialic acids.

The RDE that catalyzes the release of terminal sialic acid residues was initially incorporated in the IUB Nomenclature Recommendations of 1961 with the name of "neuraminidase," as proposed in 1957 by Gottschalk.[@bb4465] This name was changed in the IUB Enzyme Nomenclature 1984 edition[@bb4470] into "sialidase," but the name "neuraminidase" was kept as an "other name," e.g., viral "sialidases" are quite often called "neuraminidases" because of the use of "N" in their strain designation. In this context, it should be noted that bound neuraminic acid (the mother molecule) is not a substrate for the enzyme. For further enzyme nomenclature discussion, see ref. [@bb4475].

After these observations of viral and bacterial sialidases, this enzyme was also discovered in vertebrate tissues, first in both human and bovine plasma,[@bb4480] and then in the allantoic membrane of the embryonic chicken,[@bb4485] and in several organs of the rat.[@bb4490] The following years revealed an explosion of sialidase discoveries in microorganisms and animals. The enzyme turned out to be common in metazoan animals of the deuterostomate lineage from echinoderms to mammals. Various fungi, protozoa, and many pathogenic as well as nonpathogenic bacteria express sialidase. Viral sialidases have been found mainly in orthomyxoviruses, like avian, porcine, equine, and influenza viruses, and in paramyxoviruses to which belong Sendai, Simian, mumps, and Newcastle disease viruses. Presently, influenza virus sialidases, which undergo antigenic drift and are of great pathophysiological significance in influenza, are probably the most studied sialidases. Bacterial sialidases are gaining interest since they are involved in many infectious diseases. For example, *C. perfringens* sialidase, which is involved in the dangerous gas gangrene of muscle tissue, was purified[@bb4495] and can be detected by an immunoassay.[@bb4500]

The numerous sialidases known are all different regarding their molecular weight, pH dependency (mostly slightly acidic), substrate specificity, sialic acid structure specificity, kinetics, subcellular site, solubility, and susceptibility to inhibitors. They can release α-glycosidically bound sialic acids from N- and O-glycoprotein glycans, gangliosides, oligosaccharides, polysialic acids, and synthetic substrates at rather different rates ([Fig. 32](#f0165){ref-type="fig"}A). The isolated bacterial sialidases from *A. ureafaciens*,[@bb4505] *C. perfringens*,[@bb4495] *V. cholerae*,[@bb4510] and *Salmonella typhimurium*,[@bb4515] used in structural analysis studies, have similar broad substrate specificities for Neu5Ac. However, a linkage preference \[Neu5Ac(α2 → 6)Gal, Neu5Ac(α2 → 3)Gal, Neu5Ac(α2 → 8)Neu5Ac\] does exist. The sialidases from Newcastle disease virus[@bb4520], [@bb4525] and *Streptococcus pneumoniae* [@bb4530] do not cleave the Neu5Ac(α2 → 6)Gal linkage. The Newcastle disease virus sialidase is also resistant to the Neu5Ac(α2 → 6)GalNAc linkage.[@bb4525] For more information about the activity of the latter two sialidases on reduced or reductive aminated Neu5Ac(α2 → 6)GalNAc (open ring form of GalNAc), see refs. [@bb4530] and [@bb4535]. endo-Sialidase, which hydrolyzes (α2 → 8) linkages in sialic acid polymers, first observed with colominic acid, was detected in the bacteriophage E infecting *E. coli* bacteria.[@bb4540] The latter studies comprised rather tedious procedures because the source of the enzyme was feces from elephants kept in a zoo, and the smell during work-up was difficult to be tolerated by the members of the laboratories (Stephan Stirm, personal communication). Nowadays, the gene structures of many isolated sialidases have been analyzed. For reviews over the years, see refs. [@bb0035], [@bb0450], [@bb0570], [@bb3385], and [@bb4545], [@bb4550], [@bb4555], [@bb4560], [@bb4565], [@bb4570], [@bb4575], [@bb4580].Fig. 32(A) exo- and endo-Sialidase activities. (B) *trans*-Sialidase activities.Fig. 32

Microbial sialidases seem to be inducible by free or bound sialic acids. This was first observed with *V. cholerae* [@bb4585], [@bb4590] and *C. perfringens* [@bb4595] sialidases. In the case of the bacterial enzyme, an induction of a permease was observed, enabling the uptake of Neu5Ac into the bacteria. The *K* ~M~ value of such a (hypothetical) permease reaction was 3.3 × 10^− 4^  M. Furthermore, Neu5Ac lyase activity was also induced in the *Clostridia* by free Neu5Ac. Today, many sialic acid transporters are known,[@bb4600] e.g., a first characterized bacterial sialic acid transporter from *E. coli*.[@bb4605]

Sialidases are active, although at rather variable rates, with many naturally or synthetically modified α-linked sialic acids.[@bb4550], [@bb4555], [@bb4610] Two examples from the beginning in the late 1950s are the demonstration that, using *V. cholerae* culture filtrates, O-acetylated sialic acids are released from bovine submandibular mucin at a slower rate than Neu5Ac,[@bb1325] and that Neu5Gc is hydrolyzed from the stroma of bovine erythrocytes.[@bb0985] All studies revealed that Neu5Ac is released at the highest rate, and Neu5Gc and sialic acids O-acetylated at the glycerol side chain (Neu5,7Ac~2~, Neu5,8Ac~2~, or Neu5,9Ac~2~) are released at slower rates, while Neu4,5Ac~2~ shows no activity with most sialidases.[@bb0035], [@bb0125], [@bb0510] The exception is the sialidase from fowl plague virus, which can slowly hydrolyze the glycosidic bond of Neu4,5Ac~2~.[@bb4615] It should be noted that the sialic acid lyase behaves toward these naturally substituted sialic acids in a similar way, i.e., it, for example, cannot cleave Neu4,5Ac~2~.[@bb1655] Using chemically modified sialic acids, it was shown that a smaller function at the sialic acid amino group, like an *N*-formyl group, or a larger one, like an *N*-succinyl substituent, much reduces the *V. cholerae* sialidase activity, when compared with an *N*-acetyl group as in Neu5Ac. While *N*-succinylneuraminic acid is not released at all by the enzyme, the *N*-formyl derivative is slowly hydrolyzed.[@bb4305] For more details about this topic, see refs. [@bb0035] and [@bb4555].

Mammalian sialidases have been investigated very intensively, because they are involved in the regulation of sialic acid degradation, and play a great pathophysiological role in genetic, immunological, and tumor diseases. Among many other researchers, the group of Taeko Miyagi at the Miyagi Cancer Center Research Institute (Miyagi, Japan) has worked very early and intensively on this group of sialidases. Four of them, NEU1--NEU4,[@bb0570] are of great importance: (i) lysosomal sialidase NEU1 initiates the degradation of sialoglycoconjugates[@bb4620]; (ii) cytosolic sialidase NEU2 exhibits highest activity with gangliosides. It was cloned from rat skeletal muscle[@bb4625]; (iii) the plasma membrane-associated sialidase NEU3 is specific for gangliosides. It was cloned from bovine brain[@bb4630]; and (iv) sialidase NEU4, bound to the outer mitochondrial membranes via protein--protein interactions, has a wide substrate specificity from glycoproteins to gangliosides and oligosaccharides. It also occurs in the lysosomal lumen. For the cloning of NEU4, see ref. [@bb4635].

All these sialidases exert many cell biological functions from cell growth to apoptosis. Being involved in cancer, NEU3 is downregulated in some tumors like colon cancer and acute lymphoblastic leukemia (ALL).[@bb0570], [@bb4640] Importantly, increase of sialidase activity in tumor cells by transfection reduces their aggressiveness. In a recent study with transcripts of the sialidases (NEU1, NEU3, and NEU4) of 11 types of cancer tissues from 170 patients, it was found that NEU1 and NEU3 were upregulated, while NEU4 was downregulated in most cancer types. NEU3 was expressed highest in colorectal and ovarian tumors, and NEU1 in ovarian cancer.[@bb4645] The four human sialidase isoenzymes exhibited pronounced differences in their ability to hydrolyze the Neu5,9Ac~2~ α-glycosidic linkage. With the exception of NEU4, they hydrolyzed the O-acetylated species slower than Neu5Ac and Neu5Gc.[@bb4650]

The mammalian sialidases, including the bacterial and protozoal enzymes, contain a sequence motif of eight amino acids Ser/Thr-X-Asp-X-Gly-X-Thr-Trp/Phe, called the "Asp-box" and a Phe/Tyr-Arg-Ile-Pro motif near the sialidase N-terminus. These motifs, probably involved in the enzymatic cleavage reaction, were observed by comparison of the genes of a variety of mainly Clostridial exo-sialidases and the *T. cruzi trans*-sialidase.[@bb4655]

The eukaryotic *trans*-sialidases (TS) are best studied in the pathogenic trypanosomes *T. cruzi*, *Trypanosoma brucei*, and *Trypanosoma congolense*. However, *trans*-sialidase activity was also discovered, for example, in *Corynebacterium diphtheriae*, *Pasteurella multocida*, and *C. jejuni*.[@bb0570], [@bb0700] Trypanosomal *trans*-sialidases are membrane-anchored enzymes that mediate the reversible (α2→3)-sialylation of β-galactose-terminated glycans. In this way, the parasites scavenge sialyl residues from host blood serum components or cells and transfer them to their cell-surface glycans terminated with galactose ([Fig. 32](#f0165){ref-type="fig"}B). *trans*-Sialidases can also act as mere sialidases. They are virulence factors in the South American Chagas Disease, the African Sleeping Sickness, and in some African cattle diseases. For a review about their pathomechanism, see ref. [@bb0700].

First indications for the existence of such *trans*-sialidases, probably involved in the biology of trypanosomes, stem from 1983, when the group of one of the authors (R.S.) detected Neu5Ac and Neu5Gc in cultivated *T. cruzi*.[@bb3960], [@bb4660] These two sialic acid species probably were not synthesized by the parasites themselves, because their relationship corresponded to that of the culture medium. It was assumed that a sialidase, later localized on the cell membrane of *T. cruzi*,[@bb4665] was involved. This assumption was confirmed after the isolation of the first TS from *T. cruzi*,[@bb4670], [@bb4675] followed by TSs from the African species *T. brucei* and *T. congolense*.[@bb4680], [@bb4685], [@bb4690] Information about the development of a suitable test system, study of donor and acceptor specificities, reaction mechanism, inhibitors, and biotechnological application of these rare and unique *trans*-sialidases is summarized in refs. [@bb0570], [@bb0700], and [@bb4695]. The *T. brucei* group expresses TS during parasite growth in the insect stage, while in *T. cruzi* this enzyme functions mainly in the mammalian host. A wealth of literature, originating especially from South American laboratories, documents the developments during the last 20 years; see ref. [@bb0700] for an overview.

As an intramolecular *trans*-sialidase, a sialidase from the leech *Macrobdella decora* can be considered. It catalyzes the formation of 2,7-anhydro-Neu5Ac (Neu2,7an5Ac) from (α2→3)-bound sialic acid of sialyllactose and various glycoconjugates[@bb0295], [@bb0440], [@bb4700] ([Fig. 32](#f0165){ref-type="fig"}A). Whether this sialidase is autochthonous to the leech or of bacterial origin is so far unknown. *S. pneumoniae* sialidase B has also been recognized as an intramolecular *trans*-sialidase.[@bb4705] The detection of Neu2,7an5Ac in ear secretion suggests the presence of such an enzyme in human cerumen.[@bb0290] Interestingly, gut microbiota are also among the producers of this Neu5Ac derivative.[@bb4710]

Although deaminated neuraminic acid (Kdn) is α-glycosidically linked to neighboring residues,[@bb0385] the substitution of an *N*-acyl group by a hydroxyl function at C5 blocks nearly completely the action of bacterial exo- or endo-sialidases, known up to the 1990s.[@bb4715] A few years later, however, a bacterial sialidase from *Sphingobacterium multivorum* was found to be capable of releasing Kdn (α2 → 3, α2 → 6, α2 → 8), but not *N*-acylneuraminic acids.[@bb4720] Therefore, this sialidase was called KDNase. In the same period, a sialidase from the liver of the loach, *Misgurnus fossilis*, released both bound *N*-acetylneuraminic acid and deaminated neuraminic acid residues.[@bb4725] The same held for sialidase preparations isolated from the kidney, spleen, and ovary of rainbow trout.[@bb4730]

Finally, a unique sialidase was isolated from the hepatopancreas of the oyster species *Crassostrea virginica*.[@bb4735] This enzyme was capable of releasing Neu5Gc from the \[→O5)Neu5Gc(α2→\]~*n*~ polysialic acid sequence in a more efficient way than from the \[→8)Neu5Ac(α2→\]~*n*~ or \[→8)Neu5Gc(α2→\]~*n*~ polysialic acid sequences. On the disaccharide level, Neu5Gc(α2→O5)Neu5Gc and also Kdn(α2→8)Kdn were effectively cleaved, whereas Neu5Ac(α2 →8)Neu5Ac and Neu5Gc(α2→8)Neu5Gc were poor substrates.

### 11.7.1. Sialidase Inhibitors {#s0225}

*trans*-Sialidases and many members of the bacterial and viral sialidases, when involved in diseases, require the availability of inhibitory substances for the study of their mechanism of action and especially for therapeutic use. The best examples are those from influenza viruses, which are absolutely dependent on their sialidase (neuraminidase, symbolized by N) for the infection of host cells. In order to escape the immune defense of the host, they steadily mutate, which, together with the hemagglutinin (H) that also mutates, continuously produce new viruses with variable infection potential. Such mutations are indicated by numbers added to the HN of the viruses, e.g., H1N1.

Early studies on an effective inhibitor of flu were successful in the laboratory of Hans Tuppy and Peter Meindl at the Universität Wien (Vienna, Austria).[@bb0425], [@bb3195] They synthesized various 2-deoxy-2,3-didehydrosialic acids, such as 2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid (Neu2en5Ac) and the corresponding *N*-glycolyl, *N*-propionyl, *N*-butyryl, *N*-benzoyl, and *N*-carbobenzoxy derivatives. Mainly Neu2en5Ac was used for inhibition studies of the propagation of influenza viruses in cell culture. The compound inhibited most viral, bacterial, and mammalian sialidases with an inhibitor constant *K* ~i~ of about 5 μM, but not trypanosomal *trans*-sialidases. Substitution of the *N*-acetyl group in Neu2en5Ac by an *N*-trifluoroacetyl group led to a twofold better inhibitor.[@bb4740] However, these inhibitors were not strong enough to inhibit virus growth in vivo. Neu2en5Ac was also found in human urine and saliva, in the latter source at rather variable quantities up to 2 × 10^− 5^  M, which, in principle, can inhibit influenza virus sialidase and may be of pathophysiological significance.[@bb0220]

Zbiral and coworkers at the Universität Wien (Vienna, Austria) synthesized a great variety of Neu2en5Ac variants, among others, 4-amino-Neu2en5Ac,[@bb4745] which inhibited viral sialidase about 100-fold stronger than Neu2en5Ac.[@bb0035], [@bb4750] It only weakly inhibited bacterial, e.g., *V. cholerae*, sialidase. A really potent virus sialidase inhibitor was developed when Mark von Itzstein at Monash University, Melbourne (now Griffith University, Brisbane), Australia, substituted this amino group by a guanidino function.[@bb0545], [@bb4750], [@bb4755] 4-Guanidino-Neu2en5Ac ([Fig. 33](#f0170){ref-type="fig"}A) exhibited a *K* ~i~-value of 3 × 10^−^ ^11^  M with influenza virus A sialidase. This strong, selective binding to viral sialidases is possible, because a pocket exists in the binding site of viral sialidases near the 4-hydroxy group of Neu5Ac. This pocket also allows slow release of bound Neu4,5Ac~2~, which is not possible with bacterial and mammalian sialidases.[@bb4615] 4-Guanidino-Neu2en5Ac inhibited the growth of a wide range of influenza A and B viruses in a variety of in vitro systems. The resulting drug Relenza® (zanamivir) as a spray is of prophylactic significance in preventing the infection of human bronchial epithelia with influenza viruses and is well suited for medical use.Fig. 33Structures of (A) Relenza®[@bb4750] and (B) Tamiflu®.[@bb4765]Fig. 33

However, Relenza® cannot enter cells in order to fight against the viruses already present in the tissues. Therefore, a more hydrophobic derivative with similar configuration was synthesized,[@bb4760], [@bb4765] namely, Tamiflu® (oseltamivir, [Fig. 33](#f0170){ref-type="fig"}B), which can successfully reduce the symptoms of flu by inhibition of the virus sialidase inside the infected organism.[@bb4770], [@bb4775] Because Tamiflu® also has some inhibitory effect on mammalian (human) sialidases, it should not be used for an extended period of time, nor should it be used prophylactically. Since resistance against Tamiflu® has been observed,[@bb4780] searches for new and even better flu inhibitors are under way. In a recent publication, such a highly specific inhibitor against influenza viral N1--N9 sialidases, 9-cyclopropyl-carbonylamino-4-guanidino-Neu2en5Ac (cPro-GUN), has been described, which is also highly effective against a Tamiflu®-resistant strain. Furthermore, most importantly, it does not inhibit human sialidases.[@bb4785] With such inhibitors, as well as vaccination, it is hoped that such severe and deadly influenza pandemics as had occurred just 100 years ago ("Spanish flu"), claiming many millions of casualties,[@bb4790] can be prevented.

12. The Biology of Sialic Acids {#s0230}
===============================

In the previous sections, according to the chronological development of the sialic acid field, the history of the sialic acid chemistry and biochemistry was highlighted. Although in recent years the biological roles of sialic acid have been broadly studied in great detail, some important biological discoveries originate from the beginning of the 1940s. As worked out in [2.1](#s0020){ref-type="sec"}, [11.7](#s0220){ref-type="sec"}, for the progress in sialic acid chemistry, the discoveries in the Walter and Eliza Hall Institute of Research in Melbourne, i.e., the enzymatic release (using virus and microbial filtrates) of a low-molecular-weight substance (later identified as sialic acid) by an RDE (later identified as sialidase), were of great importance. Here, the biological site of this finding will be further cleared up. As mentioned earlier, George Hirst observed that at 4°C influenza viruses bound to chicken erythrocytes, leading to agglutination of the red cells.[@bb4450] However, the viruses eluted from the erythrocytes after increasing the temperature to 37°C. Remarkably, the erythrocytes became inagglutinable, but the viruses remained functional. It was concluded that the viruses attach to a receptor substance at the red cell surface, which is inactivated by a viral enzyme. Then, Frank Burnet showed that such an enzyme also existed in the culture filtrate of *V. cholerae*.[@bb0880] A mucoprotein of hen egg white (ovomucin) inhibited the reversible virus--erythrocyte binding, a property that was destroyed when the ovomucin was first incubated with influenza virus.[@bb0490], [@bb0875] Thus, the main property of sialic acid was identified in these early days, namely, to act in biological recognition as a receptor, but in due respect to its structure, a ligand. Virologists even today consider sialic acids as receptors that accept viruses. However, sialic acid as a sugar should be called a ligand as it interacts per definition (see below) with a proteinaceous receptor. The first "receptor" function of sialic acids just described represents the binding to influenza virus hemagglutinin, the history and properties of which are described in detail in refs. [@bb4795], [@bb4800].

The cell biology, pathophysiology, and pharmacology of sialic acids are a huge and fast developing area, of which only a few highlights can be discussed here. An early review describing the role of glycans and sialic acids was published in 1972.[@bb0500] When studying the biological events in which sialic acids are involved, a dual role of these sugars can be recognized, i.e., they can mask recognition sites or they are directly recognized by a lectin-like receptor, for which they represent a ligand. This all mainly happens on the surface of the cell, the so-called glycocalyx.

12.1. The "Sweet Coat of the Cell" {#s0235}
----------------------------------

In the 1960s, a study on the migration of cells on electrophoresis led to the discovery of the electronegative charge of cell membranes.[@bb4805], [@bb4810] In fact, this finding contributed to the discovery of the glycocalyx. The term "glycocalyx" was coined by Bennett in 1963 (as "sweet husk") and describes the glycoproteins and glycolipids linked to the external lamina of cells.[@bb4815] The carbohydrate composition of the glycocalyx is rather variable and depends on the cell type and function. It represents a sensory system that interacts with the environment. Sialic acids are predominant components at this outer surface, and mainly here they act as biological masks or receptors.

12.2. The Masking Role of Sialic Acids in Serum Glycoproteins and Blood Cells {#s0240}
-----------------------------------------------------------------------------

Sialic acids keep serum glycoproteins and blood cells fit, which is one of the most dominant roles of these monosaccharides. In fact, they regulate the lifetimes of soluble serum glycoproteins and cells, have great significance in all aspects of cell biology, and are most prominent in immunology and in disease states such as cancer (for reviews, see refs. [@bb0035] and [@bb4820]). The sialobiology area was greatly stimulated when Ashwell and Morell in 1974 described in a review that desialylated glycoproteins of rabbit blood serum were rapidly cleared from the circulation and taken up by hepatocytes.[@bb4825] This process was mediated by a galactose-specific receptor on the hepatocytes, which recognized galactose residues of the glycoprotein glycans, demasked by the loss of terminal sialic acids (cleavage of Neu5Ac(α2→3/6)Gal linkage). The first report, describing the fate of desialylated serum glycoproteins, is from 1971.[@bb4830] The properties, molecular biology, and biosynthesis of this Ca^2+^-dependent (galactose) receptor have been intensively investigated, e.g., see ref. [@bb4835].

In other studies, it was observed that sialidase treatment of erythrocytes drastically decreased their lifetime.[@bb4840] In man it is reduced from about 120 days to a few hours.[@bb4845], [@bb4850] A similar phenomenon was also observed for rabbit erythrocytes.[@bb4855] The clearance of asialo-erythrocytes is similar to the sequestration of asialo-glycoproteins, although the erythrocytes are degraded in Kupffer cells. The adhesion of asialo-erythrocytes is mediated by lectin-like receptors on Kupffer cells, which recognize the unmasked galactosyl residues.[@bb4850], [@bb4860], [@bb4865] Adhesion can be inhibited by glycans that possess galactose in a terminal position. This binding and phagocytosis of sialidase-treated (rat) erythrocytes occurs by a mechanism independent of opsonins.[@bb4870] Using rat peritoneal macrophages and desialylated rat erythrocytes, the attachment of the erythrocytes to the macrophages and partial phagocytosis could be clearly demonstrated ([Fig. 34](#f0175){ref-type="fig"}A).[@bb4875], [@bb4880] The galactose receptor of rat peritoneal macrophages was identified by photoaffinity labeling as a protein of 42 kDa.[@bb4885] It adds to the rapidly increasing family of lectins recognizing galactose and other sugars, as reviewed in ref. [@bb4890].Fig. 34Binding of sialidase-treated rat erythrocytes, lymphocytes, and thrombocytes to homologues rat peritoneal macrophages by the galactose-specific acceptor. (A) Scanning electron microscopy of erythrocyte--macrophage interaction. After prolonged incubation, the erythrocytes were ingested; (B) scanning electron microscopy of cultured, sialidase-treated lymphocytes bound as a rosette by a peritoneal macrophage; (C) scanning electron microscopy of the characteristic binding of a single sialidase-treated lymphocyte by a rat peritoneal macrophage. In contrast to sialidase-treated, bound erythrocytes, no deformation of phagocytosis is observed. (D) Scanning electron microscopy of sialidase-treated thrombocytes to a macrophage adherent to a Petri dish.Fig. 34Panels (A) and (D): Reproduced from Schauer, R. Sialic Acids Regulate Cellular and Molecular Recognition. In *Carbohydrates---Synthetic Methods and Applications in Medicinal Chemistry*; Ogura, H.; Hasegawa, A.; Suami, T., Eds.; Kodansha Ltd.: Tokyo, Japan, 1992; pp 340--354. Copyright Wiley-VCH Verlag GmbH & Co. KGaA.

Lymphocytes also alter dramatically their "homing" behavior after sialidase treatment. It was found that enzyme-treated rat thoracic duct lymphocytes accumulated in liver instead of the spleen and lymph nodes.[@bb4895], [@bb4900] However, this loss of orientation was reversible after about 1 day, because the cells recovered, probably by resynthesis of their sialic acid coat. Correspondingly, binding studies with sialidase-treated rat lymphocytes and homologous peritoneal macrophages also showed reversible binding to these nucleated cells (in contrast to the erythrocytes), but no phagocytosis ([Fig. 34](#f0175){ref-type="fig"}B and C).[@bb4905], [@bb4910] The interaction was inhibited by galactosides, showing the involvement of the galactose receptor. Also in this in vitro experiment the lymphocytes continuously were released from the macrophages within 1 day. This reversible binding may be due to rapid resynthesis of membrane sialic acids, as observed with human lymphocytes[@bb4915] and with rat liver plasma membranes.[@bb4920] The turnover rate of sialic acid in a rat liver cell membrane glycoprotein was 33 h, whereas that of the corresponding protein part was 70--78 h.[@bb4920]

Sialidase-treated thrombocytes from rats were also rapidly cleared from the circulation.[@bb4925] The interaction of desialylated rat thrombocytes with homologous peritoneal macrophages also occurs in a galactose-dependent manner ([Fig. 34](#f0175){ref-type="fig"}D).[@bb0370], [@bb4880]

The various experiments described in this section have shown that sialic acids are of vital importance in the regulation of the lifetimes of these blood components and to maintain homeostasis. The behavior of the fully sialylated glycoproteins and cells is called "self" when they are intact and tolerated by the organism. As soon as sialic acid is lost, the molecules and cells become "nonself" and no longer fit to the chemical architecture required for normal "behavior"; hence, they are recognized by the defense system of the organism and are eventually destroyed. This defense system is part of the immune system; therefore, the dual system "self/nonself" plays a vital role in immunology (see [Section 12.4](#s0250){ref-type="sec"}). It functions as an inhibitory "self-signal" to the vertebrate immune system.[@bb4930] Also in cancer biology, the masking role of sialic acids is of great significance, as will be discussed in [Section 12.3](#s0245){ref-type="sec"}.

12.3. Sialic Acids in Tumors {#s0245}
----------------------------

This is one of the most important areas of sialoglycobiology, and the great variety in the phenomena of tumor growth in which sialic acids are involved has been described in several thousands of publications. The most important feature is the altered, mostly elevated, sialylation of the surface of tumor cells. This is caused by α2,3-, α2,6-, and α2,8-sialyltransferases, which are often more expressed in malignant cells compared to the corresponding normal cells. This high sialylation often leads to accelerated cancer progression including cell--cell repulsion, altered binding of cancer cells to the extracellular matrix, enhanced migration, docking to the vascular endothelium, and invasion that facilitates the formation of metastases and leads to poor prognosis of the disease. An elevated expression of the selectin ligands SLe^a^ and SLe^x^ in a variety of tumor types has been observed. Higher sialylation increases the resistance of tumor cells to apoptosis. Some tumors also exhibit more Neu5Gc and changes in sialic acid O-acetylation or Kdn concentration in comparison to the normal tissues.

Many reviews have appeared before, of which only a few will be listed here. For older reviews, see refs. [@bb4935], [@bb4940], [@bb4945], [@bb4950], [@bb4955], [@bb4960], [@bb4965], [@bb4970], [@bb4975], [@bb4980], [@bb4985]. From more recent overviews, refs. [@bb4990], [@bb4995], [@bb5000] are herein selected. Here, only the very beginning---according to the aim of this chapter---of tumor sialoglycobiology will be detailed on the basis of publications available. These show the long and tedious way researchers had to go to reach our present profound knowledge on cancer biology. However, many questions still have to be answered, especially in the field of molecular biology and immunology, and, of course, for therapy.

The year 1956 may be considered as the beginning of tumor sialoglycobiology, when Ambrose and coworkers discovered that tumor cells from hamster kidneys have a much greater electrophoretic mobility than normal homologous kidney cells.[@bb5005] In addition, mouse sarcoma cells migrated faster on electrophoresis when they acquired more malignant properties.[@bb5010] At that time, the nature of the molecules responsible for the electrophoretic mobility was not yet known. However, treatment of erythrocytes, as a model, with trypsin released a "sialomucopeptide" which contained terminally linked sialic acids. This was the first demonstration of a sialoglycopeptide at the periphery of a cell.[@bb4805] The existence of sialylated carbohydrates on the surface of normal and malignant mammalian cells was nicely demonstrated by using a Hale staining technique and comparison with sialidase treatment.[@bb5015] Most interesting experiments were carried out by the groups of Leonard Warren and Mary C. Glick in the beginning of the 1970s, when they demonstrated a marked difference in cell-surface glycosylation/sialylation of normal and virus-transformed baby hamster kidney (BHK) cells by a double-label technique with \[^14^C\]- or \[^3^H\]-[l]{.smallcaps}-fucose. The radioactive pronase-released glycoproteins from the two cell types were mixed and fractionated on Sephadex G-50. The eluting radioactive glycopeptides of both biological sources showed different profiles.[@bb5020], [@bb5025] In a publicaton[@bb5025] by Warren and coworkers, an elevated (up to 11 times) sialyltransferase activity in the transformed BHK cells, when compared to the normal cells, was reported; the sialic acid content was much higher in the transformed cells. Also invasive tumors of human breast and colon expressed elevated levels of glycoprotein sialyltransferases.[@bb5030] Since then, by using various techniques, increased sialylation and altered glycosylation have been observed in many tumors, mostly derived from ectodermal tissues, for example, in the most prevalent breast and colon cancers. A wealth of information about tumor biology was obtained in the early days of this research from the study of blood serum from tumor patients; an increase of sialic acids during tumor growth in humans and mice was identified.[@bb5035], [@bb5040], [@bb5045] The increase of serum sialic acid was later recognized to be due to high levels of sialylation of both glycoproteins and glycolipids.[@bb5050] In the case of β-myeloma proteins, three to six times more sialic acid was found in blood serum.[@bb5055]

Another milestone in our understanding of tumor biology was the discovery that the four types of known human sialidases behave in different manners during carcinogenesis. Probably the first observation of higher lysosomal sialidase and lower cytosolic sialidase levels was made in rat hepatomas, when compared to that of normal liver.[@bb5060] More recently, human sialidase was established to be a cancer marker, which is downregulated in lysosomes, promoting the growth and metastatic ability of tumor cells. The enzyme is upregulated in the plasma membrane, which suppresses apoptosis of cancer cells.[@bb5065] As described in [Section 11.7](#s0220){ref-type="sec"}, the human sialidases NEU1--NEU4 are expressed differently in various tumor tissues.[@bb4645] In general, transformed cell lines express higher activities of membrane-bound sialidase that preferably desialylates gangliosides.[@bb5070] Furthermore, the SLe^x^ epitope, which is often more expressed on tumor cells and interacts with selectins, facilitates metastasis (see below). Its biosynthesis has been studied in human lung carcinoma cells.[@bb5075]

Tumor cells often express modified Neu5Ac, such as Neu5Gc, O-acetylated sialic acid, or Kdn, at concentrations different from the corresponding normal cells. A well-studied example are human colon cells, the mucin of which is highly O-acetylated in the healthy state. On tumor development, in the adenoma--carcinoma sequence, mucin O-acetylation gradually decreased with the lowest value in adenocarcinoma. This leads to a higher concentration of SLe^x^ in mucins, which had been masked before by O-acetylation in the metastatic cells, thus facilitating metastasis.[@bb5080] The *O*-acetyltransferase activity declined, also.[@bb5085] Another example are melanoma and basalioma tissues in which gangliosides with O-acetylated sialic acids, mostly 9-*O*-Ac-GD3, are much more expressed than in normal skin.[@bb5090] For example, in gangliosides from basalioma, up to 56 times higher concentration of Neu5,9Ac~2~ was determined. O-Acetylated gangliosides, which also occur in other tumors of neuroectodermal origin, represent markers for neoplastic development. Interestingly, they are also universal markers for rapidly growing normal cells and tissues. In spinalioma (squamous cell carcinoma) and in skin nevi, sialic acid O-acetylation was not increased (J. Gierthmühlen and R. Schauer, unpublished results). A ganglioside containing sialylated lacto-*N*-fucopentaose II turned out to be an antigen associated with human gastrointestinal cancer cells.[@bb5095] During the last 30 years, more knowledge about gangliosides has been gathered, especially about the signaling mechanisms, particularly in cancer cells, regulated by these sialoglycolipids. Antitumor therapy addressing these molecules has been gradually put into practice.[@bb5100]

*N*-Glycolylneuraminic acid is also a type of sialic acid, which deserves attention in tumor biology.[@bb3975] While Neu5Gc is almost completely absent from normal human tissues (only about 0.01% Neu5Gc of total sialic acid) (see [Section 11.5.1](#s0195){ref-type="sec"}), this value is often higher in tumor tissues, especially in their gangliosides (for example, 0.5% of total lipid-bound sialic acid). Elevated levels of Neu5Gc were described as chemical or tumor-associated markers in glycolipids of human breast carcinoma and other tumors and in avian lymphoma cell lines.[@bb5105], [@bb5110], [@bb5115] They are called Hanganutziu--Deicher (HD) antigens (see [Section 12.4](#s0250){ref-type="sec"}). HD antigens occur in blood serum in rather variable amounts from normal individuals to cancer patients, where the values are often increased. With regard to the origin of Neu5Gc, a dietary source is assumed, as was first studied with rats.[@bb5120] Tumor cells may be able to take up more exogenous Neu5Gc than normal cells. There is also some evidence, which, however, needs more solidification, that small amounts of Neu5Gc can also be produced in an endogeneous metabolic pathway (H.-G. Hanisch, personal communication). Hydroxylase activity was, however, never observed. Finally, an important aspect of the xenoantigen Neu5Gc is its immunological and inflammatory role. There is evidence that these processes may lead to malignancies.[@bb5125]

12.4. The Role of Sialic Acids in Immunology {#s0250}
--------------------------------------------

In this section some historical aspects of sialic acids playing a role in immunology will be summarized. The beginning of the classical immunology goes back to 1900, when Landsteiner discovered the ABO blood group system.[@bb5130] For a review, see ref. [@bb5135]. The system was originally defined in terms of the antigenic substances occurring at the surface of red blood cells. At that time the carbohydrate nature of the antigens was not yet known. In the following years, more than 100 red cell antigens were analyzed including the Lewis system and the M and N antigens.[@bb5135], [@bb5140], [@bb5145] The largest group of these glycans are human erythrocyte autoantigens that react with the corresponding antibodies. They can also occur on cells of human tissues and in animals. The antibodies are monoclonal in patients with chronic lymphoproliferation. The cold agglutinins mainly react with erythrocytes, best at 0°C. This can lead via complement activation to intravasal erythrocyte degradation, which leads to anemia. The antigens corresponding with the monoclonal anti-Gd, -Fl, -Li, -Lud, -Pr, -Sa, -Ss, and -Vo are sialylated and can be inactivated by sialidase. As an example, the abbreviation Gd means "ganglioside-dependent." Gangliosides with Neu5Gc are Gd-inactive. Sialic acids, linked (α2 → 3) or (α2 → 6) at the glycophorin glycans, can also influence the Pr antigen specificity.[@bb5150] For comprehensive reviews about this complex topic, see refs. [@bb5155], [@bb5160], [@bb5165], [@bb5170], [@bb5175].

The analysis of the sugar components of the human blood group substances was started in the late 1940s.[@bb5180], [@bb5185] Highly purified A, B, H, and Le^a^ samples from human ovarian cyst fluids were shown to contain [l]{.smallcaps}-fucose, [d]{.smallcaps}-galactose, *N*-acetyl-[d]{.smallcaps}-glucosamine, *N*-acetyl-[d]{.smallcaps}-galactosamine, and *N-*acetylneuraminic acid.[@bb5135] Neu5Ac was isolated from Le^a^ blood group substance and crystallized.[@bb5190] The structural analysis of these macromolecular substances, which occur in blood, but also other human fluids, took many years. This and the early studies of the biosynthesis of blood group substances are thoroughly described in ref. [@bb5135]. Regarding the glycosylation of immunoglobulins, as early as 1934 covalently linked carbohydrates were reported to occur on serum proteins with high antitoxin titer after immunizing horses against diphtheria toxin.[@bb5195] For a review, see ref. [@bb5200]. But it was until 1967 that sialic acid was described to be present in human IgG.[@bb5205] The variable sialic acid content altered the electrophoretic mobility of this immunoglobulin. In one of the first attempts to elucidate the three-dimensional structure of human γG1, four possible ways of joining the Fab region to a nearby Fc region were shown.[@bb5210]

A later milestone in the glycobiology of immunoglobulins was the discovery of changing sialylation and its influence on function. About 30 different glycan structures, with and without sialic acids, linked to the Fc region of the immunoglobulin are known,[@bb5215] and voluminous reviews on the impact of glycosylation on the biological function and structure of human immunoglobulins have been written.[@bb5220], [@bb5225] Immunoglobulin G mediates pro- and antiinflammatory responses through the engagement of its Fc fragment. This difference depends on the sialylation of the Fc core oligosaccharide, and it explains why therapeutic intravenous γ-globulins, if they are sialylated, have antiinflammatory effects in autoimmune diseases.[@bb5230] In a remarkable experiment, it was seen that engineered sialylation of pathogenic antibodies in vivo, at the site of autoimmune inflammation, led to an attenuation of the autoimmune disease.[@bb5235]

The pronounced significance of Neu5Gc, although its nature was not yet known, in immune reactions was observed as early as at the beginning of the last century. M. Hanganutziu in 1924 and H. Deicher in 1926 observed after the therapeutic injection of antisera from horse blood into humans the formation of antibodies, now called "HD antibodies."[@bb5240], [@bb5245] About 50 years later, the epitope, recognized by HD antibodies, turned out to be the Neu5Gc residue of gangliosides.[@bb5250], [@bb5255] The significance of these antibodies in tumor biology and in nutrition has been discussed in [Section 11.5.1](#s0195){ref-type="sec"}. Additionally, monoclonal antibodies have been described that distinguish between Neu5Ac- and Neu5Gc-containing ganglioside GD3.[@bb5260]

Monoclonal antibodies against O-acetylated sialic acids in human colon mucins were obtained by immunization of BALB/c mice with mucosal scrapings from normal human large intestine. Antibody PR.3A5[@bb5265] and antibody 6G4[@bb5270] bound to O-acetylated mucin and were useful in studying the histochemistry of the normal colon, colon cancer, and ulcerative colitis. Immunization of mice with highly purified human colonic mucin afforded the monoclonal antibody MMM-17, which strongly binds to the mucin of goblet cells of the normal colon, but not to those of colon cancer tissue.[@bb5275] Saponification of the *O*-acetyl groups in the mucin or sialidase treatment of the mucin abolished the binding. O-Acetylated gangliosides are also immunogenic, as was studied with GD3 and GD3 derivatives. Here, monoclonal antibodies were obtained that distinguish between GD3 (CD 60a), 9-*O*-acetyl-GD3 (CD 60b), and 7-*O*-acetyl-GD3 (CD 60c).[@bb5280] It was found in many investigations that the disialoganglioside GD3 is the most frequent carrier of terminal O-acetylated sialic acid. The occurrence and the roles known of O-acetylated GD3 have been reviewed[@bb4135] (see also [Section 11.5.2](#s0200){ref-type="sec"}). Among the most striking and influential effects of O-acetylation are the inhibition of apoptosis of tumor cells,[@bb5285] the inhibition of the interaction of the siglec sialoadhesin with 9-O-acetylated sialic acid ligands, and the inhibition of the binding of human complement factor H, a negative regulator of the alternative complement pathway, to sialic acids.[@bb5290], [@bb5295] Thus, a decrease of O-acetylation may help tumor cells to escape from complement-mediated lysis. A classical example of the protective effect of (unsubstituted) sialic acids from activation of the lytical alternative complement pathway is the channel catfish *Ictalurus punctatus*. Very little bactericidal activity is exerted by the alternative complement pathway against the fish pathogens containing sialic acids, in contrast to a strong response against the nonpathogenic bacteria that lack sialic acid. This phenomenon is sialidase sensitive.[@bb5300]

The assumption of the existence of non-N-acetylated neuraminic acid (Neu) in the gangliosides of some tumors was based on the detection with monoclonal antibodies and pulse-chase experiments.[@bb5305] Note that the first chemical existence for natural Neu was obtained after N-propionylation.[@bb2445] N-Deacetylation of capsular polysialic acids provided antibodies protective against *N. meningitidis* groups B and C.[@bb5310] Earlier, antibodies against the virulence factors (α2 → 8)- and (α2 → 9)-polysialic acids were produced for vaccination against meningococci and *E. coli* K1 after conjugation to tetanus toxoid.[@bb5315] An effective vaccine, applied to small-cell lung cancer patients by the application of N-propionylated group B/(α2 → 8) polysialic acid, conjugated to keyhole limpet hemocyanin, is known.[@bb5320] Natural polysialic acids are very weak antigens in humans.[@bb5325]

The previous examples have shown that sialic acids are involved in antigenic structures. To these also belong the so-called differentiation and oncodevelopmental antigens of glycoproteins and glycolipids, which are expressed during ontogenesis and also in cancer.[@bb4940] However, sialic acids often mask antigenic sites on glycoproteins, glycolipids, and carbohydrate oligo- and polymers and thus represent "antiantigens." Thus, these monosaccharides have a remarkable regulatory role in immunology (see, e.g., refs. [@bb4820] and [@bb5330]), in a similar way as already discussed for the regulation of the lifetime of blood components and cells, namely, via a dual "self/nonself" system (see [Section 12.2](#s0240){ref-type="sec"}). So, the masking effect of sialic acids renders molecules and cells as "self." After the loss of the sialic acid residues, the structures become "nonself" and may be recognized by the immune system, which may lead to autoimmune diseases. A masking role of sialic acids has early been detected for porcine submandibular gland glycoproteins. Sialidase treatment of these mucins revealed H blood group activity, because Neu5Gc had stereospecifically masked the H-determinant Fuc(α1 → 2).[@bb5335] A classical example is also the masking of the T-antigen Gal(β1 → 3)GalNAc(α1 → O)Ser/Thr and the Tn-antigen GalNAc(α1 → O)Ser/Thr of blood cells and some tumors by Neu5Ac in humans.[@bb5165] The Gal(β1 → 4)\[Fuc(α1 → 3)\]GlcNAc antigen was also found to be cryptic in different human tissues.[@bb5340] It is masked to a variable extent by Neu5Ac at the terminal Gal residue of the antigen {Neu5Ac(α2 → 3)Gal(β1 → 4)\[Fuc(α1 → 3)\]GlcNAc} or at adjacent carbohydrate chains (obscuring the antigen by steric hindrance) and can be made visible by histochemical means by using sialidase. One of the most striking and important examples for the masking of antigenic sites is the immunobarrier between mother and fetus due to the expression of highly sialylated glycoconjugates on syncytiotrophoblast cells.[@bb5345], [@bb5350] These molecules prevent the formation of antibodies by the maternal organism against fetal cells. Loss of sialic acids in kidney, e.g., by viral or bacterial infection, may lead to immunological injuries of the glomeruli leading to chronic glomerulonephritis.[@bb5355] Note that tissues rich in sialic acids tend to develop autoimmune diseases.[@bb4820] The pronounced masking of tumor antigens by sialic acids has already been discussed in [Section 12.3](#s0245){ref-type="sec"}. These observations, together with an old report[@bb5360] about the effect of sialidase to increase the immunogenicity of the Landschütz ascites tumor cells, stimulated attempts to cure cancer by sialidase treatment of tumor cells, reinjection of the cells, and thus vaccination of the patient with these cells.[@bb4820] Injection of the cells into various places of the skin ("chessboard vaccination") had been recommended. This method was successful in the treatment of dog mammary tumors,[@bb5365] while in humans the duration of the remission was extended in myelocytic or lymphatic leukemia.[@bb5370] Although some positive results were obtained, this method was not followed further.

Sialic acids on the surface of T cells mediating "delayed-type hypersensitivity" (DTH), which have developed an immune response before, control the entry of the lymphocytes into sites of antigen deposition, where an inflammatory reaction is induced. This could be shown by sialidase treatment of the sensitized T cells that caused a transient reduction of DTH reactions in the periphery. The cells were trapped in the liver, but were released after 24 h, and their biological activity returned.[@bb5375] The involvement of terminal sialic acids on the surface of T cells, in most aspects of T cell fate and function, from cell maturation, differentiation, and migration to cell survival and cell death, was reviewed 27 years later.[@bb5380]

In the context of this section, attention should also be paid to the function of (sialylated) milk oligosaccharides. As mentioned (see [Section 8.3](#s0135){ref-type="sec"} for an updated series of reviews), the extraordinary diversity of these glycans is great, varying from mammal to mammal, and comprising more than 200 different structures in man. They regulate the bacterial colonization of the intestine, prevent the growth of pathogenic bacteria, and feed the microorganisms. This protects especially children from bacterial and viral infections. The variability of the microorganisms, nowadays called "microbiome," also seems to influence the human immune system, although the exact mechanism and the role of sialic acids wait for complete elucidation. The enhancement of the biosynthesis of glycoproteins and glycolipids in the developing brain by milk oligosaccharide feeding and the corresponding stimulation of the intellectual capacities are also under study.[@bb5385], [@bb5390]

A striking example of innate, humoral immunity is limulin, a sialic acid-binding lectin from the American horseshoe crab *Limulus polyphemus*. It was isolated and characterized from the hemolymph of this animal, has a molecular weight of 335 kDa, and consists of subunits of each 19 kDa.[@bb5395], [@bb5400] Limulin binds to glycosidically linked sialic acids of glycoproteins and gangliosides, but preferably to Neu5Gc-containing gangliosides (i.e., Neu5Gc-GM3), and thus agglutinates erythrocytes and other cells.[@bb5405] A similar lectin was isolated by affinity chromatography from the hemolymph of the Asian horseshoe crab *Tachypleus tridentatus*.[@bb5410] SDS-PAGE showed three protein bands between 27 and 32 kDa. This lectin also agglutinates erythrocytes and preferably binds to sialylated O-glycans of mucins. These lectins of the phylogenetically very ancient horseshoe crabs are considered as potent innate defense systems against parasites with sialic acids or perhaps similar nonulosonic acids.

A most important chapter of modern immunology are the mammalian sialic acid-recognizing lectins, called siglecs, which, in most cases, occur on the surface of immune-competent cells, e.g., B-lymphocytes, and are involved in many immune reactions including autoimmunity.[@bb4930], [@bb5415], [@bb5420] For further details, see [Section 12.5.3](#s0270){ref-type="sec"}.

12.5. Proteins Recognizing Sialic Acids {#s0255}
---------------------------------------

In this section the history of the studies of the interaction of sialic acids as ligands with proteins as receptors (lectins) will be described. Special groups are selectins and siglecs, which will be treated separately. For an overview written by the pioneers of the research on lectins, Nathan Sharon and Halina Lis from The Weizmann Institute of Science (Israel), see ref. [@bb5425].

### 12.5.1. Plant and Other Lectins, and Virus Hemagglutinins {#s0260}

Lectins were first found almost exclusively in plants.[@bb1995], [@bb5425], [@bb5430], [@bb5435] Since they were detected by the agglutination of erythrocytes, they were named "hemagglutinins" or "phytohemagglutinins." As plant lectins are able to distinguish between erythrocytes of different blood types, as early as 1954 Boyd and Shapleigh coined the name "lectin," from the Latin *legere*, "to select."[@bb5440] This definition was later used for all carbohydrate-binding proteins, irrespective of their occurrence.

To go back in history, before 1860, S. Weir Mitchell in Pennsylvania had observed agglutination of pigeon blood by the venom of a rattlesnake.[@bb5445] The first lectin, called "ricin," was discovered in 1888 in the beans of the castor tree (*Ricinus communis*) by Hermann Stillmark at the University of Dorpat (now Tartu) in Estonia.[@bb5450] In fact, it was a mixture of weakly agglutinating protein toxins, which were later found to bind to galactose and *N*-acetylgalactosamine.[@bb5425], [@bb5455] Furthermore, Simon Flexner and Hideyo Noguchi,[@bb5460] from the Rockefeller Institute (New York, USA), described in 1902 snake venom agglutinins in some detail in the horseshoe crab (*L. polyphemus*)[@bb5395] and the American lobster *Homarus americanus*. In the first decade of the 20th century also the first bacterial agglutinins were found, which were later identified as lectins. Investigations on blood type-specific lectins stem from the early 1950s, when it was demonstrated for the first time that lectins can bind monosaccharides.[@bb5465]

The already described studies of Hirst in the 1940s on the agglutination of human erythrocytes by influenza virus (see [Sections 2.1](#s0020){ref-type="sec"} and [11.7](#s0220){ref-type="sec"}) can be considered as the first example of the involvement of a lectin/hemagglutinin, a sialic acid-binding agent. Influenza virus hemagglutination was found to be inhibited by a brain lipid fraction, known to contain gangliosides.[@bb5470] In the following decades the structure and pathophysiological significance of the viral hemagglutinin (designated "H" antigen) was most intensively studied, until today, by the group of Hans-Dieter Klenk at Philipps-Universität Marburg (Germany).[@bb4795], [@bb4800], [@bb5475] Influenza viruses demonstrate pronounced receptor binding specificity. Human influenza viruses preferentially bind to Neu5Ac(α2 → 6)Gal sequences, whereas avian influenza viruses prefer Neu5Ac(α2 → 3)Gal as ligand (or receptor in the terminology of virologists).[@bb5480] Competitive inhibitors of the binding of avian or human influenza viruses to sialylated glycans are soluble glycoconjugates carrying (α2 → 3)- or (α2 → 6)-linked sialic acids, respectively. The earlier discussed mucin from the nests of the Chinese swiftlet, genus *Aerodramus collocalia* (collocalia mucoid, edible bird\'s nest substance),[@bb5485] rich in sialic acids, is a potent inhibitor of the agglutination of myxoviruses.[@bb5490] This may have been the reason that it has been used in Chinese medicine for hundreds of years in order to prevent and cure influenza and its following bronchial diseases. The substance, which is a good substrate for sialidase, has additional health benefits and is therefore highly esteemed in Asia.[@bb5495]

The best known sialic acid-recognizing plant lectins are WGA, accepting Neu5Ac and (β1 → 4)-linked GlcNAc residues, *S. nigra* agglutinin (SNA) from the bark of the elderberry bush, recognizing (α2 → 6)-linked sialic acid to galactose, and *M. amurensis* lectin (MAA), specific for (α2 → 3)-linked sialic acid to galactose.[@bb5425] The fractions of these plant lectins are believed to protect the plants from pathogenic microorganisms and fungi, as well as from herbivorous animals. It was found that the bark lectin SNA provoked toxic effects in animals and created a reaction of avoidance ([Fig. 35](#f0180){ref-type="fig"} ).[@bb5500] One of the authors (R.S.) observed that during a very cold winter with much snow, mammals, mainly rabbits, fed on the bark of various bushes, but not on that of the elderberry bush. Both SNA and MAA are used regularly in structural analysis protocols, i.e., lectin affinity chromatography, histochemistry, or lectin microarrays.[@bb1380] Fig. 35Lectins, for example, the sialic acid-binding *Sambucus nigra* agglutinin (SNA), protect plants against herbivorous and chewing animals.Fig. 35Reproduced from Peumans, W. J.; Van Damme, E. J. M. Lectins as Plant Defense Proteins. *Plant Physiol.***1995**, *109*, 347--352. Copyright American Society of Plant Biologists.

Sialic acid-recognizing proteins are manifold in Nature. The first sialic acid-binding protein from vertebrates reported was Complement Factor H, an early response factor of the innate immune system.[@bb5505], [@bb5510] In a thorough search about 230 sialic acid-specific lectins in viruses (being the largest group), bacteria, toxins, protozoa, fungi, plants, invertebrates, and vertebrates were described.[@bb5515] In the intervening time, more sialic acid receptors have been detected, especially in the field of virus research, e.g., of the human Noro virus,[@bb5520] the Middle East Respiratory Syndrome Coronavirus (MERS-CoV),[@bb5525] and the Infectious Salmon Anemia Virus (ISAV), the latter binding to Neu4,5Ac~2~.[@bb5530] Most of these sialic acid lectins bind to Neu5Ac, but a few only to Neu5Gc or to both sialic acid types. An example of Neu5Gc as virus receptor is the transmissible porcine gastroenteritis coronavirus.[@bb5535] The various lectins may discriminate between (α2 → 3) and (α2 → 6) linkages and rarely prefer (α2 → 8) linkages, like e.g., siglec-7 and -11. Some invertebrate and viral lectins bind to 4- or 9-O-acetylated sialic acids, the best known example being influenza C virus.[@bb4135], [@bb5515]

Not much is known about how and where influenza C viruses enter the human organism, but the human respiratory tract is the most likely place. In the nasal secreted mucin of only one person studied so far, about 10% of the sialic acids were 9-O-acetylated. In a pool of nasal mucosa probes collected after surgery in 1994, a 9-O-acetylated sialoglycoprotein fraction of 100--130 kDa was detected by Western Blot analysis. This could be the influenza C virus receptor. Since also the ganglioside fraction was found to be O-acetylated, the influenza C virus receptor must be studied further.[@bb5540] Influenza C virus hemagglutinins, specific for (α2 → 3) and (α2 → 6) linkages, can differentiate between receptor determinants bearing *N*-acetyl-, *N*-glycolyl-, and O-acetylated sialic acids. This was shown by the agglutination of Neu5Ac, Neu5Gc, or Neu5,9Ac~2~ covering erythrocytes.[@bb5545]

Very recently, probes from viral sialic acid-binding proteins were developed to detect 4-*O*-acetyl, 9-*O*-acetyl, and 7,9-di-*O*-acetyl sialic acids on cells and tissues of humans and a great variety of animals.[@bb2040] It is astonishing how widely distributed these esterified sialic acids are. The HE proteins were expressed in insect cells and fused to the Fc region of human IgG1 and to a hexahistidine sequence for histochemical or microarray use (see also [Section 7.4](#s0115){ref-type="sec"}). Binding of influenza A virus and Siglec-2 (CD22) is inhibited by Neu5Ac O-acetylation.[@bb4135]

### 12.5.2. Selectins {#s0265}

The selectins mediate, as do other cell adhesion molecules, the adhesion of leukocytes from the blood stream to endothelial cells, followed by extravasation into the surrounding tissue. They are thus involved in the initiation of inflammation. Tumor cells can experience the same fate. The basis of this phenomenon is the recognition of terminal sialyl Lewis x {SLe^x^; Neu5Ac(α2 → 3)Gal(β1 → 4)\[Fuc(α1 → 3)\]GlcNAc} and sialyl Lewis a {SLe^a^; Neu5Ac(α2 → 3)Gal(β1 → 3)\[Fuc(α1 → 4)\]GlcNAc} glycan sequences on the mobile cells. The first observations of this complicated process were recorded in the 1880s by Julius Friedrich Cohnheim, a German pathologist, who also worked one year (1868) at Christian-Albrechts-Universität zu Kiel (Germany).[@bb5550], [@bb5555] This scientist studied by real-time microscopy the microvessels in the frog and proposed that postcapillary venules at sites of inflammation underwent molecular alterations that mediated the attachment of flowing leukocytes on the vessel internal surface, and subsequent emigration at sites of inflammation. Heinrich (Karl Wilhelm) Schade from the same university also observed about 40 years later the extravasation of white blood cells into inflamed tissues. He assumed that substances penetrating into the blood make the leukocytes "sticky" resulting in adhesion of the cells to the wall of the blood vessels before they extravasate into the tissue guided by chemotaxis.[@bb5560] The molecular basis of these events could not be elucidated in those times. Heinrich Schade is considered the father of molecular pathology, a new area of medical research, in completion with the then existing cellular pathology.

It took a further 30 years before researchers began to study the extensive flux of lymphocytes between blood and lymph ("lymphocyte recirculation").[@bb5555] Here, a "homing molecule" on the surface of lymphocytes was assumed, which directs their traffic to lymph nodes. Electron microscopic studies showed that microvascular structures exist in the lymph nodes, consisting of plump, cuboidal endothelial cells, known as high endothelial venules (HEV),[@bb5565] and lymphocyte adherence to HEV could be demonstrated.[@bb5570] Further studies on the leukocyte extravasation at sites of inflammation showed a dynamic process.[@bb5575] After 2 h of injury, postcapillary venules displayed adhesive properties that supported leukocyte binding, followed by endothelial transmigration. At this state of the research, it was not known that carbohydrates were involved in leukocyte extravasation, but soon after these reports the participation of carbohydrates in lymphocyte trafficking was recognized.[@bb4895] In many further studies, the HEV receptor of the lymphocytes was shown to be a lectin, whereby sialylated glycans on HEV serve as ligand for this lectin.[@bb5580], [@bb5585] Furthermore, a family of sulfated sialofucosylated glycoproteins (sulfated at position 6 of GlcNAc or Gal of SLe^x^) was found which serve as L-selectin ligands on HEV, known as "peripheral lymph node addressins."[@bb5590] While L-selectin is expressed on lymphocytes, and functions in the migration of these cells to lymphoid organs, E- and P-selectins are expressed on vascular endothelial cells and mediate the recruitment of neutrophils to sites of inflammation in tissues ([Fig. 36](#f0185){ref-type="fig"} ). P-Selectin also occurs on lymphocytes. E-Selectin is constitutively expressed on bone marrow microvessels, and human hematopoietic stem cells express high amounts of an E-/L-selectin ligand.[@bb5555] The involvement of selectins in cancer metastasis has drawn many researchers to this field.[@bb5595] Fig. 36The selectins play a key role in the control of leukocyte traffic in the body. (A) L-Selectin functions in the migration of lymphocytes to lymphoid organs. (B) E- and P-Selectins mediate the recruitment of neutrophils to sites of inflammation.Fig. 36Courtesy of Ohad Bairey, and reproduced from Sharon, N.; Lis, H. *Lectins*, 2nd ed.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2003, p 353. Copyright Kluwer Academic Publishers.

In 1989, the lymph node homing receptor, as well as E- and P-selectins, were cloned.[@bb5600] This protein family was then named "selectins," belonging to the "C-type" lectins. At the same time, studies revealed that, in addition to homing receptors, cell migration is orchestrated by chemoattractants (e.g., chemokines), which may be present within endothelial beds or inducibly expressed at sites of inflammation, and inaugurate intracellular signaling followed by endothelial transmigration.[@bb5555] According to this "multistep paradigm" the function of a homing receptor is not purely to direct cellular trafficking in a tissue-specific manner, but to function as a molecular brake in initiating binding to endothelial cells under hemodynamic shear stress.

The contribution of selectins to the well-being of mammals was shown in genetically engineered mice, lacking selectins, which were prone to severe bacterial infections, and demonstrated the role of these lectins in acute inflammatory responses.[@bb5605] In the rare leukocyte adhesion deficiency type II syndrome (LAD II),[@bb5610] the patients suffer from recurrent bacterial infections as well as from growth and mental retardation. Their neutrophils are deficient in SLe^x^ and therefore cannot bind E- and P-selectin. The reason of this defect is a decrease of the metabolism of fucose required for the synthesis of Le^x^. Correspondingly, supplementation of the patients with fucose efficiently reduced the pathological symptoms.

For further informative reviews, see refs. [@bb0650], [@bb5615], [@bb5620].

### 12.5.3. Siglecs {#s0270}

Siglecs are a group of the "latest" sialic acid-recognizing lectins discovered. In contrast to the selectins, they are involved in the regulation of inflammation. Due to this pathophysiological function and the manifold members of the siglec family, with a great variety of functions, the number of publications has exploded in the last 20 years. This area is one of the most rapidly evolving in glycobiology research, not only because of the impressive immunological and clinical potential. Therefore, only a short historical introduction to this field is presented, and a number of excellent reviews, which deal with the numerous aspects of siglec occurrence, structure, and biology, will be cited.

The investigations in this area started in 1986, when P. R. Crocker and S. Gordon found a lectin-like hemagglutinin expressed on murine tissue macrophages.[@bb5625] The lectin was called "sialoadhesin (Sn)," a sialic acid-binding receptor that was purified from murine macrophages.[@bb5630] It was shown to be a transmembrane protein with 17 extracellular Ig-like domains, 16 C2-set domains, and 1 unusual V-set domain that contains an intrasheet disulfide bridge.[@bb5635] Sialoadhesin recognizes the sequences Neu5Ac(α2 → 3)Gal(β1 → 3)GalNAc and Neu5Ac(α2 → 3)Gal(β1 → 3/4)GlcNAc on glycoproteins and glycolipids.[@bb9030], [@bb4140], [@bb4145] The macromolecule is restricted to macrophages and is highest expressed in resident macrophages of hemopoietic and secondary lymphoid tissues. The adhesion mediates interactions with developing myeloid cells in the bone marrow[@bb5630] and lymphocytes in spleen and peripheral lymph nodes.[@bb5640] Recent research has shown that adhesion is also involved both in clearance of sialylated human pathogens and in antigen presentation.[@bb5620]

In the 1990s, a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily, namely, sialoadhesin, CD22, and the myelin-associated glycoprotein (MAG) was defined.[@bb9030], [@bb4140] The number of extracellular repeats differs much in these three lectins, that of MAG being the shortest (five repeats). After the discovery of Sn, CD22, MAG, and CD33, the group of Ajit Varki proposed the term "siglec," derived from "**s**ialic acid," "**i**mmuno**g**lobulin," and "**lec**tin" for each member of the group.[@bb9020], [@bb0670] Siglecs are now considered a subset of I-type lectins, and they are numbered as follows: Sn (siglec-1), CD22 (siglec-2), CD33 (siglec-3), and MAG (siglec-4). The list of siglecs today[@bb5620] continues up to siglec-16 on macrophages and microglia. Mice express fewer, but partially similar siglecs.

CD22 is a B-cell-specific molecule which binds to the Neu5Ac(α2 → 6)Gal(β1 → 4)GlcNAc element on glycoproteins.[@bb5645] It is the best studied member of the siglec family. By cis and trans interactions, CD22 plays a role in B-cell signal transduction,[@bb0650] and it regulates immune tolerance.[@bb5620] It carries immune inhibitory domains (ITIM and ITIM-like), as do also the other eight of the human siglecs, numbers 3 and 5--11, which have been shown to suppress immune responses or are assumed to do so.[@bb5650]

The MAG is produced on myelinating oligodendrocytes at Schwann cells.[@bb5655] MAG plays roles in myelination, axonal growth regulation, and signal transduction.[@bb0650] It binds to Neu5Ac(α2 → 3)Gal(β1 → 3)GalNAc elements. Studies of the binding specificities of MAG and sialoadhesin with synthetic sialylated oligosaccharides demonstrated differences between these two siglecs.[@bb5660] Remarkably, MAG bound Kdn better than Neu5Ac, and sialoadhesin revealed the opposite.

A cDNA encoding CD33, being a differentiation antigen of myeloid progenitor cells, was isolated in 1988.[@bb5665] The antigen belongs to a related subgroup composed of siglec-3 and siglecs-5--13 in primates and similar ones in rodents.[@bb0670], [@bb9020] This subgroup appears to evolve rapidly. In contrast, siglecs-1, -2, and -4 represent an evolutionarily conserved subgroup.

The roles of siglecs in immunology and human--pathogen interactions are many and varied. Special attention was recently drawn to siglec-8, which seems to function in resolving allergic inflammation, while siglec-9 may dampen neutrophil-mediated inflammation.[@bb5620]

Focusing on the influence of various sialic acids on the binding of siglecs,[@bb9020], [@bb0670] it was observed that the frequently occurring 9-*O*-acetyl group has a strong negative effect on recognition by human CD22[@bb5670] and mouse sialoadhesin.[@bb4145] The masking of the ligand fraction of sialic acid has been observed also with influenza A/B virus hemagglutinin and with selectins. Aberrant O-acetylation of sialic acids, caused by the enzyme pair *O*-acetyltransferase and -esterase, is thought to be involved in autoimmune diseases like asthma.[@bb4430] Furthermore, mouse and human Sn prefer Neu5Ac over Neu5Gc. However, murine CD22 strongly prefers Neu5Gc over Neu5Ac, but human CD22, as well as CD33, siglec-5 and siglec-6 accept both types of sialic acids. It can be assumed that these human-specific changes are due to the dramatic alteration in the human "sialome" after the *CMAH* mutation and Neu5Gc loss.[@bb9020], [@bb0670] "Many of these binding studies with differently linked sialic acids and natural or chemically modified sialic acid derivatives, e.g., Neu5Gc and Neu5,9Ac~2~, which much helped to understand the biology of siglecs, were, in the beginning of siglec research, based on a close cooperation between Paul Crocker, Jim Paulson, and Sørge Kelm. Paul had the cells available, Jim had purified several sialyltransferases, and Sørge had developed a procedure to transfer various sialic acids to desialylated erythrocytes in order to obtain homogeneous ligands regarding sialic acid nature and linkage."

For a detailed overview of all aspects of "siglectology," see refs. [@bb0650], [@bb0670], [@bb0675], [@bb3885], [@bb5620], [@bb9020], and [@bb5675], [@bb5680], [@bb5685], [@bb5690], [@bb5695], [@bb5700].

13. Hereditary Sialic Acid Diseases {#s0275}
===================================

The last section of this chapter will deal with some diseases with an origin in genetic errors of sialic acid metabolism. Although rare, they clearly show that sialic acids have a decisive impact on health. In the following subsections, the history of the elucidation of sialuria, Salla disease, sialidosis, galactosialidosis, and GNE myopathy, the main diseases known with disturbed sialic acid metabolism, will be described. See also [Section 8.4](#s0140){ref-type="sec"} for more chemical information.

13.1. Sialuria {#s0280}
--------------

Sialuria was first reported in 1968, affecting a then 2½-year-old French boy who excreted a 10,000-fold higher amount of sialic acid (Neu5Ac) than normal children.[@bb2845], [@bb2920], [@bb2925], [@bb5705], [@bb5710], [@bb5715] The Neu5Ac concentration in the urine was so high (excretion of up to 7.2 g Neu5Ac per day) that this monosaccharide could easily be isolated in large quantities from the patient\'s urine. This helped research on this topic, since Neu5Ac was very expensive at that time, and scientists were interested in a commercial source of the compound. As said in [Section 11.4](#s0185){ref-type="sec"}, the underlying metabolic defect in sialuria is the loss of feedback inhibition of the rate-limiting enzyme of sialic acid biosynthesis, i.e., UDP-GlcNAc 2-epimerase (GNE), by CMP-Neu5Ac. This leads to enhanced enzyme activity and accumulation of Neu5Ac in sialuria fibroblasts.[@bb2935], [@bb5720] Also the mutations in the epimerase gene have been analyzed.[@bb5715] Sialuria is a very rare disease. The French patient, suffering from sialuria, remained unique for a long time, but other cases, also without lysosomal involvement, but with lower excretion of sialic acids, have been described later.[@bb2845] Sialuria patients show mild mental retardation, seizures, and slightly dysmorphic features.

13.2. Salla Disease and Infantile Sialic Acid Storage Disease {#s0285}
-------------------------------------------------------------

Salla disease is an autosomal recessive lysosomal storage disorder, first described in 1978 in four patients[@bb2905], [@bb5725] presenting severe psychomotor retardation and increased urinary excretion of Neu5Ac, combined with enlarged cellular free Neu5Ac levels. So far, about 150 cases have been reported.[@bb5710], [@bb5730] The name "Salla" is derived from a Northern area in Finland from where most of the patients originated. However, two patients with Salla disease were also detected in Turkey.[@bb5735] A similar, but more severe disease than Salla disease, with a much earlier onset, often occurring at birth, was described in 1982 in an infant of German--Swedish origin, and it was called Infantile Sialic Acid Storage Disease (ISSD).[@bb5740] Such patients are, rarely, found in several continents. The pathomechanism of these diseases is an impaired transport of free Neu5Ac across the lysosomal membrane.[@bb5745] The reason for the Neu5Ac accumulation in the lysosomes of various tissues is a defective H^+^-driven transport of sialic acid (and [d]{.smallcaps}-glucuronic acid) through the lysosomal membrane by a mutation of the integral lysosomal protein Sialin.[@bb5715], [@bb5750]

13.3. Sialidosis {#s0290}
----------------

Sialidosis belongs to the so-called group of "oligosaccharidoses," which are metabolic disorders characterized by an excessive accumulation of glycoprotein-derived oligosaccharides.[@bb2845], [@bb5755], [@bb5760] Initially, a severe deficiency of neuraminidase in the cultured fibroblasts of a patient, classified as "mucolipidosis I," was seen.[@bb5765], [@bb5770] The patient had a neurodegenerative disorder with myoclonus, skeletal changes like in Hurler disease, and cherry-red spots in the macula of the eyes. As reviewed in [Section 8.4](#s0140){ref-type="sec"}, excessive quantities of sialyloligosaccharides (sialic acid = Neu5Ac), derived from glycoprotein N- and O-glycans, were found in body fluids and urine. Fibroblasts of the patients exhibit a sialidase defect and accumulate abnormal amounts of sialic acid-containing substances. Besides this group of dysmorphic children with early beginning of the disease, there is a milder type of sialidosis with normal physical appearance of the patients, absent or mild mental retardation, and onset only in adolescence. These patients also have impaired sialidase activity and excrete unusual amounts of sialyloligosaccharides.[@bb5775] These two groups are categorized as type I and type II sialidosis, respectively. In summary, sialidosis is an autosomal recessive lysosomal storage disease, affecting the degradation of glycoproteins. It is caused by a genetic defect of the lysosomal sialidase (Neu 1) gene, first cloned in 1996.[@bb5780] Several mutations are known, which lead to different expressions of the phenotype of this disease.[@bb5785], [@bb5790]

13.4. Galactosialidosis {#s0295}
-----------------------

Galactosialidosis is a disease with a combined deficiency of sialidase and β-galactosidase activity, due to a defect of a 32 kDa protein \[lysosomal serine carboxypeptidase, protective protein cathepsin A (PPCA)\] that shields sialidase and β-galactosidase against lysosomal proteases.[@bb5795] See also refs. [@bb2845], [@bb5715], and [@bb5800], [@bb5805], [@bb5810]. Since the result of this disturbed enzyme complex is a reduced sialidase activity, like in sialidosis, there is no significant difference in the pattern of excreted glycoprotein-derived urinary sialooligosaccharides between sialidosis and galactosialidosis.[@bb5815] This suggests that sialidase deficiency, not β-galactosidase deficiency, determines the phenotype of the disease.

13.5. Hereditary Inclusion Body Myopathy (GNE Myopathy) {#s0300}
-------------------------------------------------------

Hereditary inclusion body myopathy (HIBM) encompasses several syndromes with autosomal recessive or dominant inheritance, and the patients suffer from a progressive course of muscle weakness leading to severe disability. In 2011 about 500 patients with HIBM were known worldwide.[@bb5820] The most common form is the quadriceps muscle-sparing autosomal recessive myopathy,[@bb5825] which was originally described in patients of Persian--Jewish heritage.[@bb5830] The muscle problems usually start in the second to third decade of life with weakness and atrophy of distal lower limb muscles that eventually spreads proximally. The reason for this disease is a reduced activity of the key enzyme UDP-*N*-acetyl-glucosamine-2-epimerase/*N*-acetylmannosamine kinase (GNE/MNK) (see [Section 11.1](#s0170){ref-type="sec"}), which leads to impaired Neu5Ac biosynthesis, and to rimmed vacuoles and Congo-Red-positive depositions in fibers in the muscles. So far, 154 mutations have been identified in the gene of GNE that are likely leading to reduced GNE enzyme activities.[@bb5835] It was shown that mutation of methionine 743 to threonine in GNE leads to 30% reduction of enzyme activity and to an aggressive form of GNE myopathy. The introduction of threonine offers an additional phosphorylation/O-GlcNAcylation site. Indeed, the O-GlcNAcylation of the M743T GNE variant was increased. Removal of that residue resulted in almost normal GNE activity. Hereby, the balance of phosphorylation and O-GlcNAcylation is decisively involved in regulation and efficiency of GNE. Evidence is accumulating, especially from experiments with mice, that hyposialylation is underlying the molecular mechanism of this muscle weakness.[@bb5840], [@bb5845] Also in humans, a considerable lack of free sialic acids in muscle biopsies of patients, when compared to healthy individuals, has been described.[@bb5850] It was stated that the lack of sialic acids in GNE myopathy contributes to ROS production/oxidative stress followed by muscle weakness and atrophy.[@bb5845] Correspondingly, application of antioxidants had a curative effect.[@bb5845], [@bb5855] Furthermore, oral administration to mice of Neu5Ac, sialyllactose, ManNAc, and especially per-O-acetylated ManNAc also decreased the disease symptoms.[@bb5855] In man, intravenous application of high doses of highly sialylated immunoglobulin G (IVIG) also improved the disease symptoms.[@bb5860]

14. Concluding Remarks {#s0305}
======================

In this chapter, we have presented the historical development of the different areas of sialic acid research. Most impressive was to follow the efforts of those early pioneers to identify the correct structure of the *N*-acylneuraminic acid molecule. To achieve this goal the often cooperative work of dedicated scientists during several decades was necessary, and they had to cope with erroneous conclusions. After the isolation of sialic acids with still unknown structure from bovine submandibular gland mucin, it was by pure chance that a similar substance was discovered by studies with influenza viruses, and that years later also the analysis of the product of a lyase reaction played an important role in solving the stereochemistry of the sialic acid structure. Another difficult and lengthy effort was the development of reliable techniques for the identification of sialic acids and their many derivatives in natural sources, and chemists, synthesizing, for example, sialic acid glycosides, encountered challenges by these compounds that exceeded those experienced from working with "ordinary" sugars.

Sialic acids are among the most striking molecules in higher animals and many microorganisms, and it seems that these monosaccharides play a role in all branches of cell biology. They are involved in probably most diseases, although this is a field where more research should be focused. Sialic acids are prominent molecules on the cell surface, on the glycocalyx, not only in position but also in function, and they can be considered as cytoprotectors. However, in this position, they are often attacked and conquered by pathogens, especially viruses, and they can also be misused by malignant cells. We highlighted the beginnings and discussed the following inquiries into the pathobiochemical functions of sialic acids. The increasing number of publications on this topic shows that in laboratories all over the world efforts are continuing to gather more information and to employ this knowledge, for example, to develop effective therapies for various diseases.

When citing relevant, mostly historical papers in each section, we had to select due to space restrictions. Therefore, many important publications could not be included. And since we could not cover all aspects of sialic acid research in detail, this chapter is accompanied by special reviews on the chemistry, evolution, neurobiology, tumor biology, and virology of these monosaccharides, written by other authors.

With appreciation of the support from numerous colleagues, we are closing this chapter by citing an aphorism from the 1970s by Gerhard Uhlenbruck from the University of Cologne (Germany), who is a devoted glycoimmunologist: "*Neuraminic acid (sialic acid) is a lady whose fascination has not faded away. Again and again stimulating*, *exciting and good for all kinds of surprises. A lovable molecule, which is enthusiastically courted by many, although the advertising budget never was opulent.*" (Translated from the original German version.)

More than 50 years of sialic acid research brought us in contact with many scientists from all over the world, and---although we could not mention everyone in this review---we acknowledge their contributions and their support. We also thank our numerous associates for their dedication and contributions to the sialoglycoscience field. A special word of thanks goes to Ms Elfriede Schauer, for her continuous assistance in the preparation of this chapter.

[^1]: In the case of a structure proven by mass spectrometry and/or NMR spectroscopy, reference numbers refer in general to such studies.

[^2]: For a survey of typical biological sources of sialic acids, see refs. [@bb0035], [@bb0040], [@bb0100], [@bb0165].

[^3]: Present only in bound form and considered to be derived from bound Neu5Ac in an enzymatic N-deacetylation/N-reacetylation cycle.[@bb0095] In free open form, Neu is directly converted into its labile internal Schiff base 4-hydroxy-5-\[1,2,3,4-tetrahydroxybutyl\]-Δ^1^-pyrroline-2-carboxylic acid (pH-dependent equilibrium).[@bb0080] However, Neu was picked up by GLC--EIMS of its heptafluorobutyrylated methyl ester derivative, and it was suggested that the heptafluorobutyric anhydride acylation is able to disrupt the Schiff base, followed by blocking the free amino group.[@bb0100]

[^4]: Present only in bound form and considered to be derived from bound Neu in an enzymatic dehydration reaction, catalyzed by a so-called sialic acid cyclase. Neu1,5lactam was initially called "cyclic sialic acid."[@bb0110]

[^5]: Detected in bound form in (α2→9)-linked Neu5Ac polysaccharide.

[^6]: Lactyl = [l]{.smallcaps}-Lactyl.

[^7]: Biosynthetic intermediate to Neu5Ac.

[^8]: Present only as free form.

[^9]: Neu2en5Ac, originally known as a synthetic compound with a potent inhibitory effect on various sialidases,[@bb0425] may be produced enzymatically from sialoglycoconjugates in tissues.[@bb0430] Small amounts are formed by a water elimination side reaction from Neu5Ac during influenza-B-virus-sialidase-catalyzed desialylations of sialoglycoconjugates.[@bb0435] Neu2en5Ac can be generated from CMP-Neu5Ac in a nonenzymatic elimination reaction, occurring under physiological and, much faster, under alkaline conditions.[@bb0270], [@bb0285]

[^10]: Neu2,7an5Ac can be generated from Neu5Ac(α2→3)Gal(β1→-containing sialoglycoconjugates using a sialidase isolated from the leech *Macrobdella decora*.[@bb0295], [@bb0440]

[^11]: Neu4,8an5Ac does not occur as such in nature. It is assumed to be formed under hydrolytic conditions from bound Neu4,5Ac~2~ in a multistep process, before cleavage of the glycosidic linkage.[@bb0160], [@bb0300] Also alkaline treatment of free Neu4,5Ac~2~ yielded Neu4,8an5Ac.[@bb0160] Alternatively, Neu4,8an5Ac is formed by thermal degradation of sodium *N*-acetylneuraminate.[@bb0305] In addition, two other anhydro forms of Neu5Ac were suggested by ref. [@bb0165].

[^12]: Correction in [table 3](#t0020){ref-type="table"} of ref. [@bb0170]: Fragments C and D are absent in Neu7,9Ac~2~5Gc.

[^13]: Three anhydro derivatives of Neu5Gc8Me were suggested by ref. [@bb0165].

[^14]: Neu4,9Ac~2~7Am5Gc in the text of ref. [@bb0100] is probably a typing error for Neu8,9Ac~2~7Am5Gc.

[^15]: Biosynthetic intermediate to Kdn.

[^16]: *n.a.*, not available.

[^17]: Note that in earlier reports it was not realized that during crystallization protocols, wherein methanol was used, partial methyl ester formation took place (all preparations contained one COOH function). The included chemical formulae from this study turned out to be in the end correct.

[^18]: NAc = *N*-acetyl; OAc = *O*-acetyl; NGc = *N*-glycolyl. Acetyl determination as barium acetate after acid hydrolysis; glycolyl determination as crystalline calcium glycolate after alkaline treatment (see [Section 7.1](#s0100){ref-type="sec"}).

[^19]: The bovine and equine "sialic acids" were suggested to be isomers.

[^20]: *n.d.*, value could not be determined.

[^21]: Included literature refers to first reports or revised reports.

[^22]: Initially assigned with the [d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*galacto*[@bb3615] and later with the [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*[@bb3570], [@bb3575], [@bb3620] configuration.

[^23]: Initially assigned with the [d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*galacto*,[@bb3625], [@bb3630], [@bb3635] and later with the [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto*[@bb3570], [@bb3575] configuration.

[^24]: Initially assigned with the [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*galacto* configuration.[@bb3620]

[^25]: Initially assigned with the [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*talo* configuration.[@bb3640]

[^26]: Initially assigned with the [d]{.smallcaps}-*glycero*-[l]{.smallcaps}-*galacto* configuration.[@bb3645], [@bb3650], [@bb3655]
